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Summary 
Colorectal cancer is the fourth most common cancer in the UK and contributes to over 700,000 deaths 
worldwide per year. When first diagnosed, colorectal cancer has already metastasized in 20% of 
patients to the liver and beyond (termed ‘synchronous’). In these patients, 5-year survival is less than 
7%. For patients with metastases limited to the liver, surgery and systemic chemotherapy can improve 
5-year survival up to 25-40%. 
Conventional surgery removes the colorectal primary first, followed by chemotherapy, and then 
resection of the liver metastases. Advances in critical care and innovations such as colonic stenting 
have allowed liver-first and simultaneous bowel and liver surgery to become viable options. Currently, 
there is no conclusive evidence to show which approach is optimum, and therefore no standardised 
clinical pathway.  
This thesis, Colorectal cancer with Synchronous liver-limited hepatic Metastasis: an Inception Cohort 
and Qualitative Study (CoSMIC) provides a first mixed method approach to study the process of care 
and outcomes following synchronous or staged surgery in patients with colorectal cancer and 
synchronous liver-limited metastases. CoSMIC found no significant difference in survival according to 
treatment pathway, with the exception of the No Surgery group who had a poorer survival consistent 
with more advanced disease and comorbidity. In line with previous findings, the lack of survival 
difference for the sequence of surgery suggests equipoise. However, the CoSMIC qualitative study 
found a strong clinical preference from both clinicians and patients for the choice of treatment 
pathway.  
CoSMIC has demonstrated the potential of an inception cohort approach to study patients with 
colorectal cancer with synchronous liver-limited metastases. Optimal management of synchronous 
disease is a complex research question, linking surgical and chemotherapeutic pathways. Given this 
interplay of aspects of treatment and presentation of disease, further epidemiological research may be 
the most appropriate research design to further enhance understanding. 
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1. INTRODUCTION 
Bowel cancer is the fourth most common cancer in the United Kingdom, and the third most common 
cause of cancer-related death in Europe[1]. There are over 41,000 new cases of colorectal cancer 
diagnosed annually in the UK and it contributes to over 700,000 deaths per year worldwide. Colorectal 
cancer arises from normal colonic or rectal epithelium which through genetic mutations transforms into 
benign adenomas and then to adenocarcinoma[2]. Further genetic modification causes metastatic 
spread. The liver is the most common site for metastatic disease[3]. At the time of diagnosis, colorectal 
cancer has already metastasised to the liver or further in about 20% of patients (termed ‘synchronous 
disease’)[4]. In these patients, the overall 5-year survival is less than 7%[5]. However, for patients with 
metastatic disease limited to the liver, modern management consisting of systemic chemotherapy and 
surgery to resect both the primary colorectal cancer and the liver metastases can significantly improve 
5-year survival to 24-40%[6].  
Patients who present with metastatic liver disease following diagnosis and treatment of the primary 
tumour (termed ‘metachronous disease’) receive care focused on this new metastatic disease. In 
contrast, the management of patients presenting with synchronous colorectal cancer and liver 
metastatic disease is more complex. For patients with extrahepatic and/or unresectable disease, 
systemic (and usually palliative) chemotherapy remains the mainstay of treatment. However, patients 
with synchronous liver-limited metastatic disease represent a common clinical management problem. 
The conventional approach firstly involves surgery to remove the colorectal primary, followed by a 
period of adjuvant systemic chemotherapy, and then a second operation to resect the liver metastatic 
disease. Recent advances in critical care and anaesthesiology, along with technological innovations 
such as colonic stenting, have allowed two other surgical strategies: liver-first and simultaneous bowel 
and liver surgery. 
The liver-first (or reverse) strategy is the resection of the liver metastatic disease as the first step 
followed by resection of the bowel primary[7]. There is evidence of improved outcomes in locally 
advanced rectal cancer treated by pre-operative chemoradiotherapy prior to surgical resection, 
creating a potential “window” in which liver resection may be undertaken[8]. Liver-first surgery has 
been shown to be feasible in up to 80% of patients with synchronous colorectal cancer and liver 
metastases, and perioperative morbidity and mortality is comparable to the bowel-first strategy[9].  
Synchronous or simultaneous resections of the colorectal primary and liver metastases have the 
advantage of removing the macroscopic tumour burden with a single operation. Synchronous 
resections have been shown to be oncologically equivalent to staged resections, but with the 
advantage of being more cost effective as a treatment modality[10]. There is however a higher risk of 
surgical morbidity, particularly with colorectal and major hepatic resections of more than 3 liver 
17
 
 
segments[11]. It has also been shown that patients with fewer than 4 liver metastases have a lower 
morbidity following staged procedures compared to a synchronous approach[12].  
Currently, there is no conclusive evidence to show which approach is optimum with regards to 
morbidity or survival, and therefore there is no standardised clinical pathway. Treatment is decided at 
multidisciplinary team (MDT) meetings[13-15] and is dependent on multiple factors: cancer staging, 
patient health and preferences, and clinical experience.  
This introductory chapter summarises the controversy regarding the definition of synchronous 
colorectal liver disease, the understanding of genetic mechanisms, the current clinical management in 
the NHS, and then sets out the structure of the remaining thesis 
 
1.2 Characterising the Synchronous Cancer Cohort 
Historically, accurate definition of synchronous disease was not a high priority as the mainstay of care 
was directed at surgical treatment of the colorectal primary typically followed by systemic 
chemotherapy with liver resection being undertaken in only a few patients and in highly specialist 
centres[16]. The last two decades have witnessed a profound change in the management of liver 
metastases from colorectal cancer[17]. The advent of synchronous resection of liver and bowel 
tumours, the liver-first approach and the availability of effective chemotherapy including biologic 
agents have changed the paradigm of care[18]. This increased spectrum of available treatment 
options calls for renewed emphasis on the need for accurate baseline staging and clinically and 
biologically relevant disease descriptors. 
In relation to the use of the term “synchronous” metastasis there is currently no precise definition 
provided in the staging guidelines of the American Joint Committee and Cancer, the US National 
Comprehensive Cancer Network or the World Health Organization’s International Classification of 
Disease. In the modern era, imprecision, variation or overlapping definitions of the term “synchronous” 
may compromise care.  Evidence of this variation is seen in the Table 1. These papers, drawn from a 
recent meta-analysis of synchronous colorectal hepatic metastases[19] show globally there are 
ongoing differences in the use of the term “synchronous”.  Components of variation in the definition of 
synchronous disease include firstly whether the term is restricted to those diagnosed prior to 
surgery[20] or whether or not intra-operative diagnoses made at the time of index colorectal surgery 
are included (a further element of uncertainty introduced here relates to the need for histological 
confirmation of liver metastases found at operation – a standard not applied to those detected on 
imaging either prior to or after surgery)[21]. A second and important component of variation is 
introduced by the incorporation of metastases found after diagnosis of the primary.  For example, in 
Table 1 it can be seen that several authors include metastases diagnosed up to 12 months after 
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treatment of the primary tumour in the timeline of synchronous metastases[22, 23]. This broad time 
frame is no longer practical as patients presenting at a year after treatment of their primary with liver 
metastases will have treatment directed solely at this liver metastatic burden and are therefore 
receiving care targeted at metachronous disease. 
First author and 
year of 
publication 
Geographic 
origin of 
study 
Description of synchronous colorectal cancer with liver 
metastasis 
Andres A et. al. 
2012[24]. 
European 
multi-
national 
Synchronous colorectal liver metastases were defined as 
diagnosed less than 30 days from the colorectal cancer (primary 
tumour) diagnosis. 
Broquet A et. al. 
2010[20]. 
USA Synchronous liver metastases diagnosed pre-operatively.  
Patients who had incidental discovery of synchronous liver 
metastases during operation for their primary tumours were 
excluded. 
Capussotti L 
et.al. 2006[25]. 
Italy Synchronous metastases defined as liver metastases 
diagnosed before colorectal resection or at the time of 
laparotomy. 
de Haas RJ et. al. 
2010[26]. 
France Synchronous metastases defined as diagnosed before or during 
primary tumour resection. 
Kaibori M et al. 
2010[27]. 
Japan Synchronous metastases defined as detected before primary 
tumour resection or intra-operatively at the time of surgery on 
the primary tumour. 
Taniai N et al.  
2006[22]. 
Japan Hepatic metastases detected from 0 to 12 months after primary 
resection were defined as metastases synchronous with primary 
colorectal tumours. 
Thelen A et al. 
2007[23]. 
Germany Synchronous metastases were denoted before or during 
surgery or within 12 months after primary tumour resection. 
Turrini O et. Al. 
2007[28]. 
Italy Metastases detected either before or during surgery (intra-
operative metastases must be confirmed histologically). 
Van der Pool AE 
et al. 2010[29].  
Netherlands Synchronous metastases defined as detected pre-operatively 
by CT or MR or during resection of primary tumour. 
Weber JC et. Al. 
2003[30]. 
France Synchronous liver metastases detected either before or during 
surgery or within 6 months after primary tumour surgery. 
Table 1. Definition of 'synchronous' colorectal liver metastases 
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In 2015, a multidisciplinary international conference of the expert group on oncosurgery management 
of liver metastases (EGOSLIM) produced a consensus statement on the terminology and management 
of patients with colorectal cancer and synchronous liver metastases[31]. The consensus conference 
characterized patients with metachronous disease as either early metachronous metastasis: those 
diagnosed within 12 months of the primary diagnosis or late metachronous metastasis: those detected 
more than 12 months after diagnosis of the primary tumour. Their survival data indicate significant 
differential behaviour of these two groups and the outcome of both groups is different from that of 
patients with synchronously detected liver metastases. 
The evidence is based on reported outcome data from the multinational LiverMetSurvey liver resection 
registry and makes important recommendations for an updated, modern terminology. The 
recommendations are compatible with current knowledge of the cancer genetics of bowel cancer 
which indicate that there are several different genetic subtypes of colorectal cancer carrying differential 
risks of metastasis[32]. Further, the current terminology is compatible with a view that most (if not all) 
liver metastases are present at the outset of the disease and that variations in regional cell cycle 
control in metastatic cell clusters associated with these different cancer genotypes may contribute to 
the phenomenon of early and late metastasis. Although this oncological basis of early and late liver 
metastases is not fully resolved, it is important that updated terminology is compatible with current 
understanding in this area. 
Taking these factors into consideration, the EGOSLIM group proposed that the term “synchronously 
detected liver metastases” should be adopted. This is defined as liver metastases diagnosed at or 
before diagnosis of the primary tumour. Practical requirements for application of this definition include 
adequate cross-sectional imaging typically with contrast-enhanced computed tomography of the chest, 
abdomen and pelvis at the time of diagnosis of the primary tumour, with options for additional 
sensitivity in detection of liver metastases being gained by the use of contrast-enhanced magnetic 
resonance scanning of the liver. 18Fluoro-deoxy-glucose positron emission tomography may also be 
utilized for staging. The removal of a timeframe associated with the definition does not allow for 
greater laxity in staging but implies that full-body cross-sectional imaging must be undertaken as close 
to the time of diagnosis as is practically feasible. Although the EGOSLIM collaborators do not 
elaborate on settings where these standards cannot be applied, comprehensive staging may not 
initially be possible in patients who present with emergency presentations, such as perforated bowel 
tumours or from a global perspective, this standard may not be applicable in healthcare systems 
where techniques such as computed tomography are not readily available. Accepting these limitations, 
whether applied as “synchronously detected” or as the simpler term “synchronous” the restriction of 
the time frame for diagnosis to the time of presentation of the primary (or before) is practical and may 
be readily adopted internationally. 
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In summary, there are historical inconsistences in the use of the terms used to describe disease in 
patients with liver metastases presenting at the same time as their primary colon cancer. The 
persistence of these inaccuracies into the modern era is apparent (Table 1). Recognition of this 
variation and the need for modern terminology led to the international consensus conference 
categorization of liver metastases into synchronously detected liver metastases, early metachronous 
liver metastases (detected within 12 months of the primary) or late metachronous metastases 
(detected more than 12 months after diagnosis of the primary). This categorization was based on 
evidence of differential survival drawn from the large LiverMetSurvey registry data and allows for 
practical direction of therapy. Hence, there is a need for clarity of terms, a need for timely contrast-
enhanced cross-sectional imaging, and the removal of arbitrary temporal definitions to the term 
synchronous and the need (in most circumstances) to avoid lesion biopsy. 
This modern and practical definition of the term “synchronous liver metastasis” reflects current 
knowledge of the biology and genetics of colorectal cancer and allows for rational use of the available 
spectrum of treatment options. The terminology outlined above can be widely adopted and translate 
readily into clinical practice across a range of healthcare systems. Adoption of this terminology into 
future editions of the American Joint Committee on Cancer (AJCC) cancer staging manuals, the 
National Comprehensive Cancer Network (NCCN) guidelines and national reference documents such 
as those advocated by the United Kingdom National Institute for Health and Care Excellence (NICE) 
will lead to better standardization of care and allow more meaningful comparisons of the treatment 
given to patients with meta- static colorectal cancer. 
With colleagues, I published an editorial on the definition of the term “synchronous liver metastases” in 
the journal Hepatobiliary and Pancreatic Diseases International[33]. 
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1.3 Biological Rationale 
The adenoma-carcinoma genetic model of colorectal tumorigenesis was first proposed by Fearon and 
Vogelstein in the 1990s[34], who described a multistep process involving the progressive inactivation 
of specific tumour-suppressor genes (namely APC, TP53 SMAD4 and TGF-b) and the activation of 
oncogene pathways (RAS, BRAF and PI3KCA)[35]. Together with the activation of growth factor 
pathways such as prostaglandin signalling (COX-2), epidermal growth factors (EGF) and vascular 
endothelial growth factors (VEGF), benign adenomas develop from colonic mucosa, and are 
progressively transformed into adenocarcinomas. The driver mutations that cause a primary tumour to 
metastasize have not yet been clearly identified, although progress has been made such as the 
identification of MACC1 a regulator of the HGF-MET signalling pathway[36]. 
The advent of Next Generation Sequencing (NGS) of DNA has made it possible to study individual 
mutations in the cancer genome as well as providing detailed expression profiles. Genome wide 
association studies (GWAS) have confirmed existing mutations in tumour suppressor genes and 
oncogenes in cancer as well as elucidating novel pathways and mechanisms through exome 
sequencing[37]. More recently, the study of the cancer epigenome, such as the local chromatin states 
of DNA, has been shown to play a significant role in tumorigenesis[38]. GWAS have identified more 
than 30 susceptible loci in the development of colorectal cancer[39], and recently there has been a 
consensus on the 4 molecular subtypes of colorectal cancer, with each subtype exhibiting a unique 
genotype and clinical phenotype[32] (summarised in Table 2).  
 
Subtype Description Characteristics 
 Proportion
* 
CMS1 
Microsatellite instability 
immune 
Hypermutated, microsatellite unstable, 
strong immune activation 
14% 
CMS2 Canonical 
Epithelial, marked WNT and MYC signalling 
activation 
37% 
CMS3 Metabolic 
Epithelial and evident metabolic 
dysregulation 
13% 
CMS4 Mesenchymal Prominent transforming growth factor- 23% 
*Thirteen percent of colorectal tumours are of mixed types, possibly representing a ‘transition 
phenotype or intra-tumoral heterogeneity’.  
Table 2. Consensus Molecular Subtypes of Colorectal Cancer 
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Subtype 1 (microsatellite instability/immune type) make up 14% of colorectal cancers and have high 
rates of microsatellite instability and hypermethylation across the genome. They invoke a strong 
immune response and are more prevalent in right sided colonic tumours. Subtype 2 (canonicol) 
account for a third of colorectal cancers and are usually left sided tumours. They show high rates of 
chromosome instability and mutations within the Wnt and MYC signalling pathways as well as having a 
high copy number of oncogenes and copy number loses of tumour suppressor genes. Subtype 3 
(metabolic) is associated with dysregulation of cellular metabolism, and subtype 4 (mesenchymal) 
have a high number of mutations leading to growth factor ß activation and a more aggressive clinical 
phenotype.  
Furthermore, three distinct molecular subtypes of colorectal liver metastasis have recently been 
identified[40] (summarised in Table 3). Each intrinsic subtype has a distinct mRNA expression pattern 
and is associated with a different disease prognosis. Interestingly, there is no association between the 
primary CMS subtype and overall survival in patients with resected liver metastases.  
 
Subtype Description Characteristics  Proportion 
Subtype 1 Canonical 
Decreased immune and stromal infiltration 
E2F/MYC signalling  
DNA damage and cell cycle 
NOTCH1 and PIK3C2B mutations 
Metastatic recurrence - many 
Overall survival - intermediate  
33% 
Subtype 2 Immune 
Increased immune infiltration 
Interferon signalling 
p53 pathway 
NRAS, CDK12 and EBF1 mutations 
Metastatic recurrence - few 
Overall survival - favourable 
28% 
Subtype 3 Stromal 
Increased stroma infiltration 
KRAS signalling  
EMT and angiogenesis 
SMAD3 mutations 
Metastatic recurrence - many 
Overall survival - unfavourable 
39% 
Table 3. Molecular subtypes of colorectal cancer liver metastasis 
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The practical implication for synchronous colorectal cancer and liver-limited metastatic disease is the 
hypothesis that differences in tumour biology cause metastatic disease to behave more aggressively 
and progress to inoperable disease more quickly[9, 41]. Sottoriva and colleagues postulate a ‘big 
bang’ model of colorectal tumour growth[42] which describes a high intratumoural heterogeneity within 
a tumour mass that select for sub-clones with a selective growth advantage. Lee and colleagues also 
show that only half of synchronous metastases have the same clonal origins as their patient-matched 
primary counterparts[43]. This phenomenon provides a strong rationale for a liver-first or simultaneous 
resection approach for a synchronous disease presentation where by the metastatic disease should be 
considered as a separate entity.  
 
1.4 Current Clinical Pathways 
In the current National Health Service (NHS), patients are referred either through the Primary Care 
route (where patients present to their General Practitioner (GP) before being referred to a hospital in 
Secondary Care for more specialist care) or present as an emergency directly to a hospital through the 
Accident and Emergency Department.  
The standard of care for cancer cases is that they are discussed at a specialist Multidisciplinary Team 
(MDT) meeting where individual patient management plans are agreed and documented before being 
discussed with the patient. For cancers of the pancreas, liver and biliary system and for liver 
metastatic disease, the minimum core team for a HPB review includes: 
• Two HPB surgeons 
• Two Radiologists, of which one should be an interventional radiologist 
• A medical Oncologist 
• A Pathologist 
• An HPB Cancer Nurse Specialist 
• An MDT Co-ordinator 
The regional HPB unit for Greater Manchester and Cheshire has produced regional guidelines for the 
management of synchronous colorectal liver metastases[44]. These are summarised below: 
• For ‘easily resectable’ colorectal liver metastasis (CRLM) with a resectable and non-
obstructing primary colonic tumour, surgery (either simultaneous or delayed) is 
recommended, followed by 6 months of adjuvant systemic chemotherapy 
• For multiple or borderline resectable CRLM, at least 3 months of neoadjuvant chemotherapy 
is recommended, followed by surgery and 6 months of adjuvant chemotherapy 
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• For ‘easily resectable’ CRLM with a resectable and non-obstructing primary rectal tumour, 
upfront surgery (either simultaneous or delayed) is recommended, with the option of 
neoadjuvant radiotherapy, followed by adjuvant chemotherapy for 6 months 
 
 
1.5 Characterisation of the Problem 
Synchronous colorectal cancer and liver-limited metastatic disease is a challenging clinical scenario. 
The three surgical strategies – bowel-first, liver-first and synchronous resection – have all been shown 
to be safe and viable management options with seemingly equivocal perioperative and oncological 
outcomes.  
The remaining thesis is structured into 6 chapters. The next chapter reviews and summarises the 
current evidence for the management of synchronous disease, additionally drawing upon limited 
qualitative research examining clinician and patient perspectives. These findings provide the 
foundation and rationale for a mixed methods approach to further develop the understanding of 
synchronous disease. The methods of an inception cohort study (CoSMIC) and qualitative study 
(CoSMIC-Q) are described in chapter 3. (CoSMIC stands for Colorectal Cancer and Synchronous 
Liver-Limited Metastases Inception Cohort). CoSMIC-Q patient and clinician perspectives are reported 
in chapters 4 and 5, and CoSMIC is reported in chapter 6. To conclude, the incremental knowledge of 
the new research, implications for clinical practice and future research avenues are discussed in 
chapter 7. 
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2. REVIEW OF CURRENT KNOWLEDGE 
2.1 Introduction 
In preparation for designing primary research, several systematic reviews of key themes relating to the 
thesis aims and objectives were undertaken. 
Firstly, a systematic review of the literature was undertaken looking at the differences in outcomes 
between the surgical strategies of bowel-first, liver-first and synchronous resection. Secondly, a review 
of clinical guidelines was undertaken to ascertain the current practice of patients diagnosed with 
colorectal cancer and synchronous liver-limited metastatic disease. Finally, a review of the qualitative 
literature focused on patient perspectives of their disease and care received is conducted.  
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2.2 Systematic Review of Surgical Management Outcomes  
There is currently evidential uncertainty concerning the different surgical treatment options for patients 
with liver-limited synchronous colorectal metastasis. Reports comparing the outcomes of staged and 
synchronous resections[11, 45] do not readily consider the complexity of current staged treatment 
pathways where the staged approach may comprise of either bowel-first or liver-first strategies. This 
systematic review focuses on reports where all three surgical strategies are presented for comparison, 
with the aim of assessing whether there is evidence for superior outcomes associated with a given 
strategy, or evidence to support for the use of all three strategies. 
This systematic review was registered with the International Prospective Register of Systematic 
Reviews (PROSPERO) database (CRD42016039163) in May 2016. With colleagues, I published this 
systematic review in the European Journal of Surgical Oncology[46]. The ‘Preferred reporting items for 
systematic reviews and meta-analyses’ (PRISMA) checklist[47] applied to the CoSMIC systematic 
review is shown in Appendix 8.1. 
 
2.2.1 Methods / Search Strategy 
Design 
A systematic review of the published literature reporting the outcomes of patients with colorectal 
cancer and synchronous liver metastasis following treatment with either the bowel-first, liver-first or 
synchronous approach was carried out. The review focuses on reports where all three surgical 
strategies were available and compared within the study cohort and publishing individual patient-level 
data. 
Literature Search Strategy 
The OvidSP database (encompassing Embase and MEDLINE) was queried for relevant articles from 
January 1994 to the current date (January 2014). The search strategy is shown in Table 4. Medical 
subject heading (MESH) index and text search terms included: colorectal cancer/neoplasm, liver 
cancer/neoplasm/metastasis and surgery, and combined with Boolean operators. Articles were limited 
to human studies and to those published in the English language. The article title and abstracts were 
reviewed, and two independent reviewers assessed each report to see whether or not it met the 
inclusion criteria. Any disagreements were resolved by the senior authors (AKS and JMM).  
Data Extraction 
Data from included reports were independently extracted by two reviewers using a pre-designed data 
extraction form. Disagreements were resolved by consensus or by consultation with the senior 
reviewers.  
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Evaluation of the Quality of Reports 
Two authors assessed and scored the methodological quality of the included studies using the 
modified methodology index for non-randomised studies criteria (MINORS criteria)[48]. Although the 
review is a comparative study, the criteria of “adequate control group” is not applicable and so a 
maximum MINORS score was set at 22 rather than 24.  
Analysis 
Demographic data from the study cohort as well as the rates of complications and survival comparing 
each of the three surgical strategies are reported. Details of systemic chemotherapy received by each 
group were also reported. Statistical pooling of proportional estimates was explored using fixed effect 
models using StatsDirect© Version 3.0 (StatsDirect Ltd, Altringham, Cheshire, UK).  
 
2.2.2 Results 
The search strategy (detailed in Table 4) identified 223 unique citations of which 23 provided 
comparative data. Of these, 3 cohort studies met the inclusion criteria by reporting outcomes 
separately for the three surgical treatment pathways[20, 29, 49]. A PRISMA flow diagram[47] of the 
systematic review is shown Figure 1. 
 
# Search Strategy Number of 
articles 
#10 Remove duplications from #9 223 
#9 Limit #8 to full text 392 
#8 Limit #7 to yr = “1994 – current” 3,231 
#7 Limit #6 to human 3,269 
#6 Limit #5 to English language 3,403 
#5 (#1 AND #2 AND #3 AND #4) 3,645 
#4 (simultaneous OR synchronous).mp. 679,530 
#3 surgery.mp OR colorectal surgery/ OR general surgery/ OR 
treatment.mp 
1,336,0352 
#2 liver cancer.mp OR liver neoplasm OR (liver adj2 metast*).mp 288,332 
#1 colorectal cancer.mp OR colorectal cancer OR colorectal 
neoplasm.mp OR colorectal neoplasm/ 
276,474 
* denotes a search string wildcard character 
Table 4. Ovid search strategy 
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Figure 1. Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA) 
diagram for the systematic review into outcomes following surgery for synchronous colorectal cancer 
and liver metastases 
Systematic Review Summary 
The first study by van der Pool and colleagues[29] is a retrospective cohort analysis from a 
prospectively collected database of 277 patients undergoing liver resection for colorectal liver 
metastases. Of these, 57 patients with synchronous disease all from rectal cancers were identified for 
analysis. Surgical treatment included a bowel-first or simultaneous resection in those with early rectal 
cancer and limited liver disease, and the liver-first approach in patients with advanced liver disease 
and/or locally advanced rectal cancer. The second study by Brouquet and colleagues[20] is 
prospective analysis of 156 consecutive patients in one centre undergoing surgical resection for 
synchronous colorectal liver metastasis with an intact bowel primary. Treatment decisions were 
decided at MDTs, and the criteria included the location and extent of the primary tumour, the need for 
preoperative radiotherapy in rectal primaries, the extent of metastatic disease in liver, the presence of 
extrahepatic disease and the response to preoperative chemotherapy. Overall survival and disease-
free survival were calculated from the time of final resection of all disease. Finally, the study by Mayo 
and colleagues[49] is a retrospective analysis of 1,004 patients with synchronous colorectal liver 
metastases treated at four centres, in the USA, Switzerland, Italy and Portugal. 
Literature Search
• Databases: OvidSP (Embase, MEDLINE)
• Limits: English language and human studies
Search results combined / removal of duplicates
(n = 233)
Articles screened on basis of title and abstract
(n = 233)
Full text articles assessed for eligibility
(n = 23)
Excluded
• Non relevant articles (n = 210)
Studies included in Systematic Review
(n = 3)
Excluded
• Staged procedures does not distinguish 
between bowel-first or liver first (n = 20)
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MINORS Score 
The MINORS scores were calculated for the three studies identified (Table 5). The MINORS score 
was 14/22 for the van der Pool study[29] as the prospectively collected database was not designed to 
study synchronous presentations exclusively. Disease recurrence and 5-year survival endpoints 
comparisons between the three groups were also not reported. The MINORS score was 14/22 for the 
Brouquet study[20]. The baseline equivalence of groups was not uniform, for example, there was a 
much higher rate of major liver resections of three or more segments in the liver-first group compared 
to bowel-first and synchronous groups. The MINORS score was 13/22 for the Mayo study[49], and 
was slightly lower compared to the other studies as this was a retrospective study. None of the three 
studies calculated a prospective study size or reported the proportion of patients lost to follow-up. 
Methodological items for non-randomized 
studies* 
Van der 
Pool et al. 
Brouquet et 
al. Mayo et al. 
A clearly stated aim 2 2 2 
Inclusion of consecutive patients 2 2 2 
Prospective collection of data 1 2 0 
Endpoints appropriate to the aim of the study 1 1 2 
Unbiased assessment of the study endpoint 0 0 0 
Follow-up period appropriate to the aim of the study 2 2 2 
Loss to follow up less than 5% 0 0 0 
Prospective calculation of the study size 0 0 0 
An adequate control group* - - - 
Contemporary groups 2 2 2 
Baseline equivalence of groups 2 1 1 
Adequate statistical analyses 2 2 2 
Total 14/22 14/22 13/22 
*Items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate).  
** the criteria of “adequate control group” is not applicable and so a maximum MINORS score was 
set at 22 rather than 24.  
Table 5. MINORS Scoring 
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Definitions of synchronous disease 
The definition of colorectal cancer with synchronous liver metastasis varied between studies. Van Der 
Pool and colleagues used the term synchronous to describe pre-operative diagnosis of rectal cancer 
with synchronous metastases but also included patients with liver lesions discovered intra-operatively. 
Brouquet and colleagues excluded intra-operatively discovered lesions. Mayo and colleagues did not 
elaborate on the definition of synchronous disease. 
Demographic profile 
The patient demographic profile, including the recruitment period, location of primary tumour, extent 
and lobar distribution of hepatic metastases and (where available) presence of extra-hepatic disease, 
are reported in Table 6. In total 1217 patients were included within the 3 studies, of which 1203 
completed the treatment protocols. Two studies present data on both colonic and rectal tumours and 
one study includes only rectal cancers, resulting in a study population of 405 (33.7%) patients being 
treated for rectal cancers and 796 (66.3%) for colonic cancers; in 2 cases the primary site was not 
reported. Patients reported in the studies received treatment between 1982 and 2011. 
 
First Author (Year of 
Publication) 
Brouquet 2010 Van der Pool 2010 Mayo 2013 
n 156a 57 1,004d 
Recruitment period 1992 - 2009 2000 - 2007 1982-2011 
Gender (male:female) 86:70 40:17 598:406 
Median (range) age, years 55 (25-81) 61 (43-82) 60 sd 22e 
Location of primary tumour 
(colon:rectum) 
75:81 00:57 726:278 
number of liver metastases 3 (1 -10)b 
< 3: 36 
> 3: 21 
2 sd 2.6 
>2: 325 (34%) 
Bi-lobar liver metastases 83 (53%) 26 (46%) 380 (38.4%) 
Extra-hepatic metastases na 6 (11%)c 117 (11.7%) 
na = not available; a 156 patients commenced treatment by 142 completed protocols; b Median 
(range) number of liver lesions; c Group allocation of patients with extra-hepatic metastatic disease 
not provided; 
d 1004 patients derived from the database of four institutions; e sd = standard deviation. 
Table 6. Demographic profile of patients with colorectal cancer with synchronous liver metastases. 
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Treatment allocation 
No studies provided information on how individual treatments were selected (Table 7). Only one study 
provided information on timelines for progression through a protocol[20]. Numbers of liver metastases 
were similar for patients undergoing synchronous or sequential surgery. 
First Author (year of publication) Brouquet 2010 Van der Pool 2010 Mayo 2013 
Synchronous Liver/Bowel Surgery (n) 43 8 329 
Number of liver metastases in 
synchronous 
Median (range) 
2 (1-10) 1 (1-4) 2 ± 2.4* 
Classical Bowel-first surgery 72 29 647 
Number of liver metastases  
Median (range) 3 (1-10) 2 (1-7) 2 ± 2.6 
Time interval between bowel and liver 
surgery (months) 
 6 (2 – 38)  
Liver-first category 27 20 28 
Number of liver metastases  
Median (range) 3 (1-10) 3 (1 – 8) 3 ± 3.6 
Delay from liver to bowel surgery 
(months) 
 4 (2-5)  
Number with rectal primary in liver-
first group 
 20  
Table 7. Treatment allocations 
Treatment feasibility 
Only one study reported on the feasibility of the three different treatment options. Brouquet noted that 
of the 41 patients planned for liver-first surgery, 27 patients successfully completed the treatment 
protocol. The remaining 14 patients underwent the initial liver resection, but no subsequent bowel 
resection for reasons including metastatic disease progression (8 patients) and primary tumour 
progression (1 patient), a complete response to chemoradiotherapy (2 patients), post-operative death 
(2 patients) and 1 patient was lost to follow-up. Two patients in the liver-first group were also reported 
as becoming symptomatic from their primary tumour following the initial liver resection and underwent 
surgery for colostomy formation. 
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Chemotherapy protocols 
The neoadjuvant and adjuvant chemotherapy protocols and agents used are reported in Table 8. The 
periods of the Brouquet and Mayo studies pre-dated the availability of current systemic agents such as 
oxaliplatin and irinotecan but spans the introduction of these agents. Use of neoadjuvant therapy 
varied considerably between studies but appeared most common before liver-first surgery. 
 
First 
Author 
(year) 
Synchronous 
Liver/bowel 
surgery 
Classical Bowel-first 
surgery 
Liver-first surgery 
 
NA ADJ NAFS AFS AAC NAFS AFS AAS 
Brouquet 
2010 
43 
(100%) 
5-FU: 10 
Ox: 25 
Iri: 8 
33 
(77%) 
72 
(100%) 
5-FU:22 
Ox: 31 
Iri: 19 
50 
(69%) 
46 
(64%) 
27 
(100%) 
5-FU: 1 
Ox: 20 
Iri: 6 
16 
(59%) 
21 
(78%) 
Van der 
Pool 
2010 
2 (25%)a 0 13 (45%)a 0 0 
19 
(95%)a 0 0 
Van der 
Pool 
2010 
XRTb 
 
7 (88%)  
 
11 (38%)   
 
20 
(100%) 
  
Mayo 
2013 
71 
(21.6%) 
71 
(21.6%)c 
130 
(20.1%) 
216 
(33.4%)d  
21 
(75%) 
6 
(21.4%)e  
 
NA = Neoadjuvant chemotherapy; ADJ = Adjuvant chemotherapy; NAFS = Neoadjuvant 
chemotherapy to first surgery; AFS = Adjuvant chemotherapy to first surgery; AAS = Adjuvant 
chemotherapy to all surgery; 5-FU = 5 Fluorouracil; Ox = Oxaliplatin; Iri = Irinotecan;  
a Twenty seven of 34 patients received oxaliplatin-based chemotherapy, 7 received irinotecan-
based chemotherapy and 14 had bevacizumab as additional therapy 
b XRT = Radiotherapy/chemotherapy for rectal tumours 
c 43 patients received both neoadjuvant and adjuvant chemotherapy 
d 59 patients had both pre-operative and adjuvant chemotherapy 
e These patients received both neoadjuvant and adjuvant chemotherapy 
 
Table 8. Chemotherapy protocols 
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Peri-operative outcomes 
Complications were reported according to the revised Dindo-Clavien classification[50] by all three 
studies. This system was not introduced until 2004 and thus for the Mayo and Brouquet studies 
information must have been gathered retrospectively. Only one study provides information on in-
patient stay[29]. Levels of minor complications were similar between procedures but very different 
between recruitment cohorts. Mayo reported lower minor complication rates for its combined 
procedures: 9.1% (95%CI: 7.4%-11.0%), than the other two cohorts, combined procedures: 34.5% 
(95%CI: 28.1%-41.2%). Although levels of major complications also varied between cohorts and 
procedures, generally rates were low and consistent with an overall pooled fixed estimate of 9.1% 
(95%CI: 7.6%-10.8%, I2 = 48%). Post-operative death was rare and individual cohorts and procedures 
are consistent with an overall pooled fixed effect estimate of 3.1% (95%CI: 2.2% - 4.3%, I2 = 48%). 
This is illustrated in Figure 2. 
 
 
Figure 2. Peri-operative outcomes 
Combined 0.03 (0.02, 0.04)
Mayo Liver first 0.00 (0.00, 0.12)
Van der Pool Liver first 0.00 (0.00, 0.17)
Broquet Liver first 0.04 (9.4E-4, 0.19)
Mayo Bowel first 0.03 (0.02, 0.05)
Van der Pool Bowel first 0.00 (0.00, 0.12)
Broquet Bowel first 0.03 (3.4E-3, 0.10)
Mayo Synchronous 0.03 (0.01, 0.05)
Van der Pool Synchronous 0.00 (0.00, 0.37)
Broquet Synchronous 0.05 (5.7E-3, 0.16)
0.0 0.1 0.2 0.3 0.4
Combined 0.09 (0.08, 0.11)
Mayo Liver first 0.00 (0.00, 0.12)
Van der Pool Liver first 0.05 (1.3E-3, 0.25)
Broquet Liver first 0.07 (9.1E-3, 0.24)
Mayo Bowel first 0.08 (0.06, 0.11)
Van der Pool Bowel first 0.14 (0.04, 0.32)
Broquet Bowel first 0.17 (0.09, 0.27)
Mayo Synchronous 0.09 (0.06, 0.13)
Van der Pool Synchronous 0.00 (0.00, 0.37)
Broquet Synchronous 0.19 (0.08, 0.33)
Proportion (95% CI)
Major complications Proportion (95%CI)
Post-operative death
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Resection margins  
Mayo reports a lower R0 resection margin in hepatic resections in the liver-first group, despite the high 
proportion of ‘unknown’ margins. Brouquet et al was the only study that reported bowel resection 
margins, which showed no difference between any of the groups. 
Survival  
Median follow-up from date of completion of treatment ranged from 25.1 to 40.0 months. A graphical 
representation (Figure 3) shows that although there is some variation in the smaller studies they are 
consistent with a pooled underlying 5-year survival fixed effect estimate of 44% (I2 = 39%).  
 
Figure 3. Five-year survival rates (fixed effects estimate) 
2.2.3 Discussion of Evidence Review 
The first decade of the twenty-first century witnessed major change in the diagnosis and management 
of colorectal cancer with synchronous liver metastases. The evidence-base around systemic 
chemotherapy agents such as oxaliplatin and irinotecan, the benefits of chemoradiotherapy for rectal 
cancer and the advent of newer biological agents such as cetuximab and bevacizumab has improved 
the outlook for patients with this disease and changed the management algorithm to emphasise the 
importance of systemic treatment for a systemic disease. In parallel, technical developments such as 
endoscopic colonic stenting and the advent of the liver-first approach (with the option for rectal 
preservation in complete responders) and promotion of synchronous liver and bowel surgery have 
combined to produce a very complex care scenario. To date, there is no randomised trial evidence to 
guide treatment selection: systematic review may influence the design of such a study by highlighting 
areas of evidential equipoise. Although there are a host of reports comparing synchronous and 
sequential treatment, very few address the management of synchronous disease in units or 
collaborations where all three modern approaches have been applied. Thus, it is thought that this is 
the first systematic review to assess the management of colorectal cancer with synchronous liver 
metastases managed by all three currently utilised therapeutic options.  
0.0 0.2 0.4 0.6 0.8 1.0
0.44 (0.41, 0.47)
Mayo Liver first 0.43 (0.24, 0.63)
Mayo Bowel first 0.44 (0.40, 0.48)
Mayo Synchronous 0.42 (0.37, 0.47)
Van der Pool Liver first 0.65 (0.41, 0.85)
Van der Pool Bowel first 0.28 (0.13, 0.47)
Van der Pool Synchronous 0.75 (0.35, 0.97)
Broquet Liver first 0.41 (0.22, 0.61)
Broquet Bowel first 0.49 (0.37, 0.61)
Broquet Synchronous 0.56 (0.40, 0.71)
Combined
Proportion (95% CI)
Proportion (95%CI)5 year Survival Rate
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The review presents findings from three reports which include six different centres in Europe and North 
America. Firstly, it should be noted that the definition of ‘synchronous’ or ‘metachronous’ disease is 
inconsistent, with each report presenting different inclusion criteria. Secondly, the long recruitment 
period should be noted. This introduces bias through changes in diagnostic imaging, standards of 
surgical care and possibly most importantly, the availability of bowel-cancer specific chemotherapy. In 
this regard, the data are also skewed by the largest report having an inclusion period back to 1982. 
Another potential limitation includes limiting the systematic review to articles published in the English 
language only. Whilst there is some evidence to suggest that systematic reviews excluding non-
English language publications have slightly lower quality scores and/or credibility[51], others have 
shown no evidence of any systemic bias from these restrictions[52]. Finally, no additional unpublished 
data was obtained for analysis from the authors of the included studies. Whilst the authors were 
contacted, the requested data were either missing, or only available in aggregate form from several 
centres and therefore not suitable for detailed analysis.  
Accepting these limitations, the review shows that in all studies, patients with synchronous disease 
typically had multiple liver metastases with approximately 50% being bi-lobar in distribution. The low 
numbers with extra- hepatic disease are likely to represent referral bias in the population of patients 
sent to cancer centres. Although the liver-first category was the least utilised in the reports included in 
this review (Table 7), this probably reflected the relative novelty of this approach. Chemotherapy in this 
setting is complex and this is seen in Table 8 where a host of agents and regimens were used. 
Neoadjuvant chemotherapy, although used in varying extent was utilised in all reports. Although 5-
fluorouracil (5-FU) was approved by the United States FDA (Food and Drug Administration) in 1962, 5-
FU with irinotecan was only used from 2000, and 5-FU with oxaliplatin was introduced in 2004. 
Chemotherapy regimens therefore differed not only between the reporting centres, but also within 
centres during the entire study period, making outcome comparisons difficult. Also, no objective 
measures of tumour response were reported, which would be particularly relevant in patients where 
resection was deemed possible following tumour downsizing following chemotherapy. 
This review reports a cohort of 1203 patients from 3 studies, of which 748 patients received bowel-first 
surgery, 75 liver-first surgery, and 380 synchronous surgery. Perhaps most striking is the similarity in 
major complications, post-operative death and 5-year survival given the variations in procedure within 
and between cohorts and the varying contexts of surgical care. There was also no reported difference 
in disease recurrence rates, which ranged between 57 and 74%. Interestingly, there was a significant 
difference in the median number of liver metastases between the combined group and both staged 
groups, suggesting a higher tumour burden and possibly a more aggressive disease phenotype in the 
staged group. 
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For those with this disease and for their clinicians, this review was unable to shed light on the decision-
making process behind selection of a given pathway for any individual patient. This is an important 
limitation, not only of this study but of all currently available evidence in this area. However, the 
present review demonstrates that that overall treatment-related mortality is low in all three pathways 
and that survival is similar between the three groups. Clearly, prospective evidence is required to aid 
selection of individual treatment pathways but pending the availability of such evidence the findings of 
this review support the continued use of all three treatment pathways. The next section of this chapter 
therefore explored the guidelines used by clinicians to guide management of synchronous colorectal 
cancer and liver-limited metastatic disease. 
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2.3 Systematic Review of the Guidelines 
The results of the previous systematic literature review identified no robust evidence of significant 
differences in the clinical or oncological outcomes seen in patients with colorectal cancer and liver-
limited metastatic disease treated with either a bowel-first, liver-first or synchronous surgical strategy. 
However, the current evidence base is weak, consisting of retrospective studies which may be biased 
by patient selection and clinical expertise. The development of clinical guidelines in this area may 
therefore be difficult, and different healthcare systems interpret the evidence base differently, leading 
to variations in content of guidance and strength of recommendations to end users.  
The World Health Organization (WHO) Advisory Committee on Health Research have published 
robust standards on the development of healthcare management guidelines, and recommends that 
research evidence should be used to inform best clinical practice and delivery of care[53]. However, 
there is concern that published guidelines do not always have a clear or transparent methodology for 
assessing the primary evidence, or for explicitly grading their recommendations[54]. To this end the 
WHO has published extensively on the development of guidelines[55], and uses systematic reviews 
and meta-analyses when developing its guidelines, although the choice of study designs in these 
reviews is still not clearly defined by WHO[56].  
Guidelines published by different Government health organisations and specialty societies are 
reviewed in the current section. The aim is to firstly to summarise the current guidance given to 
clinicians managing patients with synchronous colorectal cancer and liver-limited metastatic disease, 
and secondly to assess the strength of the evidence on which the recommendations are based. 
 
 
2.3.1 Methods / Search Strategy 
Design 
A systematic review of guidelines for the management of colorectal cancer and synchronous liver 
metastases was performed. The review focuses specifically on guidance for surgical strategies for 
synchronous disease where both the primary tumour and liver metastatic disease are resectable.  
Identification of Guidelines 
The PubMed database was queried for metastatic colorectal cancer guidelines using keywords 
colorectal cancer liver and guidelines. The guideline repository Guidelines International Network as 
well as colorectal and HPB society websites were also searched for guidelines using the same search 
terms. Opinion pieces, review articles and guidelines that were still in development or a consultation 
phase were excluded. 
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The inclusion criteria for the guidelines in this review were: 
1) Published articles containing guidelines rather than original research, systematic reviews or 
meta-analyses 
2) Guidelines containing guidance on the surgical management of synchronous colorectal 
cancer and liver metastatic disease 
3) Guidelines published in English within the last 10 years (August 2008 to August 2018) 
Appraisal of the Quality of the Guidelines 
The Appraisal of Guidelines for Research and Evaluation II (AGREE-II) Instrument was used to 
appraise the guidelines[57]. The AGREE-II Instrument is a 23-item framework developed by an 
international consortium of guideline developers and researchers designed to methodically assess the 
quality of healthcare guidelines over 6 domains that cover the scope and purpose of the guidelines, 
stakeholder involvement, rigor of development, the clarity of the guidance presented, its applicability to 
current practice and editorial independence. Each item in the framework is scored between 1 (strongly 
disagree) and 7 (strongly disagree), and a score for each domain is calculated as per the AGREE-II 
manual[57]. Table 10 describes each domain and item in the AGREE-II instrument, and how it was 
used in the assessment of guidelines specifically for synchronous colorectal cancer and liver-limited 
metastatic disease.  
Data Extraction and Analysis 
A descriptive summary of each of the guidelines for managing resectable colorectal cancer and 
synchronous liver metastases was extracted. The quality of the guidelines was appraised using the 
AGREE-II 23-item framework as well as the level of evidence upon which the recommendations were 
based, and are presented using a traffic light system Table 9. 
 Level of Evidence Interventions 
 
1a Systematic reviews of RCTs 
1b Individual RCTs 
 
2a Systematic reviews of cohort studies 
2b Individual cohort studies and low-quality RCTs 
3a Systematic reviews of case-controlled studies 
3b Individual case-controlled studies 
 
4 Case series and poor-quality cohort and case-control studies 
5 Expert opinion based on clinical experience 
 ? Unknown / not stated 
Table 9. Traffic light system to assess levels of evidence and strength of recommendations 
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Table 10. The AGREE-II instrument to assess current guidelines of synchronous colorectal cancer and 
liver-limited metastases 
 
Item Domain Notes
Domain 1. Scope and Purpose 
1 The overall objective(s) of the guideline is (are) specifically described. 
The reason why the guideline was developed must be stated. Examples include 
guidelines to tailored to a particular health economy or to develop areas not 
addressed by existing guidelines
2 The health question(s) covered by the guideline is (are) specifically described. 
The clinical scenario of synchronous disease and liver-limited metastatic disease 
must be specifically given and addressed
3 The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described. 
Patient populations must be well defined, such as the definitions of 'synchronous' 
disease, resectable and unresectable disease and assessment of patient co-
morbidity
Domain 2. Stakeholder Involvement 
4 The guideline development group includes individuals from all the relevant professional groups. 
Guideline development should have representation from the core specialities of 
the HPB and colorectal MDT (in particular, HPB and colorectal surgeons, 
radiologists, oncologists) and ideally thoracic surgeons, anaesthetists, critical 
care specialists, pathologists and cancer nurse specialists
5 The views and preferences of the target population (patients, public, etc.) have been sought. 
Involvement from patient and patient groups in the development of the guidelines 
must be described
6 The target users of the guideline are clearly defined. This should include guidance on which specialists are responsible for which aspects of the patient's diagnosis and/or management
Domain 3. Rigour of Development 
7 Systematic methods were used to search for evidence 
8 The criteria for selecting the evidence are clearly described. 
9 The strengths and limitations of the body of evidence are clearly described. 
10 The methods for formulating the recommendations are clearly described. 
11 The health benefits, side effects, and risks have been considered in formulating the recommendations. 
12 There is an explicit link between the recommendations and the supporting evidence. 
If insufficient evidence is the conclusion of the review, this should be clearly 
stated when presenting the guideline
13 The guideline has been externally reviewed by experts prior to its publication.
The guidelines should be independently reviewed by specialists outside the 
guideline development group
14 A procedure for updating the guideline is provided. A timeline and procedure for updating the current guidelines must be stated
Domain 4. Clarity of Presentation 
15 The recommendations are specific and unambiguous. Recommendations on synchronous presentation should be clear
16 The different options for management of the condition or health issue are clearly presented. 
If insufficient evidence is the conclusion of the review, this should be clearly 
stated when presenting the guideline
17 Key recommendations are easily identifiable. 
Domain 5. Applicability 
18 The guideline provides advice and/or tools on how the recommendations can be put into practice. 
19 The guideline describes facilitators and barriers to its application. 
20 The potential resource implications of applying the recommendations have been considered. 
21 The guideline presents monitoring and/ or auditing criteria. Monitoring and audit criteria using international or well established parameters should be described
Domain 6. Editorial Independence 
22 The views of the funding body have not influenced the content of the guideline. 
A funding statement should be provided as well as details on how the guidelines 
were influenced by the funding body
23 Competing interests of guideline development group members have been recorded and addressed. 
All competing professional, financial and personal interests must be stated in the 
guideline publication for all authors as well as the groups or companies involved
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2.3.2 Results 
The guidelines search strategy identified 302 unique articles of which 19 were identified as colorectal 
cancer and/or metastatic colorectal cancer guidelines. Of these, 1 guideline provided no 
recommendations on synchronous liver metastases and 2 guidelines were more than 10 years old. In 
total, 16 guidelines were included in the review. A PRISMA flow diagram of the systematic review is 
shown in Figure 4.  
 
Figure 4. PRISMA flow diagram for the systematic review of clinical guidelines on synchronous 
colorectal cancer and liver-limited metastases 
The principle recommendations of the guidelines are shown in Table 11, and the corresponding 
calculated AGREE-II scores are shown in Table 12. There were 10 guidelines developed by 
Government-funded health organisations[58-67], 5 from speciality societies[18, 68-71] and 1 from an 
expert group[31]. The majority of guidelines for the management of synchronous liver metastases 
were derived from systematic reviews of the literature.  There were 2 guidelines[31, 60] based 
primarily on expert panel consensus with a non-systematic literature review, and 1 guideline produced 
from a review of existing guidelines[65]. The evidence to formulate the guidelines ranged from expert 
opinion articles, to retrospective case series and cohort studies. Despite no randomised controlled trial 
evidence to inform surgical management of synchronous disease, the majority of the guideline 
recommendations were classed as ‘strong’.  
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Summary of Guidelines 
All guidelines agree that for resectable disease, surgery together with systemic chemotherapy was the 
mainstay of curative treatment. MDT discussion was also advocated by all of the guidelines reviewed. 
Most guidelines concede that there is a lack of evidence to inform the sequence of surgery and that 
currently there is no standard management for synchronous liver-limited disease. For staged surgical 
strategies for asymptomatic patients, the guidelines did not define bowel-first or liver-first surgery, with 
the exception of the Japanese Society for Cancer of the Colon and Rectum, which recommended a 
bowel-first approach[69]. No guidelines cited indications for a liver-first approach. Simultaneous 
surgery was frequently described as ‘not the standard of care’ and should only be performed in high 
volume centres, and following MDT discussion and after consultation with the patient. Patient fitness 
was also a consideration for simultaneous surgery, although the definition of this was not provided. 
Guidelines also advocated a ‘personalised approach’ when discussing treatment options with patients. 
The evidence for systemic chemotherapy reported by the EORTC 40983 RCT[1] was frequently cited 
by the guidelines, which formed the basis for chemotherapy regimens and timing recommendations. 
 
Quality Analysis of Guidelines 
The quality of the guidelines was variable, with Government funded organisations in general scoring 
higher with the AGREE-II instrument. Most guidelines scored highly in domain 1 (scope and purpose), 
with the lowest scores attributed to not accurately defining the ‘synchronous’ patient cohort. Domain 2 
(stakeholder) shows a wide range of scores particularly with the views of patients and the public not 
being sought when developing the guidelines. Some guidelines did not seek patient views whereas 
some groups included extensive patient focus groups and public consultation periods. There was less 
variation in domain 3 (rigour of development), with all guideline groups providing a methodology on 
how their recommendations were derived. Groups scored lowest when they did not provide details on 
how they critically appraised the evidence and how the resulting guidance was formulated. In the area 
of synchronous disease where research evidence is limited, ‘surgery’ was strongly recommended, but 
the specific details of surgical sequence or synchronous surgery were not addressed or were not clear. 
There were also 8 guidelines that did not provide any details on if or when their guidelines would be 
updated, and most studies did not address monitoring or audit criteria, contributing to the low scores in 
domain 5 (applicability). Most guideline groups maintained editorial independence, although it is 
argued that organisations such as NICE take in consideration healthcare rationing significantly when 
formulating their guidelines.   
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nti
nu
ed
 or
 sw
itc
he
d, 
de
pe
nd
ing
 on
 th
e q
ua
lity
 of
 re
sp
on
se
. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 S
ys
te
m
at
ic
 R
ev
ie
w
,2
b;
 S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 S
tr
on
g)
 
Ta
bl
e 
3.
 S
um
m
ar
y 
of
 g
ui
de
lin
es
 fo
r s
yn
ch
ro
no
us
 c
ol
or
ec
ta
l c
an
ce
r a
nd
 li
ve
r-l
im
ite
d 
m
et
as
ta
se
s 
(c
on
t…
) 
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 I
ns
tit
ut
io
n 
Co
un
try
 
Gu
id
eli
ne
s 
Ye
ar
 
Su
m
m
ar
y o
f R
ec
om
m
en
da
tio
ns
 
Fr
en
ch
 so
cie
ty
 
of
 
ga
st
ro
in
te
st
in
al 
su
rg
er
y (
SF
CD
) 
an
d 
th
e 
as
so
cia
tio
n 
of
 
he
pa
to
bi
lia
ry
 
su
rg
er
y a
nd
 liv
er
 
tra
ns
pl
an
ta
tio
n 
(A
CH
BT
) 
Fr
an
ce
 
Ma
na
ge
me
nt 
of 
pa
tie
nts
 w
ith
 
sy
nc
hr
on
ou
s l
ive
r 
me
tas
tas
es
 of
 
co
lor
ec
tal
 ca
nc
er
. 
Cl
ini
ca
l p
ra
cti
ce
 
gu
ide
lin
es
. 
Gu
ide
lin
es
 of
 th
e 
Fr
en
ch
 so
cie
ty 
of 
ga
str
oin
tes
tin
al 
su
rg
er
y (
SF
CD
) a
nd
 
of 
the
 as
so
cia
tio
n o
f 
he
pa
tob
ilia
ry 
su
rg
er
y a
nd
 liv
er
 
tra
ns
pla
nta
tio
n 
(A
CH
BT
)[6
8] 
20
12
 
 Af
ter
 an
aly
sis
 of
 th
e c
ur
re
ntl
y a
va
ila
ble
 da
ta,
 co
mb
ine
d m
an
ag
em
en
t o
f th
e p
rim
ar
y t
um
or
 an
d S
LM
 ca
nn
ot 
be
 
re
co
mm
en
de
d. 
It c
an
 be
 co
ns
ide
re
d a
s a
 fu
nc
tio
n o
f th
e e
xte
nt 
of 
the
 liv
er
 (e
sp
ec
ial
ly 
for
 lim
ite
d r
es
ec
tio
n o
f a
n 
ea
sil
y a
cc
es
sib
le 
les
ion
) a
nd
 co
lor
ec
tal
 pr
oc
ed
ur
es
, d
ep
en
din
g o
n t
he
 ex
pe
rtis
e o
f th
e h
os
pit
al 
tea
m.
 A
 co
mb
ine
d 
re
se
cti
on
 is
 no
t r
ec
om
me
nd
ed
 in
 ca
se
s o
f c
olo
re
cta
l re
se
cti
on
 w
he
re
 R
0 m
ar
gin
s a
re
 un
lik
ely
 or
 of
 co
mp
lic
ate
d 
co
lor
ec
tal
 (t
um
or
 pe
rfo
ra
tio
n, 
oc
clu
sio
n, 
he
mo
rrh
ag
e)
 or
 m
ajo
r li
ve
r r
es
ec
tio
ns
 (≥
 3 
se
gm
en
ts)
. 
 In 
the
 lit
er
atu
re
 as
 it 
sta
nd
s, 
sta
ge
d s
ur
ge
ry 
of 
the
 pr
im
ar
y t
um
or
 an
d S
LM
 is
 re
co
mm
en
de
d f
or
 m
ajo
r li
ve
r a
nd
 
co
lor
ec
tal
 re
se
cti
on
s 
 Th
e c
ho
ice
 be
tw
ee
n c
om
bin
ed
 su
rg
er
y a
nd
 st
ag
ed
 su
rg
er
y (
po
ten
tia
lly
 ‘‘i
nv
er
se
’’ s
tag
ed
) m
us
t b
e c
on
sid
er
ed
 as
 a 
fun
cti
on
 of
 th
e p
ati
en
t’s
 ge
ne
ra
l c
on
dit
ion
, th
e e
xte
nt 
of 
liv
er
 di
se
as
e, 
the
 ris
k o
f p
os
top
er
ati
ve
 co
mp
lic
ati
on
s 
inh
er
en
t in
 ea
ch
 pr
oc
ed
ur
e, 
an
d t
he
 ce
nte
r’s
 ex
pe
rtis
e. 
 
 (
Le
ve
l o
f E
vi
de
nc
e:
3;
 S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 W
ea
k)
 
Ta
bl
e 
3.
 S
um
m
ar
y 
of
 g
ui
de
lin
es
 fo
r s
yn
ch
ro
no
us
 c
ol
or
ec
ta
l c
an
ce
r a
nd
 li
ve
r-l
im
ite
d 
m
et
as
ta
se
s 
(c
on
t…
) 
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 I
ns
tit
ut
io
n 
Co
un
try
 
Gu
id
eli
ne
s 
Ye
ar
 
Su
m
m
ar
y o
f R
ec
om
m
en
da
tio
ns
 
Th
e F
re
nc
h 
Re
se
ar
ch
 G
ro
up
 o
f 
Re
ct
al 
Ca
nc
er
 
Su
rg
er
y (
GR
EC
CA
R)
 
an
d 
Fr
en
ch
 N
at
io
na
l 
So
cie
ty
 o
f 
Co
lo
pr
oc
to
lo
gy
 
(S
NF
CP
) 
Fr
an
ce
 
Ma
na
ge
me
nt 
of 
re
cta
l c
an
ce
r: 
the
 20
16
 F
re
nc
h 
Gu
ide
lin
es
[70
] 
20
16
 
 Th
er
e i
s n
o s
tan
da
rd
 m
an
ag
em
en
t fo
r p
ati
en
ts 
wi
th 
re
cta
l c
an
ce
r a
nd
 re
se
cta
ble
 sy
nc
hr
on
ou
s l
ive
r m
eta
sta
se
s. 
In 
the
 pr
es
en
ce
 of
 a 
mi
d o
r lo
w 
T3
/T
4 r
ec
tal
 ca
nc
er
 an
d/o
r N
+,
 su
rg
er
y w
ill 
be
 pr
ec
ed
ed
 by
 ch
em
oth
er
ap
y f
or
 th
e l
ive
r 
me
tas
tas
es
, fo
llo
we
d b
y r
ad
iot
he
ra
py
 or
 C
RT
. 
In 
the
 ca
se
 of
 an
 in
itia
lly
 re
se
cta
ble
 liv
er
 m
eta
sta
sis
, li
ve
r s
ur
ge
ry 
sh
ou
ld 
inc
lud
e a
 F
OL
FO
X-
ba
se
d r
eg
im
en
. In
 th
e c
as
e 
of 
po
ten
tia
lly
 re
se
cta
ble
 liv
er
 m
eta
sta
se
s, 
int
en
se
 ch
em
oth
er
ap
y i
nc
lud
ing
 ta
rg
ete
d t
he
ra
py
 sh
ou
ld 
be
 of
fer
ed
. 
In 
the
 ab
se
nc
e o
f s
tro
ng
 ev
ide
nc
e, 
the
 be
st 
cu
ra
tiv
e s
tra
teg
y i
s u
nk
no
wn
 an
d m
us
t b
e b
as
ed
 on
 a 
ca
se
-b
y- 
ca
se
 de
cis
ion
. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 U
nc
le
ar
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
 
Ex
pe
rt 
Gr
ou
p 
on
 
On
co
Su
rg
er
y 
m
an
ag
em
en
t o
f 
Li
ve
r M
et
as
ta
se
s 
Gr
ou
p 
(E
GO
SL
IM
) 
Int
er
na
ti
on
al 
Ma
na
gin
g 
sy
nc
hr
on
ou
s 
liv
er
 m
eta
sta
se
s 
fro
m 
co
lor
ec
tal
 
ca
nc
er
: A
 
mu
ltid
isc
ipl
ina
ry 
int
er
na
tio
na
l 
co
ns
en
su
s[3
1] 
20
15
 
Ch
em
oth
er
ap
y s
ho
uld
 be
 gi
ve
n p
re
op
er
ati
ve
ly 
un
les
s s
ur
ge
ry 
of 
the
 pr
im
ar
y a
nd
 LM
 is
 co
ns
ide
re
d e
as
y. 
Fo
r r
ec
tal
 
tum
ou
rs,
 pr
eo
pe
ra
tiv
e r
ad
iot
he
ra
py
 is
 a 
sta
nd
ar
d o
f c
ar
e, 
bu
t n
ot 
for
 hi
gh
 re
cta
l tu
mo
ur
s o
r T
2 t
um
ou
rs,
 an
d o
ne
-st
ag
e 
su
rg
er
y s
ho
uld
 no
t b
e p
er
for
me
d 
Fo
r c
olo
nic
 pr
im
ar
y t
um
ou
rs,
 on
e-
sta
ge
 su
rg
er
y i
s n
ot 
ad
vo
ca
ted
 fo
r t
um
ou
rs 
ne
ed
ing
 co
mp
lex
 su
rg
er
y, 
in 
hig
h-
ris
k 
pa
tie
nts
 or
 w
he
n h
ep
ate
cto
my
 w
ou
ld 
be
 m
ajo
r. 
Si
x m
on
ths
 of
 ch
em
oth
er
ap
y i
s r
ec
om
me
nd
ed
, in
de
pe
nd
en
tly
 of
 w
he
the
r 
giv
en
 pr
e-
 or
 po
sto
pe
ra
tiv
ely
. F
or
 bl
ee
din
g C
RC
, fo
llo
wi
ng
 tr
an
sfu
sio
ns
, p
re
op
er
ati
ve
 ch
em
oth
er
ap
y s
ho
uld
 be
 ad
vo
ca
ted
. 
Fo
r p
er
for
ati
on
s, 
re
se
cti
on
 of
 th
e p
rim
ar
y t
o r
em
ov
e t
he
 tu
mo
ur
 (r
igh
t c
olo
n)
 or
 su
tur
e o
r c
re
ati
ng
 a 
sto
ma
 (le
ft c
olo
n)
 is
 
ad
vo
ca
ted
. F
or
 pr
ov
en
 oc
clu
sio
n w
ith
 di
ste
nd
ed
 ev
ide
nc
e o
f o
bs
tru
cti
on
, r
es
ec
tio
n o
f th
e p
rim
ar
y s
ho
uld
 be
 pe
rfo
rm
ed
 
firs
t. F
or
 oc
clu
sio
ns
, s
ten
ts 
ar
e a
n o
pti
on
, b
ut 
re
su
lts
 ha
ve
 be
en
 po
or
. O
ne
-st
ag
e r
es
ec
tio
n i
s n
ot 
ap
pr
op
ria
te 
in 
all
 ca
se
s. 
W
he
n b
oth
 th
e p
rim
ar
y t
um
ou
r a
nd
 m
eta
sta
se
s a
re
 re
se
cta
ble
, s
im
ult
an
eo
us
 re
se
cti
on
 ca
n b
e p
er
for
me
d i
n s
ele
cte
d 
pa
tie
nts
 un
de
rg
oin
g l
im
ite
d h
ep
ate
cto
my
. A
 on
e-
sta
ge
 pr
oc
ed
ur
e i
s c
on
sid
er
ed
 m
or
e r
isk
y t
ha
n s
ep
ar
ate
 re
se
cti
on
s 
 (
Le
ve
l o
f E
vi
de
nc
e:
 S
ys
te
m
at
ic
 re
vi
ew
 / 
ex
pe
rt
 o
pi
ni
on
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 S
tr
on
g)
 
Ta
bl
e 
3.
 S
um
m
ar
y 
of
 g
ui
de
lin
es
 fo
r s
yn
ch
ro
no
us
 c
ol
or
ec
ta
l c
an
ce
r a
nd
 li
ve
r-l
im
ite
d 
m
et
as
ta
se
s 
(c
on
t…
) 
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 I
ns
tit
ut
io
n 
Co
un
try
 
Gu
id
eli
ne
s 
Ye
ar
 
Su
m
m
ar
y o
f R
ec
om
m
en
da
tio
ns
 
Ja
pa
ne
se
 S
oc
iet
y f
or
 
Ca
nc
er
 o
f t
he
 C
ol
on
 
an
d 
Re
ct
um
 (J
SC
CR
) 
Ja
pa
n 
Gu
ide
lin
es
 fo
r t
he
 
tre
atm
en
t o
f c
olo
re
cta
l 
ca
nc
er
[69
] 
20
14
 
If b
oth
 th
e d
ist
an
t m
eta
sta
se
s a
nd
 th
e p
rim
ar
y t
um
or
 ar
e r
es
ec
tab
le,
 cu
ra
tiv
e r
es
ec
tio
n o
f th
e p
rim
ar
y t
um
or
 is
 
pe
rfo
rm
ed
, a
nd
 re
se
cti
on
 of
 th
e d
ist
an
t m
eta
sta
se
s i
s c
on
sid
er
ed
. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 M
et
a-
an
al
ys
is
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 S
tr
on
g)
   
Co
m
pr
eh
en
siv
e 
Ca
nc
er
 C
en
tre
 th
e 
Ne
th
er
lan
ds
 (I
KN
L)
 
Ne
the
rla
nd
s 
Co
lor
ec
tal
 ca
nc
er
[61
] 
20
14
 
Si
mu
lta
ne
ou
s s
ur
ge
ry 
of 
the
 pr
im
ar
y t
um
ou
r a
nd
 sy
nc
hr
on
ou
s m
eta
sta
se
s i
s n
ot 
the
 st
an
da
rd
 in
 pa
tie
nts
 w
ith
 
sy
nc
hr
on
ou
s l
ive
r m
eta
sta
se
s. 
Th
e g
uid
eli
ne
 de
ve
lop
me
nt 
gr
ou
p i
s o
f th
e o
pin
ion
 th
at 
thi
s t
re
atm
en
t m
ay
 be
 
co
ns
ide
re
d a
fte
r c
ar
efu
l s
ele
cti
on
 in
 ce
ntr
es
 w
ith
 va
st 
ex
pe
rie
nc
e i
n b
oth
 co
lor
ec
tal
 su
rg
er
y a
nd
 liv
er
 su
rg
er
y. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 S
ys
te
m
at
ic
 re
vi
ew
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
  
 
Fe
de
ra
ció
n 
de
 
So
cie
da
de
s 
Es
pa
ño
las
 d
e 
On
co
lo
gí
a (
FE
SE
O)
 
Sp
ain
 
SE
OM
 C
lin
ica
l 
gu
ide
lin
es
 fo
r t
he
 
tre
atm
en
t o
f 
ad
va
nc
ed
 co
lor
ec
tal
 
ca
nc
er
 20
13
[60
] 
20
13
 
Co
lec
tom
y a
nd
 sy
nc
hr
on
ou
s o
r s
ub
se
qu
en
t li
ve
r r
es
ec
tio
n f
oll
ow
ed
 by
 po
sto
pe
ra
tiv
e c
he
mo
the
ra
py
. 
Pr
eo
pe
ra
tiv
e c
he
mo
the
ra
py
 fo
llo
we
d b
y s
yn
ch
ro
no
us
 or
 st
ag
ed
 co
lec
tom
y a
nd
 liv
er
 or
 lu
ng
 re
se
cti
on
, 
pa
rtic
ula
rly
 in
 pa
tie
nts
 w
ith
 bo
rd
er
lin
e r
es
ec
tab
le 
dis
ea
se
 an
d n
o i
mp
en
din
g c
om
pli
ca
tio
ns
 fr
om
 th
e p
rim
ar
y 
tum
ou
r (
i.e
. o
bs
tru
cti
on
, m
ajo
r b
lee
din
g)
. 
Co
lec
tom
y f
oll
ow
ed
 by
 po
sto
pe
ra
tiv
e n
eo
ad
juv
an
t c
he
mo
the
ra
py
 an
d a
 st
ag
ed
 re
se
cti
on
 of
 m
eta
sta
tic
 di
se
as
e. 
Ini
tia
l re
se
cti
on
 of
 th
e p
rim
ar
y t
um
ou
r is
 re
co
mm
en
de
d i
n p
ati
en
ts 
wi
th 
mo
de
ra
te 
or
 se
ve
re
 lo
ca
l s
ym
pto
ms
 su
ch
 
as
 ob
str
uc
tio
n o
r b
lee
din
g. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 U
nc
le
ar
 (e
xp
er
t r
ev
ie
w
); 
St
at
ed
 R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
  
 
Na
tio
na
l In
st
itu
te
 fo
r 
He
alt
h 
an
d 
Ca
re
 
Ex
ce
lle
nc
e (
NI
CE
) 
UK
 
Co
lor
ec
tal
 ca
nc
er
: 
dia
gn
os
is 
an
d 
ma
na
ge
me
nt 
(C
G1
31
)[6
7] 
20
11
, 
re
vis
ed
 
20
14
 
 
If b
oth
 pr
im
ar
y a
nd
 m
eta
sta
tic
 tu
mo
ur
s a
re
 co
ns
ide
re
d r
es
ec
tab
le,
 an
ato
mi
ca
l s
ite
-sp
ec
ific
 M
DT
s s
ho
uld
 
co
ns
ide
r in
itia
l s
ys
tem
ic 
tre
atm
en
t fo
llo
we
d b
y s
ur
ge
ry,
 af
ter
 fu
ll d
isc
us
sio
n w
ith
 th
e p
ati
en
t. T
he
 de
cis
ion
 on
 
wh
eth
er
 th
e o
pe
ra
tio
ns
 ar
e d
on
e a
t th
e s
am
e t
im
e o
r s
ep
ar
ate
ly 
sh
ou
ld 
be
 m
ad
e b
y t
he
 si
te-
sp
ec
ial
ist
 M
DT
s i
n 
co
ns
ult
ati
on
 w
ith
 th
e p
ati
en
t. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 S
ys
te
m
at
ic
 re
vi
ew
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
  
 
Ta
bl
e 
3.
 S
um
m
ar
y 
of
 g
ui
de
lin
es
 fo
r s
yn
ch
ro
no
us
 c
ol
or
ec
ta
l c
an
ce
r a
nd
 li
ve
r-l
im
ite
d 
m
et
as
ta
se
s 
(c
on
t…
) 
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 I
ns
tit
ut
io
n 
Co
un
try
 
Gu
id
eli
ne
s 
Ye
ar
 
Su
m
m
ar
y o
f R
ec
om
m
en
da
tio
ns
 
Sc
ot
tis
h 
In
te
rc
ol
leg
iat
e 
Gu
id
eli
ne
s 
Ne
tw
or
k (
SI
GN
) 
UK
 
SI
GN
 12
6 -
 D
iag
no
sis
 
an
d m
an
ag
em
en
t o
f 
co
lor
ec
tal
 ca
nc
er
[66
] 
20
11
, 
re
vis
ed
 
20
16
 
 10
.2.
1. 
Su
rg
ica
l re
se
cti
on
 sh
ou
ld 
be
 co
ns
ide
re
d f
or
 al
l p
ati
en
ts 
wi
th 
re
se
cta
ble
 liv
er
 m
eta
sta
se
s. 
Pa
tie
nts
 w
ith
 re
se
cta
ble
 liv
er
 m
eta
sta
se
s s
ho
uld
 be
 co
ns
ide
re
d f
or
 pe
rio
pe
ra
tiv
e c
he
mo
the
ra
py
 w
ith
 a 
co
mb
ina
tio
n 
of 
ox
ali
pla
tin
 an
d 5
-F
U/
leu
co
vo
rin
 fo
r a
 to
tal
 pe
rio
d o
f s
ix 
mo
nth
s. 
 (
Le
ve
l o
f E
vi
de
nc
e:
 3
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
 
No
rth
er
n 
Ire
lan
d 
Ca
nc
er
 N
et
wo
rk
 
(N
IC
aN
) 
UK
 
Re
gio
na
l C
olo
re
cta
l 
Ca
nc
er
 N
etw
or
k 
Gu
ide
lin
es
 fo
r t
he
 
Ma
na
ge
me
nt 
of 
Co
lor
ec
tal
 C
an
ce
r[6
5] 
20
12
 
 8.2
. R
ad
ica
l s
eg
me
nta
l re
se
cti
on
 w
ith
 po
st-
op
er
ati
ve
 ch
em
oth
er
ap
y a
nd
 st
ag
ed
 re
se
cti
on
 of
 m
eta
sta
se
s 
Ra
dic
al 
se
gm
en
tal
 re
se
cti
on
 w
ith
 si
mu
lta
ne
ou
s r
es
ec
tio
n o
f m
eta
sta
se
s 
 (
Le
ve
l o
f E
vi
de
nc
e:
 U
nc
le
ar
; S
ta
te
d 
R
ec
om
m
en
da
tio
n:
 N
ot
 s
ta
te
d)
 
Am
er
ica
n 
So
cie
ty
 o
f C
ol
on
 
an
d 
Re
ct
al 
Su
rg
eo
ns
 
 
US
A 
Pr
ac
tic
e P
ar
am
ete
rs 
for
 
the
 M
an
ag
em
en
t o
f 
Co
lon
 C
an
ce
r[7
1] 
20
12
 
Th
e t
re
atm
en
t o
f p
ati
en
ts 
wi
th 
re
se
cta
ble
 m
eta
sta
tic
 co
lon
 ca
nc
er
 sh
ou
ld 
be
 in
div
idu
ali
ze
d a
nd
 de
ter
mi
ne
d b
y 
mu
ltid
isc
ipl
ina
ry 
co
ns
en
su
s. 
W
he
n t
he
 m
eta
sta
tic
 di
se
as
e i
s p
ote
nti
all
y r
es
ec
tab
le,
 re
se
cti
on
 of
 th
e p
rim
ar
y t
um
or
 
sh
ou
ld 
be
 co
mp
let
e a
nd
 ra
dic
al 
co
ns
ist
en
t w
ith
 on
co
log
ica
l p
rin
cip
als
 of
 re
se
cti
on
 fo
r lo
ca
liz
ed
 di
se
as
e a
s p
re
vio
us
ly 
ou
tlin
ed
 in
 th
is 
do
cu
me
nt.
 In
 ge
ne
ra
l, m
ed
ica
lly
 fit
 pa
tie
nts
 w
ith
 re
se
cta
ble
 he
pa
tic
 an
d/o
r p
ulm
on
ar
y m
eta
sta
se
s w
ill 
be
ne
fit 
fro
m 
cu
ra
tiv
e r
es
ec
tio
n o
f th
e m
eta
sta
se
s. 
Th
e s
eq
ue
nc
e o
f c
he
mo
the
ra
py
, r
es
ec
tio
n o
f th
e p
rim
ar
y t
um
or
, 
an
d r
es
ec
tio
n o
f m
eta
sta
sis
 sh
ou
ld 
be
 in
div
idu
ali
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2.3.3 Discussion of Guidelines Review 
This review explores the scope and quality of current clinical guidelines for the surgical management 
of synchronous colorectal cancer and liver-limited metastases. The range of the guidance currently 
available is somewhat vague and limited, reflecting the lack of research evidence in this area to inform 
current practice. There are no recommendations to guide surgical strategy on whether bowel-first or 
liver first or synchronous resection is the optimal treatment, either in general or in specific subgroups. 
It is accepted that modern management of this complex clinical scenario cannot be addressed by a 
single pathway given the range of patient and disease factors which are currently poorly understood. 
For example, there is no detailed system for stratifying the extent of liver resection required, or how 
patient fitness influences the treatment pathway. Most of the guidelines in the review provide broad but 
constrained management options, including the early use of neoadjuvant chemotherapy and surgical 
resection as well as adjuvant chemotherapy in the final stage, based on limited randomised controlled 
trial evidence[1].  
The AGREE-II instrument may be more challenging to use in areas of healthcare where there is limited 
research evidence to formulate guidance, such as synchronous colorectal cancer and liver-limited 
metastases. It is incorrect to conflate poor evidence with poor guidance, and the conclusion that the 
clinical guidance for synchronous disease is generally poor may not be accurate. However, there 
exists considerable variation in defining the patient population (‘synchronous’) and the search 
methodology to obtain the research evidence. Using the evidence to formulate recommendations 
remains subjective when robust objective evidence is lacking, and there is significant variation of 
opinion in defining strong and weak recommendations. Some groups, such as the French Research 
Group of Rectal Cancer Surgery and French National Society of Coloproctology, were very upfront in 
their assessment of the research evidence, concluding that “in the absence of strong evidence, the 
best curative strategy is unknown and must be based on a case-by-case decision” and make no 
attempt at providing recommendations for surgical strategy[70]. 
The majority of the guidelines were developed without patient or public consultation, suggesting a 
‘paternalistic’ approach by developers. NICE recommends using the patient experience to inform 
review questions when developing clinical guidelines[73]. The WHO also recommends that the values 
of patients affected should be taken into consideration when forming guidelines[74]. Many of the 
guidelines reviewed advocate patient involvement in the management of their disease, but the 
systematic reviews from the guidelines provide little insight into factors that are important to patients. 
The next section will explore the literature for themes that are important to patients, their families and 
the clinicians responsible for their care.  
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2.4 Systematic Review of Patient Experiences and Clinician Attitudes 
In modern medicine where patient autonomy is central to healthcare, the patient involvement with the 
decision-making process of their disease management is essential. The traditional model of the 
doctor-patient relationship varies between paternalistic and informative, although it has been shown 
that most patients want to be informed about their disease and management plan, and a smaller 
proportion wanting active participation in the decision-making process[75]. The ‘ethical grid’ developed 
for clinicians making decisions in complex clinical scenarios described by Seedhouse and Lovett [76] 
includes the degree of certainty of the evidence on which action is taken as an important facet for 
consideration. In the area of synchronous colorectal cancer and liver-limited metastatic disease where 
the evidence guiding the treatment pathway is limited, the effect on patient participation in the 
decision-making process is unclear. It has been suggested that although cancer patients actively 
sought information about their diagnosis and management, the majority preferred the doctor to make 
decisions about their care[77]. More recent studies, however, have shown that the majority of cancer 
patients now preferred shared-decision making[78]. 
This section focuses on the patient perception of their disease, decisions about their management, 
and themes that are important to patients and their families. 
 
2.4.1 Methods / Search Strategy 
Design 
This systematic review of the published literature explores the themes important to patients with 
synchronous colorectal cancer and liver metastases was carried out. The review focuses on the 
perception of disease, decision-making process behind the management of synchronous disease, and 
also the patient and caregiver experiences. A study design reviewing qualitative studies only was 
chosen as the best method to explore patient perspectives. Clinical studies reporting objective clinical 
outcome measures are usually predetermined by the researcher, and do not consistently correlated 
with patient reported outcomes[79].  
Literature Search Strategy 
Both PubMed and OvidSP databases (encompassing Embase and MEDLINE) was queried for 
relevant articles from April 1997 to April 2017. The search strategy is shown in Table 13. The search 
terms chosen were broader than for the systematic review of surgical management in order to capture 
more studies reporting patient experiences of colorectal liver metastatic disease. The MESH and text 
search terms included: colorectal cancer, liver metastases, surgery/treatment, and 
phenomenological/qualitative studies which were combined with Boolean AND and OR operators.  
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Data Extraction 
Data from the included reports were independently extracted by two reviewers (AC and AI). 
Disagreements were resolved by consensus or by consultation with the senior reviewers (AKS and 
JM). 
Analysis 
The common themes drawn out from the qualitative studies identified were extracted, with a particular 
focus on the decision-making process of their management.   
 
2.4.2 Results 
The search strategy (detailed in Table 13) identified 203 unique citations of which 9 articles were 
assessed by full-text for eligibility. Of these, 7 articles were excluded as they did not include a 
qualitative component to the study, and 1 study was excluded whose primary focus was on patients 
with metastatic colorectal cancer who had undergone liver transplantation. In total, 1 article fulfilled the 
criteria for the systematic review. A PRISMA flow diagram of the systematic review is shown in Figure 
5. 
 Search Terms No. of Articles 
#6 #1 AND #2 AND #3 AND #4 AND #5 203 
#5 phenomen* OR (grounded theory) OR qualitative OR social OR ethno* OR interview 1,899,679 
#3 Surgery OR surgical OR treatment OR decision 11,409,340 
#2 ((liver AND metastas*)) OR (liver AND metastat*) 64,909 
#1 colorectal OR colon OR rectum OR rectal 396,542 
* denotes a search string wildcard character 
Table 13. Ovid Search Strategy 
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Figure 5. PRISMA flow diagram for Systematic Review into Patient and Clinician Perspectives on 
synchronous disease 
Demographic profile 
The phenomenological study by McCahill and colleagues[80] included 12 patients (7 men and 5 
women) between the ages of 43 and 75 years who had undergone treatment for colorectal cancer and 
liver metastatic disease. Of these, 10 patients were diagnosed with colonic cancer and 2 with rectal 
cancer. The timing of the diagnosis of the hepatic metastatic disease is not published, although the 
authors state “metastases were generally identified by clinicians through disease surveillance”. All 
patents received systemic chemotherapy as part of their treatment. At the time of the study, only 3 
patients had residual metastatic disease, with 9 patients having no evidence of disease.  
Interviews 
In total, 7 themes were identified through structured, in-depth interviews conducted by researchers 
vising the patient’s homes between July 2005 and August 2006. The interview guide was divided into 
three sections (before and after the surgical consultation, and the postoperative period), with prompts 
focusing on patient’s treatment journey, the understanding of their disease and expectations from 
healthcare providers and their role in the decision-making process of their treatment. The researchers 
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commented that patients perceived their liver surgery as one of several ‘battles with cancer’, and that 
the option for liver surgery was introduced to the patient through their oncologist. The patients 
interviewed held realistic beliefs about liver surgery, including the risks of surgery and potential 
recurrence of disease, leading patients to view liver surgery as an ‘opportunity to extend life’. 
Theme 1 – Communication with the Health Care Provider 
Patients described communication with their surgeon, oncologist and/or specialist nurse as the main 
factor for influencing their treatment decisions and appreciated the frank discussions about the risks of 
surgery and the potential outcomes. Patients also valued discussions between physicians and their 
relatives, and also when different specialists agreed with each other’s management plans. Patients 
described a bad experience if these consultations were hurried or if they were ‘told what to do’.  
Theme 2 and 3– Support from Others, and The Patient’s Own Attitude 
All the patients interviewed appreciated the importance of a good support system provided by relatives 
and friends, as well as co-workers and the religious groups they belonged to. Patients valued the 
encouragement provided by this support network during and after their treatments but did not 
appreciate when others tried to influence their treatment decisions. Universally, patients recognised 
that a positive attitude is important in reconciling with their disease.  
Theme 4 – Cure Uncertainty 
All patients recognised the uncertainty of surgery or chemotherapy to cure their disease, with liver 
surgery in particular providing only the potential to extend life expectancy. Most patients interviewed 
could not recall the statistics on the risks of surgery or recurrence quoted to them by their surgeon but 
were willing to undergo liver surgery. Interestingly, patients did not regret their decision to undergo 
surgery despite eventually developing an unresectable recurrence. 
Theme 5 – Coping Strategies 
Patients described a variety of coping strategies both during the decision-making process of their 
treatment and their entire treatment journey. Some patients described facing the disease being made 
easier by learning as much as possibly about their disease and stopping worrisome thoughts so as to 
be able to make more rational decisions. 
Theme 6 – Hospital Care Concerns 
Several patients interviewed described the overall impression of the quality of care during a hospital 
stay as an important factor in their treatment journey, for example, the perceived inadequate number 
of nurses on the ward. In particular, communication (or the lack of communication) provided a very 
negative patient experience.  
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Theme 7 – Internet Information 
Patients described the lack of information available on the Internet and clinical articles detailing poor 
prognosis to being particularly negative influences on their treatment journey. 
 
2.4.3 Discussion 
Whilst a number of studies have published the clinical outcomes for patients with synchronous 
colorectal cancer and liver metastases, there is currently a lack of studies exploring the patient’s 
perspective on both disease and of the decision-making process. Our systematic review identified only 
one such study published nearly a decade ago, since which there has seen a major shift in the 
paradigm of treatment in synchronous colorectal cancer and liver metastatic disease. Despite this 
limitation, the study reviewed is the first qualitative study broadly exploring the experiences of patients 
who have undergone liver resection for metastatic colorectal cancer. This study draws out the aspects 
of care that are important to this patient cohort, including good and frank communication about their 
disease with their physician, and providing patient autonomy to the decision-making process. 
Agreement amongst the specialists involved in their care as to the best management plan also 
provides confidence to patients in the subsequent treatment. The study also finds that patients have a 
realistic expectation about the treatments offered for their disease. One limitation of the study is that 
there was no focus on synchronous colorectal cancer with liver-limited metastases. As such, there was 
no exploration of patient views on the decision making of treatment, or the clinician’s experiences or 
views of disease management. For patients with synchronous colorectal cancer and liver-limited 
metastatic disease, there are a number of treatment options available to them and there is an ethical 
imperative to inform and understand patient values prior to constructing mutual treatment plans. For 
synchronous colorectal liver disease, research characterising the clinical-patient interaction and 
exchange is currently in its infancy.  
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2.5 Summary of Current Knowledge and Aims of Thesis 
Synchronous colorectal cancer and liver-limited metastatic disease represents a complex 
management problem. The current chapter has discussed the clinical outcomes for patients with 
synchronous disease who undergo surgery to remove both the primary colorectal tumour and liver 
metastatic disease. There is currently no randomised controlled trial evidence to guide treatment 
selection. The pooled data from the 3 retrospective cohort studies that make up the systematic review 
showed no significant difference between bowel-first, liver-first and synchronous surgical strategies in 
peri-operative outcomes, as well as oncological outcome and overall survival, but were not formally 
designed to quantify differences, after adjusting for patient characteristics. The current chapter has 
also discussed the current clinical guidelines for the management of synchronous disease, where, 
consistent with the review of evidence, there is limited scope to provide robust recommendations for 
the sequence of surgery. Finally, the understanding of the patient’s perspective in synchronous 
colorectal cancer and liver metastases is also limited as there have been no studies exploring the 
patient’s views and perceptions in synchronous disease. Insight into the patient’s perspective is crucial 
given the increasing role patient participation and shared decision-making plays in all aspects of 
healthcare and research.  
 
2.6 Aims and Objectives 
To develop the current evidence base and understanding, the CoSMIC inception cohort study has 
been designed to provide for the first time comparable outcome data on patients with colorectal cancer 
with liver-limited metastatic disease treated by synchronous or sequential surgery. Working to a 
prospective analysis plan, an exploratory analysis of the data will be performed by applying a 
hypothesis generating rather than hypothesis testing framework. Completion of the CoSMIC study 
protocol will provide important new evidence about the treatment of patients with colorectal cancer with 
synchronous liver-limited metastases and provide objective evidence to guide future research 
(including randomised evaluations) in this area. 
In tandem, the CoSMIC-Q study has been designed to address for the first time in a structured 
prospective fashion: 
• patient values and preferences concerning treatment  
• the role of the patient voice in decision-making 
• clinician experiences of management and decision-making 
• clinician areas of equipoise in the treatment pathway 
• patient and clinician views about future research, including participation in trials 
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CoSMIC-Q is a qualitative phenomenological study that recruits patients from within the CoSMIC 
inception cohort study of patients with colorectal cancer and synchronous liver metastases. The aim of 
the CoSMIC-Q qualitative study is to explore the patient experience of treatment by the different 
synchronous or sequential treatment pathways. The methods of the CoSMIC studies are described in 
the next chapter. 
  
58
  
 
3. METHODS OVERVIEW 
3.1 CoSMIC Inception Cohort Study 
 
3.1.1 Study Design 
An inception cohort study was designed to evaluate the treatment and outcomes of patients with 
colorectal cancer with synchronous liver-limited hepatic metastases. Patients were followed from 
inception (diagnosis) and were identified prospectively and retrospectively creating a mixed cohort 
design. 
 
3.1.2 Setting 
The study population comprised of patients diagnosed with synchronous colorectal cancer and liver-
limited hepatic metastases referred to the Hepatobiliary Surgical Unit at Manchester Royal Infirmary 
(MRI) - a National Health Service (NHS) regional cancer-network approved hepato-pancreato-biliary 
(HPB) centre with a formally constituted and National Cancer Network peer-review accredited 
multidisciplinary team (MDT). The following local NHS Trusts to which MRI provided an HPB tertiary 
service included: 
• Bolton Hospitals NHS Foundation Trust 
• Christie NHS Foundation Trust 
• East Cheshire NHS Trust 
• Mid Cheshire Hospitals NHS Trust 
• Pennine Acute Hospitals NHS Trust (comprising the Royal Oldham Hospital and North 
Manchester General Hospital) 
• Salford Royal NHS Foundation Trust 
• Stockport NHS Foundation Trust 
• Tameside Hospitals NHS Foundation Trust 
• Wrightington, Wigan and Leigh NHS Foundation Trust 
• University Hospital of South Manchester NHS Foundation Trust 
 
3.1.3 Identification of potential participants and consent process 
Potential participants were identified at the colorectal and HPB MDTs at MRI. A case note review was 
performed to ensure the potential participant fulfilled the inclusion and exclusion criteria of the study. 
Patients were approached in the outpatient clinic following their consultation with the clinical parent 
team. For patients where trial eligibility was less apparent (for example, if staging to exclude systemic 
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disease was not yet been undertaken), the patient was asked about their interest in the study by their 
own consultant. If the patient expressed an interest, the clinical team informed the research team, and 
the first approach was made by an individual from the research team. As the study involved elective 
(planned or non-emergency) interventions, there was no restriction in the amount of time allocated for 
patients to consider participation, to discuss with relatives or use the clinical contact numbers 
provided. Patients were given opportunity to discuss the study with clinicians knowledgeable about the 
protocol but who were not involved in the study. Informed consent was obtained before enrolment and 
will include permission to access patient data for research purposes during the study and for up to 10 
years from recruitment, including survival data (from demographics batch services). 
Prior to the CoSMIC study, a prospective audit of the care of patients with colorectal cancer and 
synchronous liver-limited metastases approved by the Central Manchester Foundation Trust audit 
department (Registration No. 4929) was completed at MRI. Data were collected on a proforma 
identical to that of the current CoSMIC study proforma, with the exception of Quality of Life data. The 
precursor audit was run to establish the feasibility of collection of the clinical outcome data fields in the 
CoSMIC study. The data collected covered exactly the same data fields, with baseline demographics 
of these patients being compared with that of prospective patients once recruitment was completed. If 
the two patient populations are similar statistically, by design pre-CoSMIC audit data and the main 
CoSMIC dataset would be amalgamated to provide a larger retrospective and prospective cohort. For 
patients identified in the pre-CoSMIC audit, no patient contact was necessary in order to incorporate 
outcome data from the precursor dataset and patients were not specifically be contacted for consent.   
 
3.1.4 Participants 
Potential participants identified at the MDT were patients with colorectal cancer and liver-limited 
metastatic disease at the time of diagnosis of the primary tumour, or within 3 months. Patients who 
have already started the treatment pathway (for example, a bowel-first surgical strategy following an 
emergency presentation of bowel obstruction or perforation) were also included, but not for those 
patients who have undergone both bowel and liver resection (for example, a case discussion for 
tumour recurrence). Currently, there is no consensus on the definition of ‘synchronous’ colorectal 
cancer and liver metastasis. The mean time period between the diagnosis of the colorectal primary 
and the liver metastatic disease in the studies listed in Table 1 is 3.1 months. Therefore, a cut-off 
period of 3 months for the diagnosis of liver metastasis was chosen as this would allow adequate time 
for the completion of staging investigations within an NHS service setting prior to any elective surgical 
treatment.   
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In order to be eligible for inclusion into the CoSMIC study, patients fulfilled the following criteria. 
Inclusion criteria 
1. At least 18 years of age 
2. Able to give informed consent 
3. Have a histological diagnosis of colorectal cancer 
4. No prior history of malignancy 
5. Have radiological evidence either on contrast-enhanced CT or contrast-enhanced MR 
scanning of hepatic metastatic disease at the time of diagnosis of the primary tumour or 
within 3 months thereof. Liver biopsies should not be taken to confirm the diagnosis due to 
the risk of tumour seeding 
6. CT and/or [18F]Fluorodeoxyglucose positron emission tomography / computed tomography 
([18F]FDG PET/CT) evidence of the absence of extrahepatic metastatic disease 
7. MR scan assessment of local stage in those patients with rectal primary tumours 
8. WHO performance status 0, 1 and 2 and considered by the MDT to be suitable for surgery 
and systemic chemotherapy 
Exclusion criteria 
1. Under 18 years of age 
2. Unable to give informed consent 
3. Unfit for chemotherapy regimens in this protocol 
4. Any psychiatric or neurological conditions assessed by clinical judgement to compromise the 
patient’s ability to give informed consent or to comply with oral medication 
5. Partial or complete bowel obstruction that is not amenable to resolution by endoscopic 
stenting or surgical diversion 
6. Pre-existing neuropathy (>grade 1) 
7. Another current or previous malignant process 
8. Previous chemotherapy with oxaliplatin 
9. Known hypersensitivity reactions to any of the components of the study treatments 
10. Distant extrahepatic metastatic disease 
11. A personal or family history suggestive of dihydropyrimidine dehydrogenase (DPD) deficiency 
or with known DPD deficiency 
 
3.1.5 Variables 
Patient demographics at the time of diagnosis (age and sex) was recorded as well as co-morbidity. 
The Charlson Comorbidity Index was used to assess co-morbidity as it has previously been validated 
in the prediction of co-morbidity and mortality in patients undergoing surgery for colorectal cancer[81].  
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The following variables were also collected during the course of the participant’s treatment journey. 
I. Baseline staging investigations:  Baseline staging was recorded: this should include tests for 
histological confirmation of cancer such as biopsy-confirmation of a diagnosis of primary 
colorectal cancer (from the primary and not from the metastasis); tests for assessment of the 
liver and colorectal cancer in terms of lesion size, number, nodal involvement: contrast-
enhanced CT scan and/or contrast-enhanced MR scan of the liver and pelvis and tests for 
assessment of the presence or absence of extra-hepatic metastatic disease such as 
[18F]FDG PET/CT and serum assay of carcino-embryonic antigen (CEA).  All of these tests 
are currently components of standard clinical care and no additional tests were undertaken 
for research purposes. 
II. Predictors of treatment allocation:  Factors which guide clinical decision-making in terms of 
the use of neoadjuvant chemotherapy and the choice of intervention (synchronous or 
sequential surgery). 
III. Timelines for completion of the treatment protocol. This is defined as the amount of time in 
days from enrolment to completion of the protocol. For purposes of this study, the term 
’protocol’ relates to completion of the common treatment pathway. Milestones during the 
treatment protocol, such as the time to surgery and duration of systemic chemotherapy were 
also recorded. 
IV. Failure to complete the treatment protocol. This is defined as drop-out prior to completion of 
the allocated treatment sequence. It was further categorised as due to disease progression, 
patient choice or unrelated to colorectal cancer (for example myocardial infarction) and was 
recorded as the time in days from enrolment.  
V. Study outcomes, including a range of objective and subjective health-related outcomes:  
• Disease-free survival 12 months after enrolment into protocol. This is defined as the 
absence of tumour on a CT scan of the thorax, abdomen and pelvis undertaken at the 
completion of the protocol. In the case of those patients with rectal tumours treated by a 
’watch and wait’ policy, the term disease-free can only be applied if there is a 
combination of radiological, endoscopic and clinical evidence of absence of cancer.  
• Disease progression in patients who are not disease-free at the end of protocol. 
The most sensitive measure of change is likely to involve a metric incorporating tumour 
size and number of lesions in the case of multiple metastases. Reporting was via 
RECIST criteria[82]. There is, however, evidence that CT-based volumetric assessment 
of metastases (seeded region growing method, slice-based segmentation or threshold-
based segmentation) is more accurate for assessment of disease progression than the 
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RECIST 1.1 method of largest axial diameter[83]. It is acknowledged that although 
RECIST criteria provide an objective means of assessment of solid tumour response to 
treatment, there is a risk of inter-observer bias[84]. Further, RECIST criteria may be 
insufficient to assess response to treatment in patients with colorectal liver metastases 
treated by biologic agents such as bevacizumab[85]. Thus, disease progression at end of 
protocol was assessed both by RECIST 1.1 criteria and volumetric assessment. 
• Resection margin status. R0 bowel resection and R0 liver resection (no residual cancer 
status after colorectal resection and after liver resection). 
• Complication and treatment-related morbidity profiles. Complications were recorded 
prospectively according to the criteria defined above (see treatments) and assessed at 
the end of the study. Operative outcomes were reported in keeping with the Dindo-
Clavien system of assessment of post-operative morbidity[50]. The specific post-
hepatectomy complications of haemorrhage[86], bile leakage[87] and liver failure[87] 
were recorded in compliance with the guidance of the International Study Group of Liver 
Surgery. The morbidity associated with each intervention step were recorded separately. 
Morbidity included unplanned re-admission and re-operation. Requirement for non-
elective surgery for colonic complications (obstruction, perforation, bleeding) was 
recorded.  
• Mortality. Overall and cancer-related mortality in either arm after enrolment was 
recorded.  Mortality (and cause) was determined using the Demographics Batch Service 
(DBS) to access the national electronic database of the UK NHS (National Health 
Service).  
• Avoidance of stoma after colorectal surgery. Use of a defunctioning stoma (either 
temporary or permanent) was recorded, as well as details of stoma reversal following 
oncological treatment  
• In-patient and critical care occupancy. A record was made of in-patient and critical 
care occupancy associated with interventions; findings may inform planning of economic 
evaluation in any subsequent randomised trial. 
• Quality of life. QoL was assessed using the European Organization for Research and 
Treatment of Cancer QLQ-LMC questionnaire, which has been validated for assessment 
of patient-reported outcomes during treatment of colorectal liver metastases[88]. The 
questionnaire was completed by patients at time of enrolment and at 12 and 24 months. 
The EuroQoL EQ5D-3L[89] was also completed at the same time points, again 
supporting the design of future trial-based economic analyses.  
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3.1.6 Data sources and measurements 
Data was collected prospectively using study clinical case report forms. These were anonymised for 
electronic storage and analysed prospectively during the study to maximise data completion and 
resolve emergent problems in a timely fashion. The principal source of data was the individual patient 
records. Vital status beyond the duration of the study was determined through the Demographics 
Batch Service of the NHS.  Data was reported at the end of year 3 allowing for a minimum 12 months 
outcome data in the entire cohort. It was also proposed (contingent on separate funding) that 
information on outcome will be collected for up to 10 years from study commencement, providing an 
informative survival analysis of treatment options. 
For patients who wished to enrol into CoSMIC but where the treatment pathway had already started 
(typically those who presented with an acute abdomen secondary to the bowel lesion), we 
retrospectively collected data on treatment already received. Retrospective data collection may involve 
the following local NHS Trusts to which Central Manchester Hospitals NHS Foundation Trust provides 
an HPB tertiary service: 
• Bolton Hospitals NHS Foundation Trust 
• Christie NHS Foundation Trust 
• East Cheshire NHS Trust 
• Mid Cheshire Hospitals NHS Foundation Trust 
• Pennine Acute Hospitals NHS Trust 
• Salford Royal NHS Foundation Trust 
• Stockport NHS Foundation Trust 
• Tameside Hospitals NHS Foundation Trust 
• Wrightington, Wigan and Leigh NHS Foundation Trust 
• University Hospital of South Manchester NHS Foundation Trust 
 
3.1.7 Bias 
The following potential sources of bias were identified. 
I. Referral bias: Although MRI is the only designated HPB MDT for the network, patients could 
be referred out of network. It was not possible to estimate the proportion of study-eligible 
patients thus referred but it was thought that numbers would be small. Details of these 
patients were included in an exclusion log with basic data being recorded including reason for 
transfer out of network where possible. Nevertheless, this remains a potential limitation to the 
inclusiveness of findings if particular patients (e.g. the most or least severe) were excluded 
due to referral. 
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II. Ascertainment bias: Inadequate baseline staging (in particular, inadequate assessment of 
extra-hepatic metastatic disease) might result in patients with apparently synchronous 
disease without extra-hepatic metastatic disease having poorer survival than predicted. 
III. Confounding: As this was an inception cohort study, outcomes might be influenced 
systematically by a range of factors in addition to treatments provided. Examples included 
clinician preferences, which may affect the spectrum of patients undergoing different 
treatments in the pathway or differing clinical competencies which might confound outcomes.  
The design permitted consistent ascertainment of a panel of objective and subjective 
variables with which to reduce the threat of confounding. It is not anticipated that this study 
(due to its size) would provide definitive evidence for treatment but would be hypothesise 
generating for a subsequent trial or other research, thus obviating clinical over-interpretation 
of study findings. 
 
3.1.8 Study Size 
Based on clinical registers, the HPB unit at the MRI sees approximately 75 patients with colorectal 
cancer with synchronous liver-limited hepatic metastases per annum.  As there are no study-related 
interventions, recruitment rates were predicted to be high and drop-out low and is estimated to provide 
150 patients in the two-year recruitment period.  A formal power calculation was not performed for this 
inception cohort study as CoSMIC is a hypothesis-generating study rather than a test of hypothesis. 
Instead, the sample size was informed by the need to provide stable estimates of variance for a range 
of outcomes; explore the relationship between the treatment pathway and health outcomes; estimate 
acceptability and recruitment rates; and describe patient and clinician experiences. 
3.1.9 Analysis Plan and Statistical Methods 
The care of patients within the study pathway was characterised by their principal treatment route as 
synchronous, liver-first or bowel-first. All patients with data provided outcomes included within 
analyses, grouped according to the treatment sequence received. Complication profiles in patients 
according to treatment group were reported. Summary characteristics of patients, patient care 
provided, and patient outcomes were reported. Analyses were conducted to a prospectively agreed 
analysis plan. Given the exploratory nature of the analysis and multiplicity of comparisons, a 
hypothesis generating (rather than testing) framework was applied, where statistical significance 
(arbitrarily at 5%) was viewed as a marker of potential interest for further enquiry. Exploratory analysis 
of process and clinical outcomes was undertaken to explore the influence of patient, clinician, centre 
and treatment covariates, using appropriate regression methods. The primary aim is to contrast 
survival of patients according sequence of care received (Kaplan Meier, log rank test) adjusting for 
prognostic co-variants (Cox regression). Model building followed a prospectively agreed forward 
stepwise process. All analyses were performed in Stata 15.1 (StataCorp LLC).  
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3.1.10 Patient/Participant Involvement 
i) Origination of study: 
The question of optimal management for patients with bowel cancer with synchronous liver metastatic 
disease originated from a patient (DL) in August 2008. This individual presented with a rectal primary 
tumour with synchronous liver metastases and was concerned at the lack of evidence to guide 
management. After discussion, he underwent synchronous right hepatectomy and anterior resection, 
but experienced considerable post-operative morbidity related to the synchronous nature of the 
operation. He remains alive and disease-free at 5 years after resection (but after two further liver 
resections) and has informed the design of this protocol, the incorporation of synchronous surgery into 
the management of synchronous disease and the important outcomes.  DL is familiar with the final 
version of this protocol. A second patient (NR) who presented with synchronous disease in 2010 also 
contributed to the development of the study. He underwent liver-first surgery because of anxieties 
about metastasis and emphasised that although this aspect is referred to in the protocol as ’new‘ – 
liver first surgery is in widespread clinical use. 
ii) Qualitative information from discussion with patients who are survivors of synchronous 
disease: 
The MRI HPB service held “listening events” to ascertain views on the service from patients who have 
been through the system. Although the focus of these events is general and broad-based at the last 
two meetings, patients’ opinions were sought on synchronous surgery.  Some of these patients had 
undergone synchronous surgery whilst others had undergone sequential surgery.  Discussions were 
outlined by the PI (AKS) but without further participation.  Information was gleaned from one-to-one 
conversations between patients and other members of the HPB team (such as our cancer nurse 
specialist) who then reported the following: 
• There is a lack of information on current websites (such as that of Cancer Research UK) on 
how best to treat patients who have bowel cancer with liver metastases 
• Having chemotherapy first seems a good idea.  [This was not the standard of care in the MRI 
as the ESMO guidelines are relatively recent and thus the majority of patients having liver-first 
would have had liver resection as their first intervention.  These individuals thought that there 
was sense in a short course of chemotherapy first to “treat” the disease elsewhere in the body 
before liver resection at the expense of a chemotherapy-associated liver injury].  This point 
was incorporated into the protocol 
• If possible, it would be better to have synchronous surgery unless this type of operation is 
riskier 
• If the liver acts as a filter to stop tumours spreading and if they spread to the rest of the body 
from here, it might be risky to have the bowel surgery first 
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3.1.11 Withdrawal from the Study 
Patients were able to withdraw from the study at any point. Data collected up to point of withdrawal 
were retained for use within analyses. 
 
3.1.12 Quality Control Measures 
1. Colorectal cancer cases and patients with liver metastases had their care discussed at an 
appropriately constituted, UK cancer-network approved multidisciplinary team meeting (MDT)  
2. Quality control in radiological images. Cross-sectional imaging complied with the 
recommendations for cross-sectional imaging in cancer management of the Royal College of 
Radiologists[90] 
3. Quality control in histopathological reporting. All histopathology reporting complied the 
guidelines of the Royal College of Pathologists[11] 
 
3.1.13 Health Service Cost of the Study 
The clinical pathways within this study are broadly cost neutral to the NHS as all the component steps 
are a part of current best practice. The study provided a structured template for progression through 
this pathway, but all components were currently best standard care with scientific and clinical 
equipoise are likely to be maintained subsequently.  It would be possible to explore determinants of 
resource use within the common pathway as a study outcome, as there may be differential completion 
of pathways according to the sequence of treatment received by patients, leading to variation in 
resources. For example, patients undergoing liver first surgery followed by chemotherapy may 
subsequently not require colorectal surgery if there is complete response to chemotherapy. Although 
not formally exploring resources, completion of pathways and sequence of treatment is reported.  
 
3.1.14 Adverse Event Reporting 
Adverse events were recorded, assessed for severity and attribution, and reported in line with 
European Directive 2001/20/EC. In addition, if the Quality of Life assessment indicated that a patient 
was experiencing ‘extreme problems’ with their treatment, the CoSMIC research group had an ethical 
duty to inform the clinical team involved with the care of the patient. This might introduce bias in 
subsequent quality of life assessments and would be made transparent in any publication of results by 
the CoSMIC group.  
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3.1.15 Case Report Form 
All trial data were recorded on individual-patient case report forms, anonymised and stored in a 
password-protected database for 10 years from completion of the study. This time period was selected 
to allow a planned late follow-up study if appropriately funded to assess long-term survival.   
Data were collected on all patients referred to the specialist Hepatobiliary (liver) multidisciplinary team 
meeting (MDT) at MRI during the period of the study with a new diagnosis of colorectal hepatic 
metastasis.  This provided the denominator for the proportion of patients eligible for study and 
recruitment rates.  In parallel, data were collected on patients referred to the specialist colorectal 
MDTs at the same hospital in order to capture further information on patients with primary colorectal 
cancer and liver metastases who may be eligible for trial recruitment. 
 
3.1.16 Ethical approval 
The CoSMIC study was approved by the NHS Research Ethics Committee North West (Greater 
Manchester Central) on the 19th November 2014 (REC reference 14/NW/1397). A minor amendment 
to the CoSMIC protocol allowing retrospective data collection at the referring hospitals was approved 
by the same committee on the 11th March 2016. A further substantial amendment was approved on 
the 5th September 2016 to allow the inclusion of the pre-study audit data. Local ethics approval and 
letters of access were also obtained for each of the sites where patient recruitment and data collection 
took place.  
 
3.1.17 STROBE Checklist 
The ‘Strengthening The Reporting of OBservational studies in Epidemiology’ (STROBE) checklist[91] 
applied to the CoSMIC study is shown in Appendix 8.2. 
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3.2 CoSMIC Qualitative Study (CoSMIC-Q) 
The acceptability of the different sequence of treatments and of study-related processes was assessed 
in a nested phenomenological (qualitative) study to explore patients’ and clinicians’ views and 
experiences. Patients’ views about treatment options, the common pathway and health outcomes will 
inform design of a subsequent full-scale RCT. The focus on the patient experience is important. For 
example, the NHS Outcomes Framework emphasises the importance of a positive experience of 
care[92]. This experience may vary according to the treatment pathway and thus the aim of the 
CoSMIC-Qualitative study (CoSMIC-Q) was to undertake a qualitative study of the patient and their 
caregiver experience following either synchronous surgery or sequential treatment pathways. The 
evolution of clinician work through the patients' disease trajectory is a key feature of cancer care. 
Obtaining insight into clinician’s subjective experience and views on providing care to these patients 
may help inform the knowledge of current practice and help to better understand the patient 
experience, Therefore, we included the clinician perspective in the study.  
  
3.2.1 Study Design 
Patients diagnosed with synchronous colorectal cancer and liver-limited metastatic disease were 
interviewed as part of a qualitative phenomenology study. In depth interviews with individual patients 
were conducted in the follow-up period after completion of surgery and chemotherapy. Patients were 
selected from all three main treatment pathways – synchronous surgery, sequential bowel-first and 
sequential liver-first. As we hope to explore the impact on relatives and family, we offered the patient 
the choice to nominate a close family member to be present during their interview. 
Consultant clinicians involved in the management of synchronous patients were also be interviewed 
comprised of specialities that represent the specialist HPB MDT. This included surgeons (both HPB 
and colorectal), oncologists and radiologists. Intensivists who are involved with the preoperative 
assessments, anaesthesia and postoperative critical care of synchronous patients were also 
interviewed.  
 
3.2.2 Setting 
Patients diagnosed with synchronous colorectal cancer and liver-limited metastatic disease were 
interviewed as part of a qualitative phenomenology study. Patients had already completed their 
treatment pathway and were either be under surveillance or under management of any metachronous 
disease diagnosed subsequently to successfully completing their initial treatment. All patient interviews 
took place in either a clinic room or the Macmillan Centre in the Outpatient Department at the MRI.  
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Clinicians who manage patients with synchronous colorectal cancer and liver-limited metastatic 
disease or who are involved with the decision-making process were also interviewed. Clinician 
interviews took place in a location of the clinician’s choosing.  
 
3.2.3 Identification of potential participants 
Patients were purposively recruited from the outpatient clinics, where the patient had already 
consented to participate in the CoSMIC study, and where the consultant advised the research team as 
to the suitability of the patient for qualitative interviews. Clinicians identified as being active participants 
of the HPB and colorectal MDTs at the MRI and the Christie hospital were approached to see if they 
wanted to take part in the interviews.  
 
3.2.4 Participants 
In order to be eligible for inclusion into the CoSMIC-Q study, patients fulfilled the following criteria 
Inclusion criteria (patient) 
1. Over 18 years of age 
2. Able to give informed consent 
3. Enrolled into the CoSMIC study 
Exclusion criteria (patient) 
1. Under 18 years of age 
2. Unable to give consent 
3. Unfit to take part in a structured interview 
 
In order to be eligible for inclusion into the CoSMIC-Q study, clinicians fulfilled the following criteria 
Inclusion criteria (clinician) 
1. Consultant grade 
2. In clinical practice and an active participant of the HPB MDT in one of the following 
specialities: HPB surgery, colorectal surgery, radiology, oncology 
3. Willing to give informed consent 
Exclusion criteria (clinician) 
1. Non-consultant grade 
2. Not in clinical practice 
3. Not an active participant of the HPB MDT (with the exception of intensivists who are not part 
of the MDT quorum) 
4. Unwilling to give informed consent 
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For those patients not speaking English, interest in participation will be ascertained through a local 
Trust interpreter. 
 
3.2.5 Data Collection 
An interview guide was developed after reviewing the literature and based on previous work in the 
area of patient experiences in the delivery of cancer services. We expected the interviews to last 
approx. 45 minutes, and explored (1) for patients and care givers: the experience of disease, 
particularly through the treatment pathway; understanding and expectations of timeframe for 
investigations; how they were informed of the diagnosis; how they received information related to the 
condition and treatment pathway; the type of information provided and who were the professionals 
explaining this; the nature and impact of information about diagnosis on patients and care givers, and 
on their relationship with the clinician; aspects of the process patients and care givers found useful/not 
so useful, and what could be improved; and the acceptability of entering into a future randomised 
control trial; (2) for clinicians: their experience of providing care, in particular, the perspectives and 
their views on treatment pathways; difficulties and challenges around treatment allocation and 
decision-making processes; the relationship with patients; acceptability and barriers to entering 
patients who may be under their care into a future randomized trial; any ethical issues and the 
potential clinical value of future randomized control study. 
 
3.2.6 Data Saturation 
The point of data saturation can be difficult to define as there is no ‘one-size fits all’ method[93]. A 
saturation grid method[94] was chosen based on the major topics in the interview design questions 
detailed below. It was estimated that a sample size of 4-6 patients per group, and 1-2 clinicians would 
produce data saturation. However, interviews were continued or stopped until data saturation was 
reached. 
 
3.2.7 Interview Design 
The interview design for the patient interviews and clinician interviews is shown in Table 14 and Table 
15 respectively. Question probes were designed to focus the interview onto the themes chosen. All 
questions exploring the themes were open-ended questions. For questions where a specific answer 
was desired (such as ‘would you choose to take part in a future trial’), a closed question was asked. 
Interviewees (and relatives where present) were given as much time as needed for the interview. 
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Table 14. CoSMIC-Q Patient Interview Design 
Introduction
Introduction of researcher
Reminder of the study, and comfirmation that the participant still wishes to proceed
Explanation of what happens to the data
- Interviews will be audio recorded, and all recordings will be stored securely
- For analysis, the recording will be transcribed and anonymised
Reminder that the interviewee can stop the interview at any time
Opening Question
Tell me about your experience of illness?
Focusing on the Diagnosis
Tell me about your diagnosis. How were you informed of your diagnosis?
Probes:
- Did you feel you were given enough information in a way you could understand? 
- What were your expectations for treatment after being told of your diagnosis?
- Were you told which consultant has overall responsibility for your care?
Focusing on the Treatment
Tell me about your treatment.
Probes:
What were the aspects that you found particularly good, and which were particularly worrisome?
At the outset, how much information did you receive about the treatment proposed?
Was it given in a way you could understand?
Did you feel you had a say in the treatment proposed to you?
Is there anything that could have been done to make your experience better?
[For staged-surgery patients]
Did your surgeon explain to you why you had your bowel/liver operation first?
Did you feel you had a choice between bowel-first or liver-first surgery?
Would you have had a preference?
[For synchronous resection]
Did your surgeon explain to you why you had a bowel/liver operation rather than a two-stage procedure?
Did you feel you had a choice between a synchronous resection, or a two-stage procedure?
Would you have had a preference?
Focusing on Research
I would like to talk to you about a potential research idea. If we were to design a research that would compare patients 
having bowel-first and liver-first surgery:
How do you feel about allocating patients to one of these groups?
What are the main issues that would concern you for this approach?
Hypothetically, would you choose to take part in such a trial?
Closing the Interview
Any questions from interviewee, and reminder of study contact details
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Table 15. CoSMIC-Q Clinician Interview Design 
3.2.8 Data Analysis 
Interviews were audio recorded, transcribed verbatim and anonymised. NVivo (QSR International Pty 
Ltd. Melbourne, Australia) software was used to manage this data. Interviews were analysed 
thematically, using constant comparison[95] within a modified framework approach[96]. We developed 
the codes both ‘horizontally’ (by coding each interview as a standalone hermeneutic unit) and 
‘vertically’ (by scanning across the interviews for specific terms). We then identified categories and 
developed these into broader themes. We used mind mapping techniques to visually arrange and 
conceptualize the categories, their structure and linkages. Recognizing the complexity and diversity of 
the information gathered through the interviews, we developed a matrix of themes from patients, care 
givers and clinicians. A systematic cross-comparison was then be undertaken to identify the 
similarities and differences between the different types of participant. We will discuss emerging 
categories, themes and interpretations during the regular analysis meetings. The interpretation of the 
study was compared with the previously published literature.  
Introduction
Introduction of researcher
Reminder of the study, and comfirmation that the participant still wishes to proceed
Explanation of what happens to the data
- Interviews will be audio recorded, and all recordings will be stored securely
- For analysis, the recording will be transcribed and anonymised
Reminder that the interviewee can stop the interview at any time
Opening Question
Tell me about your experiences in managing patients with synchronous colorectal cancer and liver-limited metastases
Focusing on the Current Treatment Pathways
What are the main issues in treatment allocation and decision-making?
Probes:
- Do you feel there is there consensus at the MDT
- Are your patients happy with the current treatment pathways?
- What are your views on bowel-first and liver-first resections?
- What factors are important for selecting patients for synchronous resections?
- What do you feel are the current challenges to treating synchronous patients?
Focusing on Research
I would like to talk to you about a potential research idea. If we were to design a research that would compare patients 
having bowel-first and liver-first surgery:
How do you feel about allocating one of your patients to one of these groups?
What are the main issues (both ethical and clinical) that would concern you for this approach?
Closing the Interview
Any questions from interviewee, and reminder of study contact details
73
  
 
3.2.9 Quality Control Measures 
1. All interviews were recorded and transcribed verbatim by a single transcriptionist  
2. Data analysis, theme significant statement meaning extractions were independently 
performed by two investigators with experience in phenomenological research. Any 
disagreements or inconsistencies were arbitrated to a third researcher  
3. Participants were given the option to receive their transcription by post, so they could provide 
feedback  
 
3.2.10 Validating the Findings 
The findings of the qualitative study will be validated by peer review from clinicians who are 
independent of the study, and also with concordance of the findings with the published literature.  
 
3.2.11 Stopping Rules 
Individual interviews were stopped if there is any sign of emotional distress by either the patient or 
their relatives being interviewed. For any issues raised, and with the patient’s consent, we contacted 
their clinical team to make them aware of these issues, so these could be formally addressed.  
 
3.2.12 Health Service cost of the Study 
The Statutory Duty to Involve[27] mandates patient feedback and its implementation and development 
into service pathways. Whilst there is a small cost involved in hosting and conducting the interviews, 
these were covered by local allocated or charitable funds within the Department of Surgery.  
 
3.2.13 Ethical Approval 
The study was approved by the NHS Research Ethics Committee (South Central – Oxford C Research 
Ethics Committee) following a proportionate review on the 2nd November 2016 (REC reference 
16/SC/0610). Site-specific approval was obtained from the host institution (MRI) where patient and 
clinician interviews were hosted. The appropriate Health Passports were obtained for the relevant 
researchers. 
 
3.2.14 COREQ Checklist 
The consolidated criteria for reporting qualitative research (COREQ) was used as a framework for the 
CoSMIC-Q study[97]. The completed checklist is shown in Appendix 8.3.   
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3.3 Publication of Protocol and Dissemination of Results 
The CoSMIC and CoSMIC-Q Protocol have been published in BMJ Open[98]. The CoSMIC protocol 
was registered with ClinicalTrials.gov (registration number: NCT02456285)[99]. The findings of both 
studies are planned to be reported at the appropriate international meetings and reported in a peer-
reviewed scientific journal. 
 
3.4 Summary of Methods 
In this chapter, the methods of the CoSMIC and CoSMIC-Q study have been introduced which form 
the primary research of this thesis. Chapter 4 provides findings of the enquiry of the patient experience 
when undergoing surgery for synchronous disease. Chapter 5 follows with the professional 
experience.  
 
3.5 Summary of Definitions 
A summary of definitions used for the entirety of CoSMIC and CoSMIC-Q is given below for clarity. 
Synchronous Disease 
Colorectal cancer with the synchronous liver metastatic disease diagnosed at the same time as the 
colorectal primary, or within 3 months. 
 
New Referral 
Patients presenting to the HPB MDT who are diagnosed with synchronous colorectal cancer and liver-
limited metastatic disease whose treatment plan has yet to be decided and commenced.  
 
Indeterminate Lung Lesion 
A lesion seen on cross-sectional imaging that is not diagnostic for lung metastases, and which is 
usually kept under surveillance. 
 
Bowel-first Emergency 
Patients presenting with an emergency bowel pathology. 
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4. PATIENT PERSPECTIVES 
An introduction to the CoSMIC-Q study and its methods are found in Section 3.2 (page 69).  
 
4.1 Results 
The CoSMIC-Q patient interviews were conducted between November 2017 and February 2018. All 
the interviews took place in the Macmillan centre at the MRI outpatient department at a time of the 
patient’s choosing. All but 2 patients attended the interview with a relative who was involved in their 
care previously. There were two interviewers (AC and AI) in the first 3 interviews, and 1 interviewer 
(AC) for the remaining 6 interviews. Data saturation was reached after 9 patients as indicated by a 
saturation grid which was updated following each interview (Table 17).  
 
4.1.1 Patient Demographics 
The demographics of the patient and relative participants is shown in Table 16. Data saturation was 
reached following 9 interviews. The final cohort included 3 female patients and 6 male patients all of 
whom had completed their treatment pathway, which consisted of 2 patients undergoing liver-first 
surgery, 4 patients undergoing bowel-first surgery and 3 patients after synchronous surgery. All 
patients were in their surveillance period, with 2 patients having recurrent disease and ongoing 
treatment. The interview length ranged from 16 to 82 minutes.  
Patient 
ID 
Sex Age Surgery 
Relative 
present 
Interviewers 
Interview length 
(min:sec) 
1 Female 66 Liver First Husband AC, AI 52:17 
2 Male 70 Synchronous Wife AC, AI 34:00 
3 Male 49 Bowel First None AC, AI 32:59 
4 Male 64 Liver First Son AC 22:19 
5 Female 58 Bowel First - AC 35:07 
6 Male 63 Synchronous Wife AC 16:09 
7 Male 54 Bowel First - AC 1:21:51 
8 Male 56 Synchronous None AC 48:48 
9 Female 69 Bowel First Husband AC 1:08:27 
Table 16. Demographics of patient interviewees 
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4.1.2 Thematic Analysis 
There were nineteen minor themes extracted from the patient interview transcripts, ranging from the 
patients’ personal experience and journey from diagnosis to completing treatment, their perception of 
disease and understanding of the chosen surgical management pathway to their views on research in 
synchronous disease (Table 17). Patients also discussed issues important to them, such as a 
perceived delayed or misdiagnosis, factors for disease surveillance such as carcinoembryonic antigen 
and stoma formation and reversibility. They also shared their insights into how they understood their 
disease pathology and how it relates to the sequence of surgery they underwent. Data saturation was 
reached after five patient interviews, and no new unique themes were identified after further four 
interviews. The minor themes were then classified into four major themes: patient experiences and 
their disease perceptions, patient autonomy and input into their treatment plan, treatment strategy and 
research (Figure 6). These themes are discussed in detail in this chapter.  
 
 
Table 17. Data saturation table of minor themes for CoSMIC-Q patient interviews 
 
                                                   Patient Interview
Minor Theme 1 2 3 4 5 6 7 8 9
Personal experience/journey x x x x x x x x x
Delayed or misdiagnosis x x x x
Patient's own perception of disease x x x x x x x
Understanding of surgical sequence x x x x x x x
Postoperative recovery period x x x x x x x
Monitoring factors (such as CEA) x
Alternative / complementary therapies x x
Problems during hospital stay x x x x x x
Preference for a particular surgical sequence x x x x x x x x x
Involvement in the treatment decision making process x x x x x x x x
Future research in synchronous disease x x x x
Acceptability of RCTs in synchronous disease x x x x x x
Stomas x x
Support from healthcare services x x x x
Perceptions on synchronous surgical surgery x x x x x x x
Travelling to different hospitals for treatment x
Information about their illness (written/internet) x x
Laparoscopic / open surgery x x
Communication problems x x
Key: CEA, Carcinoembryonic antigen; RCT, Randomized Controlled trial
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Figure 6. Classification of minor themes from CoSMIC-Q patient interviews into major themes 
 
4.1.3 Patient Theme 1: Patient Experiences and their Disease Perceptions 
All patients talked about their initial symptoms (or lack of symptoms) that led to their eventual 
diagnosis. Delays in diagnosis were perceived negatively, particularly if healthcare professionals were 
dismissive of their symptoms. Two patients described failures for them concerning the UK Bowel 
Screening Programme, either being below the age for receiving the test or having a normal test but 
were then subsequently found to have metastatic bowel cancer. 
He went through some questions and satisfied himself that I wasn’t particularly a 
priority case because I didn’t fit many of the criteria for the concern about bowel 
cancer. I wasn’t in the high-risk age group. I wasn’t showing any of the classic 
symptoms. (patient 3) 
And even the specialist that examined me.. and when he pressed my stomach, I 
nearly jumped. He said 'oh you are tender aren't you?' but he never referred me 
anywhere you know. And I think that was lacking a lot to be honest. (patient 6) 
Patients had mixed reactions to being told about a diagnosis of metastatic colorectal cancer. For 
some, it was a surprise given that their health was otherwise very good, but for others, the diagnosis 
was expected. Being told the cancer had already spread elicited further feelings of hopelessness and 
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futility. The information given to patients was enough, and no patients said that they either weren’t told 
enough information or were unclear about the plan.  
A colonoscopy.. erm.. at that time, I was feeling really fit. I’m quite a fit person. I’ve 
been a vegetarian for 30 odd years, and I did a lot of walking, it didn’t feel like a 
problem. (patient 2) 
For me, I interpreted that as him saying you’re going to die. And you’re going to die 
very quickly (patient 3) 
So yeah, it’s like your world had ended at that point. (patient 3) 
Patients appreciated that it was a difficult diagnosis to give and valued the presence of relatives during 
the time the diagnosis was given. Patients mentioned that upon hearing the ‘C’ word, they did not 
remember much else from the consultation and relied on relatives who were present to lead the 
discussions. 
I fully understand the situation and that people couldn’t give you a great deal of 
reassurance because it’s all about managing expectations and being realistic and 
honest isn’t it? And the statistics.. the Cancer Research UK statistics.. basically tell 
the bottom line. There’s no way of getting away from that. (patient 3) 
In general, patients and their relatives were quick to praise the treatment that they had received once 
their diagnosis was made. All patients described their journey of planning their treatment with their 
parent clinical team. Seldom were they unhappy with the treatment plan themselves, but more so with 
the care received when admitted on the hospital ward. Common reasons included the food, not 
receiving pain medication on time and experiencing side effects of certain medications. Travelling to 
different hospitals for specialist care and follow-up appointments were not perceived to be barriers to 
treatment. 
Patients with known metastatic disease at the time of the interview had insight into their condition, and 
developed mechanisms accordingly to cope with ongoing treatment. 
Containment. Its containment rather than cure. (husband of patient 1) 
 
4.1.4 Patient Theme 2: Patient Autonomy and Input into Treatment Plan 
Following their diagnosis, all patients and their families appeared happy with the degree of autonomy 
given to them with respect to deciding their treatment pathways. Patients appeared happy to follow the 
advice of their specialists on a ‘they know best’ basis, suggesting that a ‘paternalistic’ relationship was 
more prevalent in this setting. Patients were confident in the decisions made by their treating 
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clinicians, and no patient (or their families) felt that the wrong decision about their surgical strategy had 
been made, even when either they had suffered peri-operative complications or recurrence of disease 
at the time of the interview.  
I just said to them do what you think is best. I mean, I think you get a point where 
you just want it done. And they're the professionals. And let them do it how they 
want to do it. (patient 5) 
I’d tell everybody to have the operation. It doesn’t matter which order you have it in. 
You know better you doctors, and I just think that you put your life in your hands, 
and you can do what you can do. I think you should take the doctor’s advice. 
(patient 4) 
I think when it came to the medical decisions, we decided, didn’t we, that we’d let 
the doctors make those decisions. (patient 9) 
Whilst patients seemed happy with the autonomy given to them to decide treatment sequence, some 
patients questioned whether having a choice was really a choice they would make. Even in these 
circumstances, patients tended to trust their specialist as to the best treatment plan for them.  
Is it really having the option? I mean, old people go for the you know.. listening to 
the surgeon.. if he said this is going to be the best way of doing it, you just along 
with that really. Is knowledge and your lack of knowledge about that you just go 
with what they say. Even if you had an option, you’d still do which is the best. 
(patient 2) 
If we had a choice, I think we’d still go for what they’d advised that’s the thing. 
(patient 2) 
For some where there was a clear indication for a particular treatment pathway (for example, bowel-
first strategy for patients with features of bowel obstruction), there was no desire to deviate from that 
pathway. 
It wasn’t really discussed as an option, and I guess it’s because they were 
concerned about the stricture in the bowel that was more of a concern…. She was 
quite concerned in terms of the fact that the bowel might close and I’m guessing as 
a lay man that that might have prioritised the operation as well, whereas the mets in 
the liver were quite small if I remember…. I think under the circumstances I was 
quite happy.. with that logic that the bowel preceded the liver. (patient 3) 
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4.1.5 Patient Theme 3: Treatment Strategy 
All patients were very happy with the sequence of treatment that they decided with their specialist. For 
a staged surgery, patients preferred a bowel-first strategy to remove the primary tumour which they 
perceived as the source of the problem. Psychologically, particularly for patients having liver-first 
surgery, patients perceived ongoing ‘seeding’ of the tumour to other places including the liver.  
I often wondered why they didn’t attack the bowel first, but maybe the liver was a 
priority. I don’t understand, you know, when you look how sick or seriously ill I was, 
I don’t know which one was taking the priority. It was more important to get the liver 
done. I would have been perfectly happy if you said.. I actually didn’t like the 
prospect the thought that that bowel cancer was still there. And all that time, it was 
releasing things into my system. I would like that to have been taken away if that 
was possible even when I was first diagnosed, and they said ‘right, you’ve got 
bowel cancer, yes you’ve got liver cancer but we’re going to take that bowel cancer 
out because that’s the source of your problems’. And then, done the liver. But then, 
I don’t know, you know, I didn’t.. that’s my point of view.. that would have been a 
logical way of doing it. And the fact that I almost waited twelve months before.. 
knowing that I had bowel cancer before it was actually removed in the September 
and it was the year before in the October that I was diagnosed. So it was eleven 
months of me still having that bowel cancer.. it’s still doing whatever it wanted to do 
to my body.. I know it was having chemo attacked to. (patient 1)  
from a psychological point of view, I think what.. and speaking for myself.. I think 
probably most people would.. you actually want it out at the earliest possible 
opportunity. (patient 3) 
In general, the patient preference was for a single synchronous resection rather than two separate 
operations. Recovery time and a shorter time in hospital was cited as reasons for one single operation. 
Patients, however, did have an understanding about the reasons for not having a synchronous 
operation, such as the age and general fitness together with a longer operation time and anaesthesia 
time. Relatives, having been through the journey and seeing the impact of surgery on patients, were 
thankful for a staged (smaller) operations and said they would not have wanted a synchronous 
resection. One patient commented that it is not really a choice they could have made and that it would 
depend on fitness. 
I would have had it in the one, like I said, you'd have two recovery times, and you'll 
be getting over two operations. I think the sooner it was done, the better from my 
thinking. If you're leaving some in that's still got cancer, you know, it’s more likely to 
progress, isn't it? (patient 6) 
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So would I have a large operation, small wait, another large operation then a small 
wait, then another. No I wouldn't. I was quite glad they were all done in one go …. 
The short stay in hospital. Because the longer I stayed in hospital, the worse I got 
both physically and mentally. By the end of the second stay, I was a wreck. (patient 
8) 
Yeah, I think mentally, I just think about the whole scenario about me being me, 
and my body, and my age and everything. I thought it would be great to have both 
operations and just have everything, you know, malignant, removed in one fell 
swoop as it were (patient 9) 
From a relative’s point of view, they were again happy with the treatment strategy decided. There was 
also an appreciation that a synchronous operation was a much more physically demanding option.   
they said he was fit enough and well enough to have them both at the same time, 
probably if he wasn’t as good as he was, maybe they would have done the two 
separate.. (wife of patient 2) 
Yeah, I mean, for us personally, we kind of wanted him to have two operations. 
We’re still obviously confused as to why they couldn’t do both at the same time, but 
for us, we were just ‘get it done.. get it out’. That’s what we were more bothered 
about. We just wanted to get rid of the cancer. (son of patient 4) 
 
4.1.6 Patient Theme 4: Research 
In general, both patients and their relatives were of the impression that taking part in medical research 
would be desirable knowing that it would directly benefit patients with the same disease in the future. 
All patients and their relatives interviewed were very supportive of research. With regard to a 
randomised controlled trial where patients were asked if there was a possibility of changing the 
sequence their staged surgical strategy, some patients had reasoned with their beliefs that the primary 
tumour was ‘seeding’ the liver, and so explicitly said they would not have wanted to participate. 
Yes I would have gone.. I mean.. my life would be in your hands. So I know you 
wouldn’t do anything to me that’s hopefully going to shorten my life, but on the 
other hand, no I mean, you’ve got to do it one way, and another way, and you’ve 
got to look at the results in order to decide which way round seems to be the most 
successful. (patient 1) 
Its whether you're prepared to take the chance and do it. I know why they did my 
operations the way they did, and they explained that to me because of the mass 
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because they needed to get it smaller. But, if you can change anything, for the 
good of the patient, I'm all for it. 
You mean if they had done the liver first? No. I wouldn't. Because the tumour was 
the main one. And that was the primary. The liver was where it had spilled out into. 
And I think personally, you have to get rid of the primary. (patient 5) 
I don’t think I would have liked the idea of the randomness of the plan. I would have 
liked to kind of discussed with the doctors, worked out the pros and cons of these 
two things.. and they did discuss it with me, and I mean, <the oncologist> said you 
know, that they had an MDT meeting I think, and they did decide that probably the 
best route was to do the bowel first, because of the time scale.. that it would be 
good to do the two operations within a short time scale. (patient 9) 
Regarding the study design of a randomised controlled trial where the sequence of surgery could be 
changed, patients did not think that ethically, this was a problem.  
Yeah, I can’t see a problem with the ethics of it. And if it was to improve knowledge 
about which is the best route, then yeah, I would.. I would say it was.. because 
there’s always the difficulty down the line where a group of people that find out that 
their treatment was inferior with hindsight, which is a great thing, but how else 
would you find out? (patient 3) 
 
4.2 Discussion of Patient Perspectives 
Patients with synchronous colorectal cancer and liver-limited metastatic disease represent an 
important subset of patients with advanced colorectal cancer that can potentially be cured through 
surgery and systemic chemotherapy. The patient experience and disease perceptions of metastatic 
colorectal cancer was similar to the two mindsets of ‘public image’ of cancer as described by Robb and 
colleagues[100]. The first is the rapid sense of dread and imminent death which the patients in this 
study have described. The second is a rational reaction whereby patients accept their condition is 
manageable and with the hope of a cure. One patient (patient 1) in this study who had recurrent 
disease at the time of the interview described how chemotherapy was her way to “keeping the cancer 
under control”, and that she felt very positive about it.  
The majority of patients interviewed were satisfied with the level of autonomy during their treatment 
journey and trusted their clinicians to make the right decisions for them. Despite the lack of research 
evidence to support their treatment strategy, no patients considered this to be an issue. The beliefs 
patients held about metastatic colorectal cancer was that the bowel primary was continually seeding 
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the body, and that they would not have control until the primary was removed. Chemotherapy provided 
little reassurance to prevent seeding if the primary tumour was in situ. Liver-first patients questioned 
why they had the resection of metastatic disease first but trusted their clinician’s decision-making. This 
belief about the bowel primary and continual seeding was psychologically very strong to a point where 
if patients were given a genuine choice through a randomised controlled trial, some would not take 
part because they would favour a bowel-first strategy.  
Synchronous surgery has the advantage of removing all the macroscopic tumour burden in one 
operation. As expected, patients would prefer this option if possible and to avoid two separate staged 
operations. Patients and their relatives, however, had good insight into the magnitude of a 
synchronous resection in terms of operating time and the perioperative risk. Patients who had a staged 
resection were happy with their treatment plan and said they would not have wanted a synchronous 
resection. These perceptions were also mirrored by the patient’s relatives. 
The implications of these findings for specialist care include: 
1) Developing a personalised treatment strategy to patients and communicating the reasons for 
this strategy. Patients would support a synchronous surgical strategy, but are mindful about 
the risks of surgery on the background of age and pre-existing co-morbidities 
2) Whilst patients are happy to be involved in research, a randomised controlled trial which 
drastically changes the sequence of surgery may be unacceptable to some patients who hold 
beliefs about which sequence they deem more logical, namely a bowel-first approach to 
remove the source of tumour seeding the body 
As highlighted in the systematic review, there are few studies published into the patient perspectives of 
synchronous colorectal cancer and liver-limited metastatic disease. This study represents the views of 
patients at the end of the treatment pathway. This approach was chosen to show a reflective view on 
treatment received as well as gaining an insight into patient beliefs. The current study is limited by a 
non-longitudinal approach.  
As part of my research training, I participated as an interviewer but am also part of the surgical team 
involved with the care of participants. Thus, it is possible that patient responses may have been 
conditioned by my perceived professional status, relationship with clinical colleagues and potential 
ongoing involvement (directly or indirectly) in care. 
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5. CLINICIAN PERSPECTIVES 
An introduction to the CoSMIC-Q study and its methods are found in Section 3.2 (page 69).  
 
5.1 Results 
The CoSMIC-Q patient interviews were conducted between December 2017 and April 2018. All 
interviews took place at the MRI. All clinicians were core members of the HPB or colorectal MDT, with 
the exception of the anaesthetist / critical care specialist who is an integral part of the team in terms of 
pre-operative CPET assessment and perioperative critical care management. Data saturation was 
reached after 9 clinicians as indicated by a saturation grid which was updated following each interview 
(Table 19). 
 
5.1.1 Clinician Demographics 
The demographics of the clinicians interviewed is shown in Table 18. The final cohort of clinicians 
included 3 HPB surgeons, 3 colorectal surgeons, an Oncologist, a Radiologist and an Anaesthetist. All 
clinicians at the time of the interview were active members of the HPB MDT and practising clinicians at 
the level of a Consultant. 
Clinician 
ID 
Specialty 
Interview length 
(min:sec) 
1 HPB Surgeon 9:11 
2 HPB Surgeon 13:08 
3 HPB Surgeon 12:25 
4 Colorectal Surgeon 12:03 
5 Colorectal Surgeon 9:55 
6 Colorectal Surgeon 13:13 
7 Oncologist 25:11 
8 Radiologist 10:49 
9 Anaesthetist 35:10 
Table 18. Demographics of Clinician Interviewees 
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5.1.2 Thematic Analysis 
There were twenty minor themes extracted from the clinician interview transcripts. These ranged from 
their perceptions of the MDT decision-making process and the current evidence and guidelines in 
synchronous disease, to the factors they consider important when deciding treatment for synchronous 
disease (Table 19). Clinicians also discussed their rationale for bowel-first or liver-first treatment 
strategies and how this relates to their perception of synchronous disease pathology. The feasibility for 
a potential future randomised controlled trial in synchronous disease was also discussed, as were 
research topics they deemed to be important. Data saturation was reached after six patient interviews, 
and no new unique themes were identified after a further three interviews. The minor themes were 
then classified into five major themes: perceptions about the order of staged resections, patient 
selection for synchronous resection, decision-making at the MDT, current challenges in synchronous 
disease and research (Figure 7). These themes are discussed in detail in this chapter.  
 
 
Table 19. Data saturation table of minor themes for CoSMIC-Q clinician interviews 
 
                                                          Clinician Interview
Minor Theme 1 2 3 4 5 6 7 8 9
MDT decision-making x x x x x x x
Factors important when considering synchronous resection x x x x x x x
When to consider neoadjuvant chemotherapy x x x x x
Order of staged resections (bowel- or liver-first) x x x x x x x x
Current evidence/guidelines for deciding surgical strategy x x x x x x
Discussing treatment plans with patients x x x x x
Patient perspectives as understood by a clinician x x x x
Feasibility of RCTs in synchronous disease x x x x x x x x x
Quality of life and surgical strategy x x x
Clinical rationale for liver-first surgery x x x x x x x x
Clinician's approach to synchronous disease x x x x x
Clinical rationale for bowel-first surgery x x x x x x x
Important factors when considering staged resection x x
Laparoscopic surgery and synchronous disease x x x x
Pre-habilitation / Preoperative optimisation x
Pathway failure x x x
Stoma formation x x x x x
Personalised medicine x x
Bowel or liver first during synchronous resection x x x
Problems in planning a synchronous resection x
Key: RCT, Randomized Controlled trial
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Figure 7. Classification of minor themes from CoSMIC-Q clinician interviews into major themes 
 
5.1.3 Clinician Theme 1: Perceptions about the order of staged resections 
All clinicians expressed concern at the lack of evidence base to guide the order of staged resections in 
patients who were currently asymptomatic or not requiring emergency bowel intervention. Clinicians, 
particularly colorectal surgeons, were concerned that leaving the bowel primary in situ risks 
subsequently developing a bowel emergency such as obstruction or perforation. This was also the 
point of view from an oncologist, that once the bowel primary was resected, it eliminates the risk of 
bowel perforation or obstruction (particularly more so if the patient is symptomatic from the bowel 
tumour). 
Part of the concerns if you were to leave in situ to perform a liver resection, you 
would potentially put the patient at risk of developing emergency bowel 
presentations. (colorectal surgeon) 
My preference is to take the bowel out first. That's the offending neoplasm, that's 
the metastatic seeding source and I'd like to take control of that, and it’s the one 
that's going to cause more acute emergency presentations. (colorectal surgeon) 
I know it doesn’t, but my gut feeling is that I want to primary out first. Every week at 
MDT when we discuss this, I have a huge problem going liver-first, or going 
chemotherapy, then liver then bowel, because to me, if the primary is still there, it’s 
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still sending out all the seedlings and I’ve just got an issue with that. (colorectal 
surgeon) 
And so it’s often more straightforward when the patient has had the bowel tumour 
resected before you start the chemo because you’re just worrying about the liver. 
So I know that’s slightly anecdotal, but I guess that’s one of the things when a 
patient is quite symptomatic, you might as well just get on and do the bowel. 
(oncologist) 
The indications for a liver-first resection are also limited, with one clear indication being the 
‘therapeutic window’ between long course chemoradiotherapy and the bowel resection. Progression of 
the liver metastatic disease did not appear to be a deciding factor from a colorectal point of view. 
I’ve always been under the impression that the role for liver-first is quite limited... 
The first indication is if you have synchronous disease where the primary is in the 
rectum and needs some sort of radiotherapy… - short or long – and then perform 
the liver resection while you wait to do the bowel surgery.... The other option is 
when you have unresectable liver disease - borderline unresectable disease - at 
presentation. You give neoadjuvant chemotherapy. The lesions in the liver shrink, 
and shrink to a level where they become resectable…. In that case, a reverse 
approach is advisable to clear the liver while its resectable, so to avoid losing 
control of the disease. (HPB Surgeon) 
if you’re looking at somebody who is needing long course, then in many ways that 
defines quite a bit of the pathway, and you’re trying to fit your other interventions 
around it. (Oncologist) 
Yes, the liver can progress, but typically, if the liver does progress, it would have 
progressed anyway... that's what we've seen. (colorectal surgeon) 
There was also a belief amongst both HPB and colorectal surgeons that the bowel primary is the 
source of metastatic disease, and that leaving the bowel primary in situ risked further seeding of 
tumour through the portal venous system to distant organs and thus developing more extensive 
metastatic disease. From a radiologist’s point of view, this belief seems less important so long as the 
disease is resectable, although they can appreciate the patient’s point of view and the psychological 
impact. 
We want to neutralise the primary tumour before it spreads further, and also to give 
time for the disease to declare itself. So, I can’t think of a scenario where I would 
perform a reverse approach in a patient who is chemo-naïve. (HPB Surgeon) 
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I always think doing the bowel first seems sensible because you’ve removed the 
source of the metastases. I can also understand why people say do the liver first 
because if that gets out of control, it becomes more difficult and less likely to be 
resectable and therefore curative. (colorectal surgeon) 
Effectively, I see disease and I want to get rid of all of it as soon as possible. In 
terms of the radiology side of things, I don't think it really matters. I get the theory 
that this is the tumour and it’s going to spread if it’s still in there, but it’s going to 
resection because of the fact that there's something that's resectable… I suppose if 
its borderline, I would go for the bowel resection anyway, because like I said, it’s a 
psychological thing for the patient as well. (radiologist) 
Clinicians also felt that patients would prefer the first surgery to remove the bowel primary, which they 
perceive as the ongoing source of the metastatic disease. For bowel-first and synchronous surgical 
strategies, clinicians feel it’s an easier discussion to have with their patients regarding surgery. A liver-
first strategy is more difficult to discuss as there is a perception (from both the clinician and the patient) 
that the source of the problem is not being treated. 
It’s really difficult, because they’re going to say ‘it’s already spread, and if you leave 
it in, isn’t it going to spread even further?’ That’s really difficult to answer. 
(colorectal surgeon) 
I think it depends on how you explain it to them. If you explain the rationale behind 
the decision, most patients are agreeable to it. I think its easiest to explain to 
someone that they’re having a synchronous resection, because from their point of 
view, everything is being dealt with in one go. (colorectal surgeon) 
 
5.1.4 Clinician Theme 2: Patient Selection for Synchronous Resection 
The general consensus from clinicians is that synchronous resections can be performed, providing 
patients are deemed fit enough, if both the liver metastatic disease and bowel primary are deemed 
‘minor’ resections. Factors such as tumour bulk that would prolong resection time are seen as factors 
favouring a staged resection rather than synchronous resection. 
If is a minor liver resection and a minor bowel resection, then it’s an easy decision. 
The difficulty in decision-making comes when you have a major bowel resection 
and minor liver resection, or vice versa. (HPB surgeon) 
Quite an easily resectable colonic cancer, so if it’s a really bulky T4 tumour invading 
things, it’s going to take time, then I tend to veer away from the joint resections. 
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There’s no evidence for this, just my gut feeling is they should be done separate at 
that time. (colorectal surgeon) 
For other surgeons, the risks lie in the patient themselves in terms of pre-existing co-morbidities rather 
than the extent of the bowel or liver resection.  
In the right patient, any bowel resection, in the right patient. If they're fit enough, I 
would happily do an anterior resection or a right hemi. (colorectal surgeon) 
Patients treated by surgeons seemed to generally prefer synchronous resection than a staged strategy 
as it reduces the number of operations to one.  
Yes, universally, patients have said they prefer one operation, so they would 
prefer synchronous surgery if asked. (HPB surgeon) 
It’s pretty niche surgery, so patients don't have any sort of knowledge base to 
draw their decisions from, and I think they're just guided by us. But patients are 
usually happy with their synchronous resections. They're happy to get it all out in 
one go. (colorectal surgeon) 
The majority of experience regarding the order of resection during a synchronous resection seems to 
be the liver resection first, followed by the bowel resection.  
Liver first, because you keep the blood pressure too low for our liking. It makes 
sense, as you do it under a low blood pressure, you put the blood pressure up at 
the end to make sure there’s no bleeding, and we like the blood pressure high for 
when we do the anastomosis to look at the marginal artery. (colorectal surgeon) 
Challenges, for whatever reason, we like to do the liver resection first, where the 
Pringle is on, and we have low CVPs because we don't like the colorectal 
anastomoses with low MAPS. But we have done one or two where we did the 
bowel first, and we've anastomosed, and then they've done the liver, and the 
patient has done absolutely fine. (colorectal surgeon) 
Colorectal surgeons are much more likely to consider a covering stoma during a synchronous 
resection than a staged resection, with one surgeon saying they would defunction the anastomosis in 
all synchronous cases. The reasons stated are mainly the physiological insult to the patient 
undergoing a prolonged procedure together with more potential blood loss and an overall lower blood 
pressure. A defunctioning stoma would also provide a ‘safety net’ to protect against the co-morbidities 
of an anastomotic leak. 
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Significant. Significant, because of the double surgical stress of the colonic and 
liver resection, I would want to have the safety net of the loop ileostomy. I would be 
much more likely to defunction a synchronous than a straightforward anterior. 
(colorectal surgeon) 
Because if we’re doing a synchronous I would cover it. Across the board, I would 
personally. (colorectal surgeon) 
it depends on the length of the surgery, and blood loss, blood pressure, and the 
fitness of the patient. So, I suppose if we’re saying the length of the resection, the 
liver is going to take longer, it’s probably going to have more blood loss, and you’re 
more likely to do a covering stoma. (colorectal surgeon) 
 
5.1.5 Clinician Theme 3: Decision Making at the MDT 
The clinicians interviewed agree that there is no clear treatment pathway for patients with synchronous 
colorectal cancer and liver-limited metastatic disease. Discussions at the MDT provide an educated 
consensus only. Clinicians in this setting felt that treatment should be individualised given the number 
of variables to consider, including both disease and patient factors. Who is present at each MDT 
meeting also makes a difference to the outcome of the discussion.  
The MDT usually comes to an educated consensus. However, I think there is 
unfortunately a lack of evidence to guide or to help in which is the best direction to 
take. There are hints, and ideas which are more solid than others, but we lack 
consensus. (HPB surgeon) 
Quite frustrating in that there is no clear pathway, but then, that’s not too bad 
because each individual case shouldn’t be a pathway, it should be individualised so 
that its best for patients. (colorectal surgeon) 
No, we all argue. It depends who’s there, and it can change week on week. It also 
depends on which oncologist you’ve got there… But some can be very rigid and 
say that’s what we always do. I think it should be individualised because I don’t 
think one size fits all, even though we do that for colonic. (colorectal surgeon) 
I think the consensus isn't the problem. Everyone agrees, but I do think week by 
week, because there isn't a structure, there isn't a trial, there isn't any evidence - it 
is a little ad hoc. It depends on who's running the MDT. (radiologist) 
For the majority, its straightforward. For some, particularly those that are less 
definitely resectable, or have got nodal disease that is on the edge of what is 
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resectable, it’s more difficult to say. There are some, particularly if you’re 
combining it with chemotherapy preoperatively, I think you can argue it several 
ways, and all would be sensible and acceptable. So, do you go for resection 
followed by chemo followed by resection? Do you go chemo, liver resection, then 
bowel resection? Or do you do bowel, liver, then chemo? I think all of them can 
be viable options. (colorectal surgeon) 
Clinicians also feel that having representation from both HPB and colorectal subspecialties at one 
MDT would also be beneficial, particularly for discussing synchronous resections (as currently at the 
MRI, the HPB MDT and colorectal MDT are separate meetings). 
There seems to be a quite significant delay to synchronous, and I think we need to 
come together earlier. Whether the beginning of someone’s MDT or the end, 
whether we need the colorectal or hepatobiliary? A core member from each to 
discuss cases or a smaller group? I’m not saying all MDT, but I’m just saying we 
need to get to the earlier because by the very nature, when the patient having 
metastases, they come from elsewhere to you, then there is a delay, and then we 
get involved, and then that delays even more. (colorectal surgeon) 
 
5.1.6 Clinician Theme 4: Current challenges  
Different surgeons had different views about the current challenges that they face in clinical and 
surgical practice. Better collaboration between the colorectal and HPB surgeon was cited as a current 
challenge in practical issues such as laparoscopic port placement and the sequence of surgery during 
a simultaneous resection. One surgeon also proposed a closer working relationship with the 
anaesthetic team, as they felt anaesthesia for synchronous patients was becoming more and more 
subspecialised.  
we like to do all our colonic work laparoscopically, and laparoscopic liver resection 
is coming along very nicely and quickly. We are doing more lefts, and even rights 
now. But I think that's where the future is, where we can set up our case and our 
ports in an equitable way to serve both the bowel and the liver laparoscopically. 
That to me is the next challenge to overcome - the technical set up, and we have 
done it, but I'm just thinking it deserves a bit more thought. (colorectal surgeon) 
did the bowel before the liver have a higher anastomotic leak rate, a higher 
anastomotic stricture rate, from a higher ischaemia time. I don't know. (colorectal 
surgeon) 
92
  
 
The anaesthetist should be one of the group. Not at MDT, but they should be one of 
the group that do bowel and liver. Having a random anaesthetist sent to a list 
should be, no, we’re not doing it. (colorectal surgeon) 
No surgeons expressed an interest or raised concerns about robotic techniques. 
 
5.1.7 Clinician Theme 5: Research 
For any randomised controlled trials that involve changing the order of surgery for patients with 
synchronous colorectal primary and liver metastatic disease, clinicians had mixed opinions about 
whether they thought it was an ethical study to do. One clinician felt that, as both a bowel-first and 
liver-first strategy is already part of current treatment pathways which are ‘randomised’ according to 
non-evidence-based decisions, ethically, it wouldn’t be seen as a problem. Another clinician felt that it 
wouldn’t be ethical based on their own beliefs on the primary tumour as the source of seeding. All 
clinicians concede, however, that there is currently no evidence-base to support decision making. 
Well we do that already, so why are you changing the treatment? Some of the 
consultants at the moment, some will do liver-first, some will do bowel-first, some 
will do synchronous. So, the only difference is that we’re allocating them at 
random as opposed to allocating by consultant’s non-evidence-based preference, 
which is biased or skewed at random by nature, so no, I don’t think it’s a problem. 
(colorectal surgeon) 
Ethically, I wouldn't be happy if it was my bowel cancer to be left inside while 
someone took my liver, so I'm not sure if I would be able to argue if it would be 
ethically correct for my patients either. But again, it’s not based on any hard 
science. (colorectal surgeon) 
No, I don’t think it is <ethical> because every cancer you deal with it can be 
completely different. I think it just depends on the aggressiveness of the cancer 
and I don’t think we take that into account enough. (colorectal surgeon) 
Other areas of research that clinicians mentioned included: 
• During a synchronous resection, should you do the liver or the bowel part first? 
• For a bowel-first and liver-first staged strategy, there’s enough interest, and it would be a 
valuable question to answer 
• I’m curious to understand the difference in quality of life, if there is a change if you do 
sequential or synchronous, and obviously what is the long-term benefit, which will need a trial 
to answer. 
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5.2 Discussion of Clinician Perspectives 
Interviews with clinicians revealed a juxtapose of uncertainty about evidence for the sequence of 
surgery with an apparently firm belief that they understood the best pathway for individual patients and 
thus apparent lack of equipoise. Established beliefs and consequent patterns of clinical management 
appeared empirically entrenched. Thus, there was a reticence to participate in trials while 
acknowledging the lack of an evidence base for the sequence of care. Clinicians appeared unaware 
that patient beliefs affirming their views of surgical management may just reflect the explanations 
provided to them, or the lack of patient autonomy. The findings here of a preference for a bowel-first 
approach is mirrored by other studies exploring the decision making by surgeons for patients with 
synchronous disease. Many colorectal surgeons, but not non-colorectal surgeons, did not favour a 
liver-first approach[101]. Interestingly, the HPB surgeons interviewed in this study also favoured a 
bowel-first resection strategy to prevent any bowel emergencies developing and stop further ‘seeding 
of tumour’. The implications from these views may also extend into the research setting, where 
clinicians may show a bias towards a bowel-first resection strategy. 
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6. CoSMIC INCEPTION COHORT STUDY 
An introduction to the CoSMIC-Q study and its methods are found in Section 3.1 (page 59).  
 
6.1 Results 
 
6.1.1 Contextualising the Liver and Liver Metastases HPB MDT Population 
In the study period between April 2015 and March 2017, there were 210 'Liver' and 'Liver Metastases' 
MDT cancer meetings, comprising 3,646 case discussions for 2,302 unique patients (Table 20). MDT 
meetings took place every Wednesdays with the exception of public Bank Holidays. One MDT meeting 
was cancelled due to equipment technical failure. The most commonly discussed cases were primary 
HPB malignancies (43.0%), which included hepatocellular carcinoma, intrahepatic, hilar and 
extrahepatic cholangiocarcinoma as well as gallbladder cancers. Liver metastatic disease from 
gastrointestinal malignancies was discussed in over a quarter of cases, with the vast majority of these 
comprising colorectal liver metastatic disease (19.9% of all MDT cases). Gastrointestinal stromal 
tumours (GIST) and neuroendocrine tumours (NETs) accounted for 0.7% and 1.5% of cases 
respectively. A large proportion of case discussions were focused on the diagnosis and management 
of benign liver lesions (17.4%) such as cysts and haemangiomas, infectious conditions such as liver 
abscesses and hydatid disease (1.3%) and also benign gallbladder conditions such as gallstones and 
gallbladder polyps. Other case discussions included metastatic breast (2.0%), respiratory (1.5%), 
urological (0.9%) and gynaecological (0.3%) cancers as well as sarcoma (0.5%) and lymphomas 
(0.5%). Cancer of Unknown Primary (CUP) formed 3.9% of all cases discussed.  
The mean age for all patients discussed at the HPB Liver MDTs was 66.4 ± 14.1 years, with 55.5% of 
male sex. The mean age was slightly lower than the average in patients with benign disease (60.7 ± 
16.8 years), breast malignancies (60.0 ± 16.5 years) and other malignancies such as sarcomas (53.0 
± 17.0 years) and lymphomas (59.9 ± 15.7 years). The mean age was slightly higher for primary HPB 
malignancies (70.0 ± 12.5 years), particularly hilar cholangiocarcinoma (72.9 ± 12.1 years) and 
gallbladder cancers (73.6 ± 11.4 years). For patients with colorectal liver metastases, the mean age 
was 65.4 ± 11.2 years, with a higher incidence of male sex (63.9%).  
95
  
 
 
Table 20. Contextualising the HPB Liver MDT (Patients discussed between April 2015 - March 2017) 
Benign 401 17.4% 155 38.7% 60.7 16.8
Adenoma 14 0.6% 2 14.3% 42.9 13.3
Haemangioma 56 2.4% 23 41.1% 57.3 15.1
Focal Nodular Hyperplasia 44 1.9% 11 25.0% 41.4 14.3
Liver Cyst 85 3.7% 32 37.6% 66.4 14.2
Splenic Cyst 5 0.2% 1 20.0% 49.2 9.0
Choledocal cyst 10 0.4% 4 40.0% 55.1 19.0
Bbiliary cyst 15 0.7% 4 26.7% 62.9 18.8
Gallstones 66 2.9% 33 50.0% 70.6 13.1
Gallbladder 23 1.0% 9 39.1% 63.1 14.8
Choledocal fistula 1 0.0% 1 100.0% 68.0 .
Other 82 3.6% 35 42.7% 62.6 14.0
Infectious 30 1.3% 15 50.0% 64.9 18.8
Infectious - Liver abscess 21 0.9% 11 52.4% 70.0 15.5
Infectious - Hydatid 9 0.4% 4 44.4% 52.8 21.0
Primary HPB Malignancy 989 43.0% 610 61.7% 70.0 12.5
Hepatocellular Carcinoma 508 22.1% 384 75.7% 68.4 12.0
Intrahepatic Cholangiocarcinoma 162 7.0% 81 50.0% 70.9 12.8
Hilar cholangiocarcinoma 75 3.3% 39 52.0% 72.9 12.1
Extrahepatic cholangiocarcinoma 89 3.9% 45 50.6% 69.0 14.8
Gallbladder Cancer 156 6.8% 61 39.1% 73.6 11.4
Gastrointestinal Malignancy 593 25.8% 362 60.8% 65.5 12.0
Colorectal liver metastases 458 19.9% 294 63.9% 65.4 11.2
Colorectal (locally advanced) 2 0.1% 1 50.0% 66.0 11.3
Anal Squamous Cell Carcinoma 1 0.0% 0 0.0% 61.0 .
Oesophageal 1 0.0% 1 100.0% 94.0 .
Gastric 8 0.3% 5 62.5% 62.6 14.4
Duodenum 11 0.5% 6 54.5% 69.4 17.9
Pancreas 61 2.6% 31 50.8% 69.3 13.5
Gastrointestinal Stromal Tumours 16 0.7% 9 56.3% 58.3 9.5
Neuroendocrine Tumours 34 1.5% 15 44.1% 61.9 15.6
Primary peritoneal 1 0.0% 0 0.0% 79.0 .
Breast Malignancies 47 2.0% 2 4.3% 60.0 16.5
Gynaecological Malignancies 8 0.3% 1 12.5% 68.1 8.1
Ovarian 7 0.3% 1 14.3% 69.6 7.6
Endometrial 1 0.0% 0 0.0% 58.0 .
Urological Malignancy 20 0.9% 11 55.0% 64.8 13.6
Renal 17 0.7% 9 52.9% 62.6 13.5
Bladder 3 0.1% 2 66.7% 77.0 6.1
Respiratory Malignancy 35 1.5% 23 65.7% 68.9 10.6
Lung 33 1.4% 21 63.6% 69.8 10.2
Nasopharyngeal 2 0.1% 2 100.0% 53.5 2.1
Other 45 2.0% 22 50.0% 57.6 15.3
Sarcoma 12 0.5% 6 50.0% 53.0 17.0
Lymphoma 12 0.5% 5 41.7% 59.9 15.7
Melanoma 13 0.6% 9 75.0% 61.3 11.2
Other 8 0.3% 2 25.0% 55.5 18.2
Cancer of Unknown Primary 90 3.9% 56 62.2% 67.5 15.2
No HPB Malignancy 43 1.9% 20 46.5% 61.4 13.4
Total 2,302 1,277 55.5% 66.4 14.1
Total, % Male , % Mean Age, SD
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6.1.2 Summary of the CoSMIC Study Prospective Population 
Between April 2015 and March 2017, 2,302 patients were discussed at the HPB MDT, including 458 
patients diagnosed with colorectal liver metastatic disease (Table 21). There were 220 patients 
diagnosed with metachronous metastatic disease (which for the purposes of this study is defined as 
metastases diagnosed more than 3 months following the diagnosis of the colorectal primary), and 49 
patients presented with extrahepatic disease. There were 18 patients who were found not to have 
metastatic disease following MDT review.  
Of the 171 patients with synchronous colorectal cancer and liver-limited metastatic disease, 35 
patients did not meet the inclusion criteria for CoSMIC. There were 13 patients with previous or current 
non-related malignant disease and 8 patients had already undergone both liver and bowel surgery at 
the time of MDT discussion. One patient did not have a primary histological diagnosis. Seven patients 
were deemed unfit to receive the standard chemotherapy regimens for colorectal cancer and 
metastatic disease (assessed through performance scores and clinical assessment), 1 patient was 
unable to consent to the study, and 1 patient had pre-existing neuropathy secondary to type 2 diabetes 
mellitus. Only 4 patients did not wish to participate in the study. In addition, 38 patients did not attend 
the outpatient department at the MRI for consent into the study, 9 patients were already part of the 
Pre-CoSMIC audit and 12 patients were missed at recruitment and not assessed for eligibility for 
inclusion (see also Table 23 for a summary of inclusion). 
 
 
Table 21. Patients discussed at the HPB MDT with colorectal liver metastatic disease 
 
  
Patients Discussed with Colorectal Liver Metastatic Disease n %
Synchronous (Liver-limited) 171 37.3%
Synchronous (Extra-hepatic disease) 49 10.7%
Metachronous 220 48.0%
No Metastatic Disease 18 3.9%
Total 458
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6.1.3 Pre-CoSMIC Retrospective Audit 
The pre-CoSMIC audit was completed by the HPB unit prior to the CoSMIC inception cohort study. 
This was an audit performed between April 2014 and March 2015 that looked at compliance with the 
treatment guidelines for patients diagnosed with synchronous colorectal cancer and liver-limited 
metastatic disease. The standard for the audit were the ESMO guidelines. The audit identified patients 
at the HPB MDT using inclusion and exclusion criteria identical to the CoSMIC inception cohort study. 
The dataset for these patients was the same as CoSMIC, with the exception of quality of life data, 
which was not collected during the pre-CoSMIC audit. During the study period, the pre-CoSMIC audit 
identified 48 eligible patients. In order to increase the numbers for the final analysis, the pre-CoSMIC 
audit patients were added to the CoSMIC study population, forming a retrospective cohort. 
There were no statistical differences in baseline demographics between patients recruited in CoSMIC 
study and the Pre-CoSMIC audit (Table 22). There was also no difference in patient co-morbidity and 
smoking and alcohol status. The pre-CoSMIC audit patients therefore pooled together with the 
prospective CoSMIC patients for subsequent analysis for a larger sample size. Patients (n = 48) from 
the pre-CoSMIC audit constitutes 38.4% of the final CoSMIC population for analysis.  
 
Table 22. A Comparison between the Pre-CoSMIC Audit and CoSMIC Prospective Patient Population 
 
  
All Pre-CoSMIC Audit CoSMIC Prospective Statistical Test p-value
n 125 48 77
Median Age, years 66.5 66.7 65.8
Median Age Range, years 30.8 - 85.6 34.7 - 85.6 30.8 - 80.6
Sex, male (%) 80 (64.0%) 36 (75.0%) 44 (57.1%) Fisher's exact 0.056
Mean Height (SD), m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) t-test 0.732
Mean Weight (SD), kg 78.2 (16.1) 80.8 (17.4) 76.4 (15.0) t-test 0.160
Mean BMI (SD), kg/m2 27.3 (5.9) 27.8 (6.8) 27.0 (5.3) t-test 0.528
Charlson Score (median) 9 9.5 9
Charlson Score (range) 6 - 14 6 - 12 6 - 14
Smoker (%) 13 (11.5%) 5 (12.5%) 8 (11.0%)
mean/day (range) 10 (5 - 80) 10 (6 - 10) 18 (5 - 80)
Ex-smoker (%) 31 (27.4%) 8 (20.0%) 23 (31.5%)
Non-smoker (%) 69 (61.1%) 27 (67.5%) 42 (57.5%)
Current Alcohol 60 (56.1%) 21 (56.8%) 39 (55.7%)
Median units/week 8 5 10
BMI, Body Mass Index
Fisher's exact 1.000
t-test 0.512
Mann-Whitney 0.354
Fisher's exact 0.454
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6.1.4 Summary of the CoSMIC Study Population 
The final number of patients prospectively recruited was 77, and together with 48 patients 
retrospectively identified in the Pre-CoSMIC audit, gives a total study population for CoSMIC of 125 
patients identified over the period between April 2014 and March 2017 (Table 23).  
 
 
Table 23. Patients eligible for inclusion into the CoSMIC inception cohort study 
 
A CONSORT flow diagram for CoSMIC is shown in Figure 8. In total, 75 patients (60.0%) underwent a 
bowel-first treatment strategy, 18 patients (14.4%) underwent a liver-first approach, 16 patients 
(12.8%) underwent a synchronous colorectal and liver resection and 16 patients (12.8%) had no 
surgery. Only 17 patients (13.6%) presented as an emergency to their local hospital with either colonic 
obstruction or perforation which necessitated a bowel-first approach.  
 
Patients with synchronous liver-limited metastatic disease n %
Patients assessed for eligibility into CoSMIC 171
No primary histological diagnosis 1 0.6%
Previous / Current Malignancy 13 7.6%
Previous Liver and Bowel Surgery 8 4.7%
Unfit for chemo 7 4.1%
Pre-existing Neuropathy 1 0.6%
Unable to consent 1 0.6%
Did not wish to participate 4 2.3%
Did not attend clinic to consent 38 22.2%
Already in Pre-CoSMIC Audit 9 5.3%
Missed Recruitment / Not assessed 12 7.0%
Total Patients Consented Prospectively 77 45.0%
Total Patients in Pre-CoSMIC Audit 48 -
Total CoSMIC Population 125
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Figure 8. CoSMIC CONSORT Flow Diagram 
 
6.1.5 Tertiary Referral Patterns 
Referrals direct from Primary Care or Emergency admission to the Central Manchester tertiary centre 
sites (MRI and Trafford General Hospital) accounted for only 15.2% (19 patients) of the CoSMIC 
population (Table 24). The majority of patients (107, 85.6%) were referred to the MRI from 1 of the 15 
regional secondary care hospitals around the Greater Manchester, Lancashire and Cheshire 
catchment areas. Of these secondary referrals, 13 patients (12.1%) were emergency presentations 
requiring surgical intervention prior to discussion at the HPB MDT.  
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Table 24. Tertiary Referral Patterns 
Patients who had no previous surgical resection and were referred to the HPB MDT with both the 
colorectal primary and liver metastatic disease in situ were classed as ‘new referrals’. Of the 125 
patients in CoSMIC, 91 patients (72.8%) were new referrals. Of those who had treatment in the form of 
a bowel resection prior to referral to the HPB MDT, only 17 patients had an emergency presentation 
which necessitated an urgent bowel resection. Thirty-two patients (25.6% of the CoSMIC cohort) had 
elective bowel surgery prior to referral to the HPB MDT. Patients who had undergone defunctioning 
procedures such as stomas or colonic stent insertions were included in this group. New referral 
patients comprised on 72.8% of the study population. 
 
Emergency Elective
Patients (n) 125 17 108 91 48
HPB Tertiary Centre
Central (MRI Site) 14 4 (28.6%) 10 (71.4%) 12 (85.7%) 6 (42.9%)
Central (Trafford Site) 4 0 (0.0%) 4 (100.0%) 4 (100.0%) 2 (50.0%)
Regional Secondary Centres
Bolton 13 1 (7.7%) 12 (92.3%) 10 (76.9%) 2 (15.4%)
Christie 5 1 (20.0%) 4 (80.0%) 12 (240.0%) 3 (60.0%)
East Cheshire 7 2 (28.6%) 5 (71.4%) 5 (71.4%) 6 (85.7%)
Lancaster 1 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Mid Cheshire 16 2 (12.5%) 14 (87.5%) 12 (75.0%) 5 (31.3%)
North Cumbria 1 0 (0.0%) 1 (100.0%) 1 (100.0%) 1 (100.0%)
Pennine Acute 21 1 (4.8%) 20 (95.2%) 15 (71.4%) 8 (38.1%)
Preston 0 0 0 0 0
Salford Royal 11 1 (9.1%) 10 (90.9%) 8 (72.7%) 1 (9.1%)
South Manchester 7 1 (14.3%) 6 (85.7%) 3 (42.9%) 4 (57.1%)
Stockport 11 2 (18.2%) 9 (81.8%) 4 (36.4%) 2 (18.2%)
Tameside 8 1 (12.5%) 7 (87.5%) 3 (37.5%) 6 (75.0%)
Warrington 1 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%)
Wigan 4 1 (25.0%) 3 (75.0%) 1 (25.0%) 2 (50.0%)
Other 1 0 (0.0%) 1 (100.0%) 1 (100.0%) 0 (0.0%)
Total Secondary Referrals 107 13 (12.1%) 94 (87.9%) 75 (70.1%) 40 (37.4%)
Total (% of cohort) 125 17 (13.6%) 108 (85.6%) 91 (72.8%) 48 (38.4%)
All
Presentation
New Referralsa
Pre-CoSMIC 
Audit
aPatients are classed as 'new referrals' if they have not undergone any surgical resection at the time of tertiary referral. MRI, Manchester Royal 
Infimary
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6.1.6 Patient and Baseline Characteristics 
 
CoSMIC Baseline Demographic Data 
The baseline demographics for the CoSMIC population according to the surgical treatment strategy is 
shown in Table 25. The median age at the time of diagnosis for all patients in CoSMIC was 66.5 years, 
ranging from 30.8 to 85.6 years. Patient age varied from 65.9 years (range 30.8 to 85.6 years) in the 
bowel-first group to 65.9 years (45.9 to 84.1 years) in the liver-first group and 69.3 years (54.5 to 80.6 
years) in the synchronous resection group. The median age in the No Surgery group was 72.4 years 
(range 44.1 to 82.4 years). There was no statistical significance between the groups (ANOVA, 
p=0.351). Overall, more patients were male (64.0%), and significantly higher number of female 
patients received no surgery (67.5%) compared to bowel-first (28.0%), liver-first (33.3%) and 
synchronous (50.0%) groups (Fisher’s exact test, p=0.042). There was no difference in patient height, 
weight, BMI or Charlson co-morbidity scores (ANOVA, p>0.050). There was also no difference in 
patient smoking status or alcohol intake comparing the groups (Fisher’s exact test, p>0.050). No 
patients in the CoSMIC population had hepatitis or cirrhosis of the liver.  
 
Table 25. CoSMIC Patient Demographics 
 
The following sections describe a number of further pairwise comparisons of groups. 
  
All Liver First Bowel First Synchronous No Surgery Statistical Test p-value
n 125 18 75 16 16
Median Age, years 66.5 65.9 65.7 69.3 72.4
Median Age Range, years 30.8 - 85.6 45.9 - 84.1 30.8 - 85.6 54.5 - 80.6 44.1 - 82.4
Sex, male (%) 80 (64.0%) 12 (66.7%) 54 (72.0%) 8 (50.0%) 6 (37.5%) Fisher's exact 0.042
Mean Height (SD), m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) ANOVA 0.628
Mean Weight (SD), kg 78.2 (16.1) 79.2 (20.1) 77.4 (14.4) 77.3 (14.3) 82.2 (21.0) ANOVA 0.803
Mean BMI (SD), kg/m2 27.3 (5.9) 26.2 (4.8) 27.2 (5.4) 28.4 (7.2) 28.8 (8.9) ANOVA 0.419
Charlson Score (median) 9 9 9 10 10
Charlson Score (range) 6 - 14 7 - 11 6 - 12 8 - 11 7 - 14
Smoker (%) 13 (11.5%) 3 (18.8%) 8 (11.9%) 1 (6.2%) 1 (7.1%)
mean/day (range) 10 (5 - 80) 30 (30 - 30) 10 (5 - 40) 55 (30 - 80) #
Ex-smoker (%) 31 (27.4%) 1 (6.2%) 17 (25.4%) 6 (37.5%) 7 (50.0%)
Non-smoker (%) 69 (61.1%) 12 (75.0%) 42 (62.7%) 9 (56.2%) 6 (42.9%)
Alcohol 60 (56.1%) 6 (40.0%) 41 (63.1%) 9 (60.0%) 4 (33.3%)
Median units/week 8 5 8 7 20
# Insufficient data; BMI, Body Mass Index.
ANOVA 0.351
Fisher's exact 0.169
Fisher's exact 0.137
ANOVA 0.308
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Staged Surgery vs Synchronous Surgery Groups 
A comparison of demographics of those patients undergoing staged surgery (either bowel-first or liver-
first) and those having a synchronous resection is shown in Table 26. There was no statistical 
difference in demographics between the staged and synchronous groups. There appeared a higher 
proportion of male patients in the staged surgery group (71.0% vs 50.0%), although this was not 
significantly different (Fisher’s exact test, p=0.145). There was no difference between mean height, 
weight or BMI (individual t-test, all p>0.050). Interestingly, there was no difference in Charlson co-
morbidity score between the two groups (Mann-Whitney, p=0.419). There was also no difference 
between the smoking status (Fisher’s exact test, p=0.463) and alcohol intake (Fisher’s exact test, 
p=1.000) between the two groups.  
 
Table 26. Demographics of Patients undergoing Staged Surgery vs Synchronous Surgery 
Emergency vs elective surgery (bowel-first) groups 
A comparison of patients who received bowel-first surgery presenting as an emergency and those 
having a planned elective procedure is shown in Table 27. In total, 75 patients underwent a bowel-first 
surgical strategy, of which the majority (59 patients, 78.7%) had elective bowel surgery. There was no 
difference in patient age (t-test, p=0.603) or sex (Fisher’s exact test, p=0.082) between the two groups. 
The median Charlson co-morbidity score was 9 for both groups, ranging between 6 and 12 (Mann-
Whitney, p=0.700). There was also no difference in patient smoking status (Fisher’s exact test, 
p=0.307) or alcohol intake (Fisher’s exact test, p=0.193).  
All Staged Surgery Synchronous Surgery Statistical Test p-value
n 125 93 16
Age, Median (yrs) 66.5 65.7 69.3
Age(range) 30.8 - 85.6 30.8 - 85.6 54.5 - 80.6
Sex, male(%) 80 (64.0%) 66 (71.0%) 8 (50.0%) Fisher's exact 0.145
Mean Height (SD), m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) t-test 0.312
Mean Weight (SD), kg 78.2 (16.1) 77.8 (15.6) 77.3 (14.3) t-test 0.915
Mean BMI (SD), kg/m2 27.3 (5.9) 27.0 (5.2) 28.4 (7.2) t-test 0.421
Charlson Score (median) 9 9 10
Charlson Score (range) 6 - 14 6 - 12 8 - 11
Smoker (%) 13 (11.5%) 11 (13.3%) 1 (6.2%)
per day (median) 10 (5 - 80) 10 (5 - 40) 55 (30 - 80)
Ex-smoker 31 (27.4%) 18 (21.7%) 6 (37.5%)
Non-smoker 69 (61.1%) 54 (65.1%) 9 (56.2%)
Current Alcohol 60 (56.1%) 47 (58.8%) 9 (60.0%)
Units per week, median 8 8 7
Fisher's exact 1.000
t-test 0.247
Mann-Whitney 0.419
Fisher's exact 0.463
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Table 27. Demographics of Patients with an Emergency vs Elective Presentation 
 
Surgery vs No Surgery 
A comparison of patients undergoing either staged or synchronous surgery (including those patients 
who were planned from the outset for a staged resection but fail to progress to a second staged 
operation), and those who have no surgery is shown in Table 28. There is little demographic difference 
between the two groups, with the exception of a higher proportion of male patients in the surgery 
group (67.9%) compared to the No Surgery (37.5%) group (Fisher’s exact test, p=0.025). The age of 
the patients in the surgery group was slightly lower (65.8 years, ranging between 30.8 to 85.6 years) 
compared to the No Surgery group (72.4 years, ranging between 44.1 to 82.4 years), although this 
was not statistically different (t-test, p=0.165). There was no difference in height, weight BMI, Charlson 
co-morbidity index, smoking status or alcohol intake. 
Bowel-first
(All)
Bowel-first 
(Elective)
Bowel-first 
(Emergency) Statistical Test p-value
n 75 59 16
Median Age, years 65.7 62.3 66.7
Median Age Range, years 30.8 - 85.6 34.7 - 85.6 30.8 - 81.1
Sex, male (%) 54 (72.0%) 43 (72.9%) 11 (68.8%) Fisher's exact 0.082
Mean Height (SD), m 1.7 (0.1) 1.7 (0.1) 1.6 (0.2) t-test 0.217
Mean Weight (SD), kg 77.4 (14.4) 78.0 (15.1) 75.2 (12.1) t-test 0.503
Mean BMI (SD), kg/m2 27.2 (5.4) 27.1 (4.9) 27.8 (7.7) t-test 0.690
Charlson Score (median) 9 9 9
Charlson Score (range) 6 - 12 6 - 12 6 - 12
Smoker (%) 8 (11.9%) 7 (13.2%) 1 (7.1%)
mean/day (range) 10 (5 - 40) 10 (6 - 40) 10 (5 - 15)
Ex-smoker (%) 17 (25.4%) 14 (26.4%) 3 (21.4%)
Non-smoker (%) 42 (62.7%) 32 (60.4%) 10 (71.4%)
Current Alcohol 41 (63.1%) 34 (65.4%) 7 (53.8%)
Median units/week 8 10 6
BMI, Body Mass Index
Fisher's exact 0.193
t-test 0.603
Mann-Whitney 0.700
Fisher's exact 0.307
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Table 28. Demographics of Patients undergoing Surgery vs No Surgery 
 
  
All Surgery No Surgery Statistical Test p-value
n 125 109 16
Median Age, years 66.5 65.8 72.4
Median Age Range, years 30.8 - 85.6 30.8 - 85.6 44.1 - 82.4
Sex, male (%) 80 (64.0%) 74 (67.9%) 6 (37.5%) Fisher's exact 0.025
Mean Height (SD), m 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) t-test 0.526
Mean Weight (SD), kg 78.2 (16.1) 77.7 (15.4) 82.2 (21.0) t-test 0.366
Mean BMI (SD), kg/m2 27.3 (5.9) 27.2 (5.5) 28.8 (8.9) t-test 0.443
Charlson Score (median) 9 9 10
Charlson Score (range) 6 - 14 6 - 12 7 - 14
Smoker (%) 13 (11.5%) 12 (12.1%) 1 (7.1%)
mean/day (range) 10 (5 - 80) 10 (5 - 80) #
Ex-smoker (%) 31 (27.4%) 24 (24.2%) 7 (50.0%)
Non-smoker (%) 69 (61.1%) 63 (63.6%) 6 (42.9%)
Current Alcohol 60 (56.1%) 56 (58.9%) 4 (33.3%)
Median units/week 8 8 20
# Insufficient data; BMI, Body Mass Index.
Fisher's exact 0.125
t-test 0.165
Mann-Whitney 0.149
Fisher's exact 0.147
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6.1.7 Presentation 
Presenting symptoms are shown in Table 29. The majority of patients (72.0%) were symptomatic at 
the time of presentation, with symptoms including alteration of bowel habit (40.8%), rectal bleeding 
(32.0%), abdominal pain (22.4%), weight loss (8.8%) and/or a palpable abdominal mass (2.4%). A 
higher number of patients presented with symptoms underwent a liver-first surgical strategy (94.4%) 
compared to bowel-first (62.7%) and synchronous groups (68.8%). Overall, the majority of patients 
presented with alteration of bowel habit and/or rectal bleeding. A smaller proportion of patients (15.2%) 
were asymptomatic, presenting either through the UK’s Bowel Cancer Screening Programme (10.4%), 
with iron-deficient anaemia (12.0%) or incidentally with imaging for another clinical reason (3.2%). No 
patients presented as a cancer of unknown primary (CUP). Of the 16 patients who presented as an 
emergency to their local hospital, 15 patients (12.0%) presented with intestinal obstruction, and 3 
patients (2.4%) with clinical signs of peritonitis/perforation. Only 15 patients (12.0%) required an acute 
intervention with either a colonic stent (7 patients, 8.3%) or a defunctioning stoma (8 patients, 6.4%).  
 
Table 29. Presenting Symptoms 
 
  
All Liver First Bowel First Synchronous No Surgery
n 125 18 75 16 16
Asymptomatic Presentation* 19 (15.2%) 1 (5.6%) 11 (14.7%) 5 (31.2%) 2 (12.5%)
Bowel Screening Programme 13 (10.4%) 1 (5.6%) 8 (10.7%) 2 (12.5%) 2 (12.5%)
Incidental Finding 4 (3.2%) 0 (0.0%) 3 (4.0%) 1 (6.2%) 0 (0.0%)
Iron Deficient Anaemia 15 (12.0%) 0 (0.0%) 7 (9.3%) 3 (18.8%) 5 (31.2%)
Liver Met as CUP 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Symptomatic Presentation* 90 (72.0%) 17 (94.4%) 47 (62.7%) 11 (68.8%) 14 (87.5%)
Alteration of Bowel Habit 51 (40.8%) 9 (50.0%) 28 (37.3%) 7 (43.8%) 7 (43.8%)
Rectal Bleeding 40 (32.0%) 11 (61.1%) 17 (22.7%) 6 (37.5%) 6 (37.5%)
Palpable Mass 3 (2.4%) 0 (0.0%) 2 (2.7%) 1 (6.2%) 0 (0.0%)
Abdominal Pain 28 (22.4%) 1 (5.6%) 19 (25.3%) 6 (37.5%) 2 (12.5%)
Weight Loss 11 (8.8%) 1 (5.6%) 5 (6.7%) 1 (6.2%) 4 (25.0%)
Emergency Presentation* 16 (12.8%) 0 (0.0%) 16 (21.3%) 0 (0.0%) 0 (0.0%)
Intestinal Obstruction 15 (12.0%) 0 (0.0%) 15 (20.0%) 0 (0.0%) 0 (0.0%)
Perforation / Peritonitis 3 (2.4%) 0 (0.0%) 3 (4.0%) 0 (0.0%) 0 (0.0%)
Emergency Intervention
Colonic Stent 7 (8.3%) 0 (0.0%) 5 (8.1%) 2 (13.3%) 0 (.%)
Defunctioning Stoma 8 (6.4%) 2 (11.1%) 5 (6.7%) 0 (0.0%) 1 (6.2%)
* Patients may have presented with more than one symptom; CUP, Cancer of Unknown Primary.
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6.1.8 Primary Disease 
The location of the colorectal primary is summarised in Table 30. The majority of patients presented 
with left sided colorectal primary tumours (74.4%), with the rectum (34 patients, 27.2%) and sigmoid 
colon (44 patients, 35.2%) being the most common primary site. The medial distance from the anal 
margin was 9 cm (range 0 – 20 cm). The caecum was the most common site for right sided colonic 
tumours, presenting in 15 (12.0%) of patients. T3 was the most common tumour stage (79 patients, 
64.2%), with a smaller proportion presenting with T4 tumours (34 patients, 27.6%). TNM staging was 
not recorded in 2 patients in the No Surgery Group. There were similar proportions of patients with T3 
and T4 disease across the groups, including the No Surgery group. Nodal disease, however, was 
more extensive in the No Surgery group, where 42.9% presented with N2 disease.  
In the CoSMIC cohort, all patients undergoing a liver-first strategy presented with a distal left sided 
primary, most commonly the rectum (13 of 18 patients, 72.2%). This may represent the ‘window’ for 
liver resection for patients undergoing neoadjuvant long course chemoradiotherapy for the rectal 
primary. Other reasons for the liver-first strategy cited from the HPB MDT was disease progression in 
the liver which may become inoperable if liver resection is delayed whilst undergoing a bowel-first 
strategy. The most common primary location for patients undergoing a bowel-first resection was the 
sigmoid colon (30 of 75 patients, 40.0%), with a smaller proportion of caecal (13.3%), ascending 
(8.0%) and transverse (8.0%) colonic tumours. There was a higher proportion of patients undergoing a 
synchronous resection who presented with a caecal tumour (4 of 16 patients, 25.0%), although the 
most common primary location was still the sigmoid (6 patients, 37.5%) and rectosigmoid (3 patients, 
18.8%) colon. No patients in the synchronous group presented with rectal tumours. For patients not 
having surgery, rectal (6 of 16 patients, 37.5%) and sigmoid (5 patients, 31.2%) were the most 
common primary locations. 
Eighty-three patients (66.4%) were tested for the KRAS mutant status, of which 37 patients (44.6%) 
exhibited a KRAS mutation. There was a similar proportion of KRAS wild-type and mutant patients 
across all treatment strategies. Interestingly, only 1 patient (16.7%) in the No Surgery group exhibited 
the KRAS mutation, although this may be a chance finding due to the small numbers tested (37.5%). 
Of the patients tested for the NRAS mutant status (60 patients, 48.0%), no patients exhibited an NRAS 
mutation. 
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Table 30. Colorectal Primary Tumour Location and Staging 
 
6.1.9 Liver Metastatic Disease 
The metastatic liver disease burden at diagnosis is described in Table 31. Contrast-enhanced CT of 
the liver was performed in all patients. MR liver also was performed prior to liver surgery in the majority 
of patients (91.2%) as was [18F]FDG PET/CT (75.6%). All patients undergoing liver resection in the 
liver-first strategy underwent an MR liver as did the majority of patients (93.8%) in the synchronous 
group. Two-thirds of patients presented with unilobar metastatic liver disease which was predominantly 
distributed in the right lobe (77.3%). Only 4 patients (3.2%) presented with disease in the caudate 
lobe. All patients in CoSMIC undergoing a liver-first strategy with unilobar liver metastases presented 
All Liver First Bowel First Synchronous No Surgery
n 125 18 75 16 16
Primary CRC Location
Caecum 15 (12.0%) 0 (0.0%) 10 (13.3%) 4 (25.0%) 1 (6.2%)
Ascending Colon 7 (5.6%) 0 (0.0%) 6 (8.0%) 0 (0.0%) 1 (6.2%)
Transverse / splenic 10 (8.0%) 0 (0.0%) 6 (8.0%) 2 (12.5%) 2 (12.5%)
Descending 4 (3.2%) 0 (0.0%) 3 (4.0%) 1 (6.2%) 0 (0.0%)
Sigmoid 44 (35.2%) 3 (16.7%) 30 (40.0%) 6 (37.5%) 5 (31.2%)
Rectosigmoid 11 (8.8%) 2 (11.1%) 5 (6.7%) 3 (18.8%) 1 (6.2%)
Rectal 34 (27.2%) 13 (72.2%) 15 (20.0%) 0 (0.0%) 6 (37.5%)
Median Distance from 
Anal Margin, cm (range)
9 (0 - 20) 7 (0 - 15) 9 (3 - 20) 18 (16 - 20) 6.5 (2 - 9)
TMN Staging
T1 1 (0.8%) 0 (0.0%) 0 (0.0%) 1 (6.2%) 0 (0.0%)
T2 9 (7.3%) 0 (0.0%) 6 (8.0%) 2 (12.5%) 1 (7.1%)
T3 79 (64.2%) 16 (88.9%) 42 (56.0%) 11 (68.8%) 10 (71.4%)
T4 34 (27.6%) 2 (11.1%) 27 (36.0%) 2 (12.5%) 3 (21.4%)
TX 2 (1.6%) - - - 2 (12.5%)
N0 22 (17.9%) 5 (27.8%) 10 (13.3%) 5 (31.2%) 2 (14.3%)
N1 58 (47.2%) 7 (38.9%) 36 (48.0%) 9 (56.2%) 6 (42.9%)
N2 43 (35.0%) 6 (33.3%) 29 (38.7%) 2 (12.5%) 6 (42.9%)
NX 2 (1.6%) - - - 2 (12.5%)
KRAS Status
No. Patients tested (%) 83 (66.4%) 14 (77.8%) 55 (73.3%) 8 (50.0%) 6 (37.5%)
KRAS Mutant Status (%) 37 (44.6%) 6 (42.9%) 26 (47.3%) 4 (50.0%) 1 (16.7%)
NRAS Status
No. Patients tested (%) 60 (48.0%) 9 (50.0%) 45 (60.0%) 3 (18.8%) 3 (18.8%)
NRAS Mutant Status (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
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with disease in the right liver only. The proportion of unilobar right sided disease was also greater in 
bowel-first (77.3%) and synchronous (80.0%) patients. There were 50 patients (40.0%) presenting with 
bilobar liver metastatic disease with similar proportions in each treatment group (Fisher’s exact test, 
p=0.887). There was no difference in the distribution of liver metastatic disease across the couinaud 
segments between the treatment groups (individual Fisher’s exact test, all p>0.050). The median 
number of liver lesions was 2, ranging from 1 to 20 lesions, and did not differ significantly between 
treatment groups (Fisher’s exact test, p=0.428). The mean average diameter of the largest liver lesion 
was 3.3 ± 2.8 cm, with patients undergoing no surgery having the largest average of 5.5 cm. The size 
of the largest lesion was statistically different between the treatment groups (ANOVA, p=0.018).  
 
 
Table 31. Distribution of Liver Metastatic Disease and Indeterminant Thoracic Lesions 
All Liver First Bowel First Synchronous No Surgery
n 125 18 75 16 16
Liver Metastases
Unilobar Distribution 75 (60.0%) 10 (55.6%) 44 (58.7%) 10 (62.5%) 11 (68.8%)
Right (% of unilobar distribution) 58 (77.3%) 10 (100.0%) 34 (77.3%) 8 (80.0%) 6 (54.5%)
Left (% of unilobar distribution) 17 (22.7%) 0 (0.0%) 10 (22.7%) 2 (20.0%) 5 (45.5%)
Bilobar Distribution 50 (40.0%) 8 (44.4%) 31 (41.3%) 6 (37.5%) 5 (31.2%)
Median Number of Lesions (range) 2 (1 - 20) 2 (1 - 7) 2 (1 - 20) 1.5 (1 - 11) 1.5 (1 - 12)
Size of Largest Lesion, cm (SD) 3.3 (2.7) 3.2 (2.0) 2.8 (2.3) 3.7 (3.1) 5.2 (4.3)
Couinaud Segmentsa
I 4 (3.2%) 2 (11.1%) 1 (1.3%) 0 (0.0%) 1 (6.2%)
II 32 (25.6%) 4 (22.2%) 18 (24.0%) 4 (25.0%) 6 (37.5%)
III 17 (13.6%) 0 (0.0%) 12 (16.0%) 2 (12.5%) 3 (18.8%)
IV 44 (35.2%) 6 (33.3%) 26 (34.7%) 5 (31.2%) 7 (43.8%)
V 50 (40.0%) 6 (33.3%) 31 (41.3%) 4 (25.0%) 9 (56.2%)
VI 52 (41.6%) 7 (38.9%) 33 (44.0%) 6 (37.5%) 6 (37.5%)
VII 62 (49.6%) 8 (44.4%) 40 (53.3%) 8 (50.0%) 6 (37.5%)
VIII 52 (41.6%) 9 (50.0%) 29 (38.7%) 7 (43.8%) 7 (43.8%)
MR Liver 114 (91.2%) 18 (100.0%) 68 (90.7%) 15 (93.8%) 13 (81.2%)
[18F]FDG PET/CT 93 (75.6%) 12 (66.7%) 62 (83.8%) 11 (73.3%) 8 (50.0%)
Indeterminant Thoracic Lesions 14 (11.3%) 4 (22.2%) 6 (8.0%) 4 (25.0%) 0 (0.0%)
Bilateral 11 (78.6%) 3 (75.0%) 5 (83.3%) 3 (75.0%) 0 (.%)
Number of Lesions, Median (range) 1.4 (1.0-5.0) 1.2 (1.0-2.0) 1.2 (1.0-2.0) 2.0 (1.0-5.0) -
Size of largest lesion, cm (SD) 0.5 (0.5) 0.4 (0.4) 0.8 (0.8) 0.5 (0.5) -
a, Lesions may be present across segments; MR, Magnetic Resonance.
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A small proportion of patients (11.3%) also presented with indeterminant thoracic lesions, most of 
which were bilateral (78.6%). The number of lesions ranged between 1 and 5, with the average 
diameter being 0.5 ± 0.5 cm. There was a significantly higher number of patients presenting with 
indeterminate thoracic lesions in those patients undergoing a liver-first (22.2%) or synchronous 
(25.0%) strategy (Fisher’s exact test, p=0.039) although this may be a chance finding. 
 
 
6.1.10 Pre-operative Investigations 
Preoperative investigations in the form of blood tests and cardiopulmonary exercise testing (CPET) for 
patients in CoSMIC are shown in Table 32. Preoperative blood testing shows that patients not 
undergoing surgery were more likely to have a low haemoglobin level than any of the surgical groups 
(ANOVA, p=0.036). There was also a significantly higher platelet count in the No Surgery group 
(ANOVA, p=0.004). Although patients undergoing bowel-first surgery exhibited a significantly higher 
bilirubin level (ANOVA, p=0.004), the values were not at a level to signify jaundice. There was no 
difference in serum urea and creatinine, C-reactive protein, prothrombin time, alkaline phosphatase 
and alanine transaminase (ANOVA, all p>0.05). 
There is no difference between patient groups undergoing surgery in terms of the WHO Performance 
Score, where the median score was 0 (defined as ‘fully active, able to carry out all normal activity 
without restriction’). Patients not undergoing surgery had a higher WHO Performance Score, but this 
was not significantly different (Fisher’s exact test, p=0.186). CPET was also carried prior to liver 
resection in just under half of the CoSMIC patient cohort, with more patients undergoing CPET testing 
in the synchronous group (75.0%) compared to the liver-first (66.7%) and bowel-first (44.0%) groups. 
Only 3 of 16 patients (18.8%) in the No Surgery group underwent CPET testing, which resulted in a 
change of treatment strategy in all of those patients to having no surgery. The anaerobic threshold was 
between 12.0 and 12.4 ml/min/kg for patients undergoing surgery, and a lower threshold (9 ml/min/kg) 
in the No Surgery group (ANOVA, p=0.055). The maximum oxygen uptake (VO2) was also significantly 
higher in those undergoing surgery (18.0 to 18.9 ml/min/kg) than those in the No Surgery group (11.9 
ml/min/kg) (ANOVA, p=0.037). The maximal volume of carbon dioxide (VCO2) was also found to be 
significantly higher in patients not undergoing surgery (Fisher’s exact test, p=0.028). 
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Table 32. Pre-operative Investigations 
 
6.1.11 Surgery – Colorectal Primary Resection 
Details of the colorectal primary resection is shown in Table 33. In total, 109 patients (87.2% of the 
CoSMIC cohort) were planned for a colonic resection. Of these, 1 patient (0.9%) had a complete 
oncological response to chemoradiotherapy and so opted for a surveillance strategy for the bowel 
primary rather than surgery. One patient in the No Surgery group also reported a complete response 
of the primary tumour to chemoradiotherapy (data not shown). In both patients, the response was seen 
radiologically (MR) and endoscopically. Overall, 8 patients (7.3% of those started on a surgical 
pathway) failed to proceed to a bowel resection, of which 7 were in the liver-first group. 
The colonic resections reflecting the frequency distribution of the bowel primary described are Table 
30, where most patients presented with a sigmoid tumour and underwent a left sided colonic resection. 
Between groups, there was a higher number of patients undergoing a caecal resection in the 
synchronous and bowel-first groups than in the liver first group. The majority of colorectal resections 
were open procedures (67.0%), with all synchronous resections recorded in CoSMIC performed as 
open procedures. Of the 25 patients who underwent a laparoscopic resection, 2 patients (2.0%) were 
laparoscopic-assisted procedures and 4 patients (4.0%) were converted to an open procedure, all in 
All Liver First Bowel First Synchronous No Surgery Statistical Test p-value
n 125 18 75 16 16
Hb, g/L 124.0 (20.8) 132.5 (13.3) 122.7 (23.8) 128.6 (13.9) 111.2 (17.6) ANOVA 0.036
Platelets, x109/L 299.6 (84.0) 265.5 (67.9) 295.7 (78.6) 288.3 (94.6) 375.6 (71.9) ANOVA 0.004
Urea, mmol/L 6.4 (13.6) 4.6 (1.2) 8.0 (18.7) 4.7 (1.4) 5.0 (1.3) ANOVA 0.717
Creatinine, µmol/L 81.0 (18.2) 79.3 (13.6) 83.5 (18.2) 77.1 (20.8) 78.3 (21.0) ANOVA 0.562
CRP, mg/L 18.2 (23.9) 8.8 (21.8) 25.7 (28.3) 10.6 (13.0) 28.4 (21.1) ANOVA 0.074
PT, seconds 12.3 (1.9) 12.5 (1.4) 11.8 (1.6) 13.0 (2.8) 12.4 (2.1) ANOVA 0.263
ALP, µ/L 113.7 (76.2) 94.5 (37.9) 127.5 (99.3) 97.0 (46.2) 111.2 (27.1) ANOVA 0.347
ALT, IU/L 26.4 (18.8) 34.6 (19.3) 27.5 (23.0) 21.4 (7.8) 17.6 (11.0) ANOVA 0.081
Bilirubin, µmol/L 8.3 (4.9) 5.8 (2.1) 10.2 (5.8) 7.3 (4.0) 6.6 (3.0) ANOVA 0.004
Albumin, g/L 38.0 (5.9) 37.5 (2.9) 38.7 (6.3) 37.7 (4.4) 36.7 (9.0) ANOVA 0.711
CEA, ng/L 110.0 (402.9) 53.5 (140.5) 95.8 (452.3) 196.3 (464.1) 143.0 (226.5) ANOVA 0.774
WHO PS, Median (Range) 0 (0 - 3) 0 (0 - 1) 0 (0 - 3) 0 (0 - 2) 1.5 (0 - 3) Fisher's exact 0.186
CPET (%) 60 (48.0%) 12 (66.7%) 33 (44.0%) 12 (75.0%) 3 (18.8%) Fisher's exact 0.004
VO2 @ AT, ml/kg/min 12.0 (2.0) 12.0 (2.0) 12.2 (1.9) 12.4 (1.8) 9.0 (0.9) ANOVA 0.055
VO2 peak, ml/kg/min 17.9 (3.8) 18.9 (4.5) 18.0 (3.5) 18.3 (3.4) 11.9 (2.5) ANOVA 0.037
VE/VCO2 @ AT 31.1 (6.1) 31.6 (4.2) 30.9 (5.5) 28.6 (7.8) 40.3 (6.0) ANOVA 0.028
CPET changes treatment 4 (7.1%) 0 (0.0%) 1 (3.2%) 0 (0.0%) 3 (100.0%) Fisher's exact 0.000
Hb, Haemoglobin; CRP, C-Reactive Protein; PT, Prothrombin Time; ALP, Alkaline Phosphatase; ALT, Alaline Transaminase, CEA, Carcinoembryonic 
antigen; WHO PS, World Health Organization Performance Score; CPET, Cardiopulmonary Exercise Testing; VO2 @ AT, oxygen uptake at the anaerobic 
threshold; VO2 peak, maximum oxygen uptake; VE/VCO2 @ AT, minute ventilation/carbon dioxide production ratio at the anaerobic threshold.
Blood tests, mean (SD)
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the bowel-first group. A primary anastomosis was performed in the majority of patients (70 patients, 
87.5%), including all patients undergoing a synchronous bowel and liver resection (figures exclude 
Hartmann’s procedures and abdominoperoneal resections). Where a primary anastomosis was 
formed, a defunctioning stoma was created in 20 patients (34.3%), with a large proportion formed in 
those undergoing a liver-first resection (83.3%) which reflects the observation that the majority of these 
patients have left sided tumours requiring anterior resection. Four patients (33.3%) in the synchronous 
group had defunctioning stomas formed.  
 
Table 33. Resection of the Colorectal Primary  
Perioperative outcome data following colorectal primary resection is shown in Table 34. The resection 
margins were R0 in the majority of colorectal resections (90.0%), with only a small number of R1 
(9.0%) and R2 (1.0%) margins. 
All Elective Emergency
n 109 18 75 58 17 16
Operation
Right Hemicolectomy 20 (18.2%) 0 (0.0%) 16 (21.3%) 12 (20.3%) 4 (25.0%) 4 (25.0%)
Extended Right Hemicolectomy 7 (6.4%) 0 (0.0%) 6 (8.0%) 2 (3.4%) 4 (25.0%) 1 (6.2%)
Left Hemicolectomy 4 (3.6%) 0 (0.0%) 4 (5.3%) 3 (5.1%) 1 (6.2%) 0 (0.0%)
Sigmoid Colectomy 6 (5.5%) 0 (0.0%) 3 (4.0%) 3 (5.1%) 0 (0.0%) 3 (18.8%)
Hartmanns 14 (12.7%) 0 (0.0%) 10 (13.3%) 4 (6.8%) 6 (37.5%) 4 (25.0%)
High Anterior Resection 21 (19.1%) 3 (16.7%) 16 (21.3%) 16 (27.1%) 0 (0.0%) 2 (12.5%)
Low Anterior Resection 18 (16.4%) 5 (27.8%) 12 (16.0%) 12 (20.3%) 0 (0.0%) 1 (6.2%)
Abdominoperoneal Resection 6 (5.5%) 2 (11.1%) 4 (5.3%) 4 (6.8%) 0 (0.0%) 0 (0.0%)
Subtotal Colectomy 3 (2.7%) 0 (0.0%) 3 (4.0%) 2 (3.4%) 1 (6.2%) 0 (0.0%)
Local / Wedge Resection 1 (0.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
No Surgery (Complete Response) 1 (0.9%) 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
No Surgery (Failed Pathway) 8 (7.3%) 7 (38.9%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
Total Patients Undergoing Bowel Surgery 100 10 74 58 16 16
Modality
Open 67 (67.0%) 6 (60.0%) 45 (60.8%) 30 (51.7%) 15 (93.8%) 16 (100.0%)
Laparoscopic 27 (27.0%) 4 (40.0%) 23 (31.1%) 23 (39.7%) 0 (0.0%) 0 (0.0%)
Laparoscopic-assisted 2 (2.0%) 0 (0.0%) 2 (2.7%) 2 (3.4%) 0 (0.0%) 0 (0.0%)
Laparoscopic-converted to Open 4 (4.0%) 0 (0.0%) 4 (5.4%) 3 (5.2%) 1 (6.2%) 0 (0.0%)
Primary Anastomosis, n (%) * 70 (87.5%) 6 (75.0%) 52 (86.7%) 45 (90.0%) 7 (70.0%) 12 (100.0%)
Defunctioning Stoma, n (%) ** 20 (28.6%) 5 (83.3%) 11 (21.2%) 10 (22.2%) 1 (14.3%) 4 (33.3%)
*Primary Anastomoses performed for all patients undergoing bowel sugery (excludes Hartmann's Procedures and Abdominoperoneal Resections); **Defunctioning 
stomas fashioned for those undergoing primary anastomoses.
All Surgical 
Patients Liver First
Bowel First
Synchronous
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Table 34. Perioperative outcomes following bowel surgery 
 
6.1.12 Surgery - Liver Resection 
Details of liver resection surgery is shown in Table 35. Liver resections in CoSMIC are classified using 
the Brisbane 2000 Terminology of Liver Anatomy and Resections[102]. Parenchymal-sparing liver 
resections are presented separately or as part of an anatomical resection[103]. There were 109 
patients in CoSMIC who were on a surgical pathway with a view to liver resection. Ten patients on the 
bowel-first strategy failed to progress to the liver resection stage of the pathway, and 3 patients (2.8%) 
- 2 from the bowel-first group and 1 synchronous patient - were found to have inoperable disease at 
the time of surgery and so liver resection was abandoned. One patient had a complete response from 
chemotherapy and so opted not to undergo liver resection, and another patient underwent 
radiofrequency ablation rather than surgery. In total, 94 patients in the CoSMIC cohort underwent a 
liver resection. The majority of liver resections were performed as open procedures (87.6%), with all 
patients in the liver-first and synchronous groups undergoing open procedures.  
The type of hepatectomy varied significantly between the different surgical strategies. Synchronous 
patients were more likely to undergo parenchymal-sparing resections, which reflects the significantly 
lower liver transection time and the Pringle time in the synchronous group compared to the staged 
group (t-test, p=0.033 and t-test, p=0.004 respectively). There was no difference in the estimated 
blood loss between any of the groups (t-test, p=0.369). No liver-first patients underwent a 
parenchymal-sparing resection as the primary procedure.  
All Elective Emergency
Total Patients Undergoing Bowel Surgery 100 10 74 58 16 16
Grade I 50 (64.1%) 8 (88.9%) 38 (71.7%) 33 (76.7%) 5 (50.0%) 4 (25.0%)
Grade II 20 (25.6%) 0 (0.0%) 12 (22.6%) 9 (20.9%) 3 (30.0%) 8 (50.0%)
Grade IIIA 5 (6.4%) 1 (11.1%) 1 (1.9%) 0 (0.0%) 1 (10.0%) 3 (18.8%)
Grade IIIB 2 (2.6%) 0 (0.0%) 2 (3.8%) 1 (2.3%) 1 (10.0%) 0 (0.0%)
Grade IV 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
Grade V 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Missing data 22 1 21 15 6 0
Anastomotic Leak Rate 2 (4.3%) 1 (16.7%) 1 (1.9%) 0 (0.0%) 1 (14.3%)% 0 (0.0%)
Reoperation 3 (3.4%) 0 (0.0%) 2 (3.2%) 1 (2.0%) 1 (7.1%) 1 (6.2%)
Length of Critical Care Stay, days (SD) 2.8 (3.7) 1.9 (1.6) 2.0 (3.8) 1.1 (1.7) 5.9 (6.8) 5.2 (2.9)
Length of Hospital Stay, days (SD) 10.6 (7.9) 10.9 (7.5) 8.7 (6.2) 6.9 (3.5) 16.7 (9.1) 16.8 (10.3)
R0 90 (90.0%) 8 (80.0%) 67 (90.5%) 52 (89.7%) 15 (93.8%) 15 (93.8%)
R1 9 (9.0%) 2 (20.0%) 6 (8.1%) 5 (8.6%) 1 (6.2%) 1 (6.2%)
R2 1 (1.0%) 0 (0.0%) 1 (1.4%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
Resection Margin
Postoperative Complications (Clavian-Dindo Classification)
All Patients Liver First
Bowel First
Synchronous
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More than half of patients underwent a major liver resection (defined as more than 3 segments of the 
liver removed). A similar proportion of bowel-first and liver-first patients underwent a right hepatectomy 
compared to a smaller proportion in the synchronous group. A higher proportion of synchronous 
patients, however, underwent left lateral sectionectomy than staged resection patients. These data 
suggest that synchronous patients generally undergo more minor liver resections than staged patients. 
Although there was a slightly lower rate of major liver resection for synchronous patients (40%), this 
was not statistically significant (Fisher’s exact test, p=0.090).  
Three patients overall underwent a two staged liver resection: 2 patients in the bowel-first group and 1 
patient who had the first stage of his liver resection during a synchronous resection. Similar numbers 
are seen with preoperative portal vein embolization. 
Perioperative outcomes following liver resection is shown in Table 36. Overall, 13 patients (13.8%) had 
serious postoperative complications that required endoscopic or radiological intervention, or a return to 
the Critical Care Unit. The mean length of critical care stay was 3.9 days, and the overall hospital stay 
was 9.4 days. There were no deaths within a 30 days period. A small minority of patients (2.1%) 
experienced liver failure following resection. The overall bile leak rate was 6.5%, of which only 3 
patients (3.2%) had clinically significant bile leaks (ISGLS grades B and C). There were no return-to-
theatre cases.  
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Table 35. Resection of Liver Metastatic Disease 
All Elective Emergency
n 109 18 75 59 16 16
Right Hepatectomy 28 (25.7%) 4 (22.2%) 22 (29.3%) 17 (28.8%) 5 (31.2%) 2 (12.5%)
Right Anterior Sectionectomy 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Right Posterior Sectionectomy 7 (6.4%) 2 (11.1%) 4 (5.3%) 3 (5.1%) 1 (6.2%) 1 (6.2%)
Right Trisectionectomy 3 (2.8%) 1 (5.6%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 1 (6.2%)
Left Hepatectomy 4 (3.7%) 0 (0.0%) 4 (5.3%) 4 (6.8%) 0 (0.0%) 0 (0.0%)
Left Lateral Sectionectomy 7 (6.4%) 0 (0.0%) 5 (6.7%) 3 (5.1%) 2 (12.5%) 2 (12.5%)
Left Trisectionectomy 3 (2.8%) 1 (5.6%) 2 (2.7%) 1 (1.7%) 1 (6.2%) 0 (0.0%)
Caudate Lobe Resection 2 (1.8%) 1 (5.6%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
Segmentectomy 10 (9.2%) 3 (16.7%) 4 (5.3%) 2 (3.4%) 2 (12.5%) 3 (18.8%)
Bisegmentectomy 9 (8.3%) 5 (27.8%) 3 (4.0%) 3 (5.1%) 0 (0.0%) 1 (6.2%)
Parenchymal-Sparing Resection 21 1 15 12 3 5
One Segment 3 (14.3%) 0 (0.0%) 2 (13.3%) 2 (16.7%) 0 (0.0%) 1 (20.0%)
Two Segments 6 (28.6%) 0 (0.0%) 5 (33.3%) 4 (33.3%) 1 (33.3%) 1 (20.0%)
Three Segments 5 (23.8%) 0 (0.0%) 4 (26.7%) 4 (33.3%) 0 (0.0%) 1 (20.0%)
Four or More Segments 7 (33.3%) 1 (100.0%) 4 (26.7%) 2 (16.7%) 2 (66.7%) 2 (40.0%)
Parenchymal-Sparing Resection (as part of 
anatomical resection) 32 7 21 16 5 4
One Segment 14 (43.8%) 3 (42.9%) 8 (38.1%) 5 (31.2%) 3 (60.0%) 3 (75.0%)
Two Segments 10 (31.2%) 1 (14.3%) 8 (38.1%) 6 (37.5%) 2 (40.0%) 1 (25.0%)
Three Segments 8 (25.0%) 3 (42.9%) 5 (23.8%) 5 (31.2%) 0 (0.0%) 0 (0.0%)
Four or More Segments 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Inoperable at time of resection 3 (2.8%) 0 (0.0%) 2 (2.7%) 1 (1.7%) 1 (6.2%) 1 (6.2%)
No Surgery (Failed Pathway) 10 (9.2%) 0 (0.0%) 10 (13.3%) 9 (15.3%) 1 (6.2%) 0 (0.0%)
No Surgery (Complete Response) 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
No Surgery (Radiofrequency Ablation) 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 0 (0.0%)
Total Patients Undergoing Liver Surgery 94 18 61 47 14 15
Open 85 (87.6%) 18 (100.0%) 51 (81.0%) 38 (79.2%) 13 (86.7%) 16 (100.0%)
Laparoscopic 9 (9.3%) 0 (0.0%) 9 (14.3%) 8 (16.7%) 1 (6.7%) 0 (0.0%)
Laparoscopic-assisted 1 (1.0%) 0 (0.0%) 1 (1.6%) 1 (2.1%) 0 (0.0%) 0 (0.0%)
Laparoscopic-converted to Open 2 (2.1%) 0 (0.0%) 2 (3.2%) 1 (2.1%) 1 (6.7%) 0 (0.0%)
Major Resection (>3 segments) 54 (57.4%) 11 (61.1%) 37 (60.7%) 28 (59.6%) 9 (64.3%) 6 (40.0%)
Planned Two-Stage Resection 3 (3.2%) 0 (0.0%) 2 (3.3%) 1 (2.1%) 1 (7.1%) 1 (6.7%)
Preoperative PVE 4 (22.2%) 1 (5.6%) 2 (2.7%) 2 (3.4%) 0 (0.0%) 1 (6.2%)
Mean Operative Time, mins ± SD 239.6 ± 93.0 254.6 ± 71.9 211.9 ± 66.6 214.2 ± 63.5 204.7 ± 77.6 329.7 ± 135.1
range 69.0 - 612.0 145.0 - 422.0 69.0 - 340.0 69.0 - 328.0 76.0 - 340.0 115.0 - 612.0
Mean Transection Time, mins ± SD 47.9 ± 25.4 56.3 ± 26.2 49.5 ± 25.1 48.5 ± 24.8 53.1 ± 27.8 34.2 ± 21.7
range 0.0 - 120.0 33.0 - 120.0 0.0 - 110.0 0.0 - 90.0 27.0 - 110.0 12.0 - 90.0
Mean Pringle Time, mins ± SD 22.1 ± 18.5 27.9 ± 15.2 23.9 ± 19.8 24.2 ± 20.4 22.7 ± 18.4 9.6 ± 12.2
range 0.0 - 80.0 0.0 - 60.0 0.0 - 80.0 0.0 - 80.0 0.0 - 52.0 0.0 - 37.0
Mean Est. Blood Loss, ml ± SD 479.8 ± 415.3 531.2 ± 510.6 500.0 ± 433.1 508.3 ± 428.0 466.7 ± 493.6 366.7 ± 255.0
range 50.0 - 1800.0 100.0 - 1500.0 50.0 - 1800.0 50.0 - 1800.0 100.0 - 1400.0 100.0 - 900.0
Median Blood Transfusion, units (range) 0.0 (0.0 - 1.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 1.0)
All Surgical 
Patients Liver First
Bowel First
Synchronous
Operation
Modality
Intraoperative
 PVE, Portal Vein Embolisation.
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Table 36. Perioperative Outcomes following liver surgery 
 
6.1.13 Overall Pathway 
A summary of the overall treatment pathway is shown in Table 37. Of the 125 patients enrolled onto 
CoSMIC, 109 patients were started on a potentially curative treatment pathway at the time of 
diagnosis. Upon completing the pathway (the endpoint at which we defined as either finishing planned 
adjuvant chemotherapy or the final stage of surgery if adjuvant chemotherapy was given), 82 patients 
(76.1%) were radiologically restaged, of which 53 patients (48.6%) were found to be disease free.  
Overall, 21 patients (19.3%) had failed the treatment pathway by way of not completing the intended 
surgical strategy. The highest rate of failure is seen in the liver-first group, where 7 out of 18 patients 
(38.9%) of patients had failed to proceed to a subsequent bowel resection. One patient in the 
synchronous group failed the pathway as the liver metastatic disease was found to be unresectable 
intraoperatively. For patients undergoing a bowel-first strategy, a slightly higher proportion of patients 
undergoing elective surgery failed to proceed to liver resection (18.6%) compared to those who 
underwent an emergency bowel resection (12.5%), although this was not statistically significant (Chi-
square test, p=0.490).  
All Elective Emergency
Total Patients Undergoing Liver Surgery 94 18 61 47 14 15
Grade I 53 (56.4%) 8 (47.1%) 42 (67.7%) 34 (72.3%) 8 (53.3%) 3 (20.0%)
Grade II 28 (29.8%) 4 (23.5%) 16 (25.8%) 10 (21.3%) 6 (40.0%) 8 (53.3%)
Grade IIIA 11 (11.7%) 5 (29.4%) 3 (4.8%) 2 (4.3%) 1 (6.7%) 3 (20.0%)
Grade IIIB 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade IV 2 (2.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade V 0 (0.0%) 0 (0.0%) 1 (1.6%) 1 (2.1%) 0 (0.0%) 1 (6.7%)
Liver Failure 2 (2.1%) 1 (5.6%) 1 (1.6%) 1 (1.6%) 0 (0.0%) 0 (0.0%)
Grade A 6 (6.5%) 0 (0.0%) 5 (8.2%) 4 (8.5%) 1 (7.1%) 1 (6.7%)
Grade B 3 (3.2%) 2 (11.8%) 1 (1.6%) 1 (2.1%) 0 (0.0%) 0 (0.0%)
Grade C 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Re-operation 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Length of Critical Care Stay (mean days) 3.9 (2.3) 4.1 (2.5) 3.4 (1.9) 3.3 (1.9) 3.7 (1.8) 5.3 (2.9)
Length of Hospital Stay (mean days) 9.4 (6.8) 10.1 (5.9) 7.4 (4.5) 7.1 (4.6) 8.6 (3.8) 16.6 (10.0)
Readmission within 30 days 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
R0 62 (66.0%) 12 (66.7%) 39 (63.9%) 28 (59.6%) 11 (78.6%) 11 (73.3%)
R1 32 (34.0%) 6 (33.3%) 22 (36.1%) 19 (40.4%) 3 (21.4%) 4 (26.7%)
R2 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Postoperative Complications (Clavian-Dindo Classification)
Resection Margin
ISGLS, International Study Group for Liver Surgery.
Bile Leak (ISGLS Grading)
All Patients Liver First
Bowel First
Synchronous
116
  
 
 
Table 37. Summary of overall surgical pathways 
 
6.1.14 Neoadjuvant Chemotherapy 
The neoadjuvant chemotherapy regimens used are detailed in Table 38. Nearly half (46.3%) of 
patients diagnosed with synchronous disease with the intention of surgery received neoadjuvant 
systemic chemotherapy. However, in contrast to other groups, the vast majority of liver-first patients 
(16 patients, 94.1%) received a single line of chemotherapy over a median 4.3 months, before 
proceeding to surgery 3.1 months later. Neoadjuvant agents were either oxaliplatin or irinotecan 
based, with the majority of regimes (83.3%) administered concurrently with 5-FU. We identified no 
patients who failed to progress to surgery following neoadjuvant chemotherapy. The majority of 
patients who were restaged prior to surgery were found to have either a partial (66.7%) response to 
chemotherapy or stable disease (16.7%). The adverse events (as classified by the Common 
Terminology Criteria for Adverse Events version 4.0) experienced by patients undergoing neoadjuvant 
chemotherapy is detailed in Table 39. 
All Elective Emergency
n 109 18 75 58 17 16
Neoadjuvant Chemotherapy 50 (46.3%) 16 (94.1%) 28 (37.3%) 26 (44.8%) - 6 (37.5%)
Mean Duration of Neoadjuvant Chemotherapy, months (SD) 4.6 (5.4) 4.3 (5.8) 4.9 (5.8) 4.2 (4.3) 14.3 (16.0) 4.2 (2.5)
Mean Duration between starting Neoadjuvant Chemotherapy to Surgery, months (SD) 7.2 (5.7) 7.4 (6.0) 7.3 (6.1) 6.6 (4.9) 15.9 (16.2) 6.5 (2.5)
Mean Duration between finishing Neoadjuvant Chemotherapy to Surgery, months (SD) 2.6 (2.0) 3.1 (1.3) 2.4 (2.4) 2.5 (2.5) 1.6 (0.2) 2.3 (0.5)
Failure to Progress to Surgery following Neoadjuvant Chemotherapy, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) - 0 (0.0%)
Chemotherapy between Surgeries 37 (42.0%) 6 (35.3%) 31 (43.7%) 21 (29.6%) 10 (14.1%) -
Mean Chemotherapy Duration, months (SD) 5.0 (5.3) 3.6 (4.2) 5.3 (5.5) 5.0 (3.8) 6.0 (8.1) -
Mean Duration between Stage 1 Surgery to Chemotherapy, months (SD) 2.7 (2.4) 3.7 (1.6) 2.5 (2.5) 2.0 (1.3) 3.5 (4.0) -
Mean Duration between Stage 1 Surgery to finishing Chemotherapy, months (SD) 7.4 (6.1) 7.3 (3.7) 7.4 (6.6) 6.4 (4.7) 9.5 (9.4) -
Mean Duration between finishing chemotherapy to Stage 2 Surgery, months (SD) 3.2 (2.6) 2.0 (.) 3.2 (2.7) 3.6 (3.3) 2.7 (0.9) -
Mean Duration between Staged Surgeries, months (SD) 3.6 (4.7) 2.2 (2.4) 4.7 (5.2) 4.1 (3.9) 7.1 (7.9) -
Failure to Progress to Stage 2 Surgery following Chemotherapy, n (%) 20 (21.5%) 7 (38.9%) 13 (17.3%) 11 (18.6%) 2 (12.5%) -
Adjuvant Chemotherapy 54 (62.1%) 5 (50.0%) 39 (61.9%) 30 (61.2%) 9 (64.3%) 10 (71.4%)
Mean Adjuvant Chemotherapy Duration, months (SD) 4.8 (4.4) 4.1 (2.6) 4.7 (5.0) 5.0 (5.6) 3.8 (1.9) 5.5 (2.8)
Mean Duration between Surgery and Adjuvant Chemotherapy, months (SD) 2.8 (2.3) 2.5 (1.8) 2.5 (2.1) 2.4 (2.3) 2.8 (1.4) 4.0 (2.7)
Mean Duration between Surgery and finishing Adjuvant Chemotherapy, months (SD) 7.6 (4.7) 6.6 (4.0) 7.2 (5.2) 7.3 (5.8) 6.6 (2.1) 9.5 (2.7)
Failure to Complete Surgical Pathway 21 (19.3%) 7 (38.9%) 13 (17.3%) 11 (18.6%) 2 (12.5%) 1 (6.2%)
No Disease 53 (48.6%) 8 (44.4%) 37 (49.3%) 29 (49.2%) 8 (50.0%) 8 (50.0%)
Disease present 29 (26.6%) 2 (11.1%) 21 (28.0%) 17 (28.8%) 4 (25.0%) 6 (37.5%)
Failed Pathway 21 (19.3%) 7 (38.9%) 13 (17.3%) 11 (18.6%) 2 (12.5%) 1 (6.2%)
Status Unknown 6 (5.5%) 1 (5.6%) 4 (5.3%) 2 (3.4%) 2 (12.5%) 1 (6.2%)
Disease Status on Exit Imaging
All Surgical 
Patients Liver First
Bowel First
Synchronous
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Table 38. Neoadjuvant Chemotherapy 
n 125 109 18 75 16 16
Neoadjuvant Chemotherapy 61 (49.6%) 50 (46.3%) 16 (94.1%) 28 (37.3%) 6 (37.5%) 11 (73.3%)
Neoadjuvant Chemotherapy Duration, mean months (SD) 5.6 (6.9) 4.6 (5.4) 4.3 (5.8) 4.9 (5.8) 4.2 (2.5) 9.7 (10.9)
Lines of Neoadjuvant Chemotherapy Lines, mean (SD) 1.2 (0.4) 1.1 (0.3) 1.0 (0.0) 1.1 (0.3) 1.2 (0.4) 1.5 (0.7)
Chemotherapy Agents
5-FU 59 (47.2%) 48 (44.0%) 15 (83.3%) 27 (36.0%) 6 (37.5%) 11 (68.8%)
Oxaliplain 38 (30.4%) 29 (26.6%) 7 (38.9%) 17 (22.7%) 5 (31.2%) 9 (56.2%)
Irinotecan 23 (18.4%) 17 (15.6%) 6 (33.3%) 10 (13.3%) 1 (6.2%) 6 (37.5%)
Raltitrexed 1 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
Mitomycin 1 (0.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
Biologic Agents
Bevacizumab 3 (2.4%) 2 (1.8%) 1 (5.6%) 1 (1.3%) 0 (0.0%) 1 (6.2%)
Cetuximab 13 (10.4%) 10 (9.2%) 3 (16.7%) 6 (8.0%) 1 (6.2%) 3 (18.8%)
Panitumumab 2 (1.6%) 2 (1.8%) 0 (0.0%) 1 (1.3%) 1 (6.2%) 0 (0.0%)
Long-course Chemoradiotherapy 12 (19.4%) 11 (21.6%) 7 (43.8%) 4 (13.8%) 0 (0.0%) 1 (9.1%)
Short-course Chemoradiotherapy 10 (15.9%) 9 (17.6%) 2 (12.5%) 7 (24.1%) 0 (0.0%) 1 (8.3%)
Restaged (RECIST) prior to Surgery 49 (92.5%) 49 (94.2%) 16 (100.0%) 27 (93.1%) 6 (85.7%) -
Complete Response 1 (2.1%) 1 (2.1%) 0 (0.0%) 1 (3.7%) 0 (0.0%) -
Partial Response 32 (66.7%) 32 (66.7%) 10 (62.5%) 18 (66.7%) 4 (80.0%) -
Stable Disease 8 (16.7%) 8 (16.7%) 4 (25.0%) 3 (11.1%) 1 (20.0%) -
Progressive Disease 7 (14.6%) 7 (14.6%) 2 (12.5%) 5 (18.5%) 0 (0.0%) -
Non-evaluable 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) -
CTCAE Adverse events, mean (range)
Grade 1 3.4 (0.0 - 11.0) 3.2 (0.0 - 11.0) 2.9 (0.0 - 8.0) 3.3 (0.0 - 11.0) 3.5 (1.0 - 7.0) 4.3 (0.0 - 9.0)
Grade 2 0.6 (0.0 - 4.0) 0.5 (0.0 - 4.0) 0.5 (0.0 - 2.0) 0.4 (0.0 - 4.0) 0.8 (0.0 - 2.0) 1.1 (0.0 - 2.0)
Grade 3 0.0 (0.0 - 1.0) 0.0 (0.0 - 1.0) 0 0.0 (0.0 - 1.0) 0 0
Grade 4 0 0 0 0 0 0
Grade 5 0 0 0 0 0 0
Synchronous No SurgeryBowel First*
*Excludes all emergency bowel-first resections; RECIST, Response Evaluation Criteria In Solid Tumours; CTCAE Common Terminology Criteria for Adverse Events v2.
All Liver FirstPatients on a surgical pathway
118
  
 
 
Table 39. Adverse events experienced by patients undergoing neoadjuvant chemotherapy 
 
Patients (n)
                                               Adverse Event Grade
CTCAE All G1 G2 G3 All G1 G2 G3 All G1 G2 G3 All G1 G2 G3
Neutropenia 2 1 1 0 2 1 1 0 0 0 0 0 0 0 0 0
Cardiac chest pain 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dry eye 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Watering eyes 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Abdominal pain 2 2 0 0 0 0 0 0 2 2 0 0 0 0 0 0
Anal pain 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0
Constipation 19 16 3 0 9 8 1 0 4 4 0 0 6 4 2 0
Dental caries 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
GORD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nausea 17 15 2 0 10 8 2 0 4 4 0 0 3 3 0 0
Oral pain 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Vomiting 5 5 0 0 3 3 0 0 1 1 0 0 1 1 0 0
Diarrhoea 21 14 7 0 11 8 3 0 8 5 3 0 2 1 1 0
Dry mouth 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Mucositis oral 20 19 1 0 12 12 0 0 5 4 1 0 3 3 0 0
Fatigue 15 13 2 0 6 5 1 0 7 7 0 0 2 1 1 0
Sepsis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Thrush 2 2 0 0 1 1 0 0 1 1 0 0 0 0 0 0
Urinary tract infection 1 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hypokalaemia 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Hypomagnesemia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Joint range of motion decreased 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Dysgeusia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Lethargy 17 16 1 0 12 11 1 0 2 2 0 0 3 3 0 0
Peripheral Motor Neuropathy 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Peripheral Sensory Neuropathy 26 23 3 0 15 14 1 0 7 6 1 0 4 3 1 0
Depression 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hiccups 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Alopecia 6 4 2 0 4 3 1 0 1 0 1 0 1 1 0 0
Dry Skin 4 4 0 0 3 3 0 0 1 1 0 0 0 0 0 0
Palmar-plantar erythrodysesthesia syndrome 10 8 1 1 7 5 1 1 3 3 0 0 0 0 0 0
Pain of skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Paronychia 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Prutitus 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Rash acneiform 7 6 1 0 6 6 0 0 0 0 0 0 1 0 1 0
Rash papulopustula 2 1 1 0 0 0 0 0 2 1 1 0 0 0 0 0
Thromboembolic event 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Psychiatric disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Vascular disorders
Key: CTCAE, Common Terminology Criteria for Adverse Events (version 4.0)
Blood and lymphatic system disorders
Cardiac disorders
Eye disorders
Gastrointestinal disorders
General disorders conditions
Infections and infestations
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Nervous system disorders
All patients undergoing surgery 
receiving neoadjuvant 
chemotherapy
Bowel First Liver First Synchronous
50 29 15 6
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6.1.15 Chemotherapy Between Staged Surgeries 
The chemotherapy given between staged surgeries is detailed in Table 40. There were 93 patients 
who underwent a staged resection strategy, with 75 patients (80.6%) having a bowel-first resection 
and 18 patients (19.4%) having a liver-first resection. Overall, 37 patients (41.4%) received one line of 
chemotherapy with an average of 3.6 months duration between surgeries. The time between the first 
stage of surgery and to receiving chemotherapy was 2.7 ± 2.4 months, and the time from finishing 
chemotherapy to the second stage of surgery was 3.2 ± 2.6 months. Of patients undergoing the liver-
first strategy, only a third of patients received chemotherapy before their colorectal resection. There 
was a higher proportion of bowel-first patients (64.7%) who initially presented as an emergency who 
were given chemotherapy prior to their liver resection than those who presented electively (32.8%). 
Most patients (80.7%) were restaged prior to second stage surgery, with nearly half of patients 
showing progressed disease. Less than half of patients had a partial response or stable disease state 
following chemotherapy between surgery. Twenty patients (21.5%) failed to progress to the second 
stage surgery, with a higher proportion failing the pathway in the liver-first group. 
The adverse events experienced by patients undergoing chemotherapy between their staged 
surgeries is shown in Table 41. 
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Table 40. Chemotherapy given between Staged Surgery 
All Elective Emergency
n 93 18 75 58 17
Chemotherapy between Surgeries 37 (42.0%) 6 (35.3%) 31 (43.7%) 21 (29.6%) 10 (14.1%)
Chemotherapy Duration, mean months (SD) 5.0 (5.3) 3.6 (4.2) 5.3 (5.5) 5.0 (3.8) 6.0 (8.1)
Lines of Chemotherapy Lines, mean (SD) 1.2 (0.4) 1.2 (0.4) 1.2 (0.5) 1.1 (0.5) 1.2 (0.4)
5-FU 37 (33.9%) 6 (33.3%) 31 (41.3%) 21 (35.6%) 10 (62.5%)
Oxaliplain 26 (23.9%) 2 (11.1%) 24 (32.0%) 15 (25.4%) 9 (56.2%)
Irinotecan 12 (11.0%) 3 (16.7%) 9 (12.0%) 8 (13.6%) 1 (6.2%)
Raltitrexed 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%)
Mitomycin 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Bevacizumab 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%)
Cetuximab 1 (0.9%) 1 (5.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Panitumumab 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%)
Aflibercept 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%)
Restaged (RECIST) prior to Surgery 46 (80.7%) 11 (73.3%) 35 (83.3%) 27 (79.4%) 8 (100.0%)
Complete Response 3 (6.5%) 1 (9.1%) 2 (5.7%) 0 (0.0%) 2 (25.0%)
Partial Response 11 (23.9%) 0 (0.0%) 11 (31.4%) 9 (33.3%) 2 (25.0%)
Stable Disease 10 (21.7%) 2 (18.2%) 8 (22.9%) 7 (25.9%) 1 (12.5%)
Progressive Disease 22 (47.8%) 8 (72.7%) 14 (40.0%) 11 (40.7%) 3 (37.5%)
Non-evaluable 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade 1 3.7 (0.0 - 7.0) 3.3 (0.0 - 6.0) 3.7 (0.0 - 7.0) 3.7 (0.0 - 7.0) 3.8 (1.0 - 7.0)
Grade 2 0.4 (0.0 - 2.0) 0.7 (0.0 - 2.0) 0.4 (0.0 - 2.0) 0.3 (0.0 - 2.0) 0.5 (0.0 - 2.0)
Grade 3 0.1 (0.0 - 1.0) 0 0.1 (0.0 - 1.0) 0.0 (0.0 - 1.0) 0.1 (0.0 - 1.0)
Grade 4 0 0 0 0 0
Grade 5 0 0 0 0 0
All Liver First
Bowel First
RECIST, Response Evaluation Criteria In Solid Tumours; CTCAE Common Terminology Criteria for Adverse Events v2.
Chemotherapy Agents
Biologic Agents
CTCAE Adverse events, mean (range)
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Table 41. Adverse events experienced by patients undergoing chemotherapy between surgeries 
Patients (n)
                                               Adverse Event Grade
CTCAE All G1 G2 G3 All G1 G2 G3 All G1 G2 G3
Neutropenia 2 1 1 0 2 1 1 0 0 0 0 0
Cardiac chest pain 1 0 0 1 1 0 0 1 0 0 0 0
Dry eye 0 0 0 0 0 0 0 0 0 0 0 0
Watering eyes 1 1 0 0 1 1 0 0 0 0 0 0
Abdominal pain 4 4 0 0 3 3 0 0 1 1 0 0
Anal pain 0 0 0 0 0 0 0 0 0 0 0 0
Constipation 8 7 1 0 8 7 1 0 0 0 0 0
Dental caries 1 1 0 0 1 1 0 0 0 0 0 0
GORD 0 0 0 0 0 0 0 0 0 0 0 0
Nausea 18 17 1 0 15 15 0 0 3 2 1 0
Oral pain 0 0 0 0 0 0 0 0 0 0 0 0
Vomiting 4 3 1 0 3 2 1 0 1 1 0 0
Diarrhoea 25 20 5 0 20 15 5 0 5 5 0 0
Dry mouth 0 0 0 0 0 0 0 0 0 0 0 0
Mucositis oral 14 13 1 0 10 9 1 0 4 4 0 0
Fatigue 7 7 0 0 5 5 0 0 2 2 0 0
Sepsis 1 0 1 0 1 0 1 0 0 0 0 0
Thrush 1 1 0 0 1 1 0 0 0 0 0 0
Urinary tract infection 0 0 0 0 0 0 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 0 0 0 0 0
Hypokalaemia 0 0 0 0 0 0 0 0 0 0 0 0
Hypomagnesemia 0 0 0 0 0 0 0 0 0 0 0 0
Joint range of motion decreased 0 0 0 0 0 0 0 0 0 0 0 0
Dysgeusia 0 0 0 0 0 0 0 0 0 0 0 0
Lethargy 25 25 0 0 21 21 0 0 4 4 0 0
Peripheral Motor Neuropathy 1 1 0 0 1 1 0 0 0 0 0 0
Peripheral Sensory Neuropathy 25 22 2 1 20 18 1 1 5 4 1 0
Depression 0 0 0 0 0 0 0 0 0 0 0 0
Hiccups 0 0 0 0 0 0 0 0 0 0 0 0
Alopecia 8 8 0 0 8 8 0 0 0 0 0 0
Dry Skin 0 0 0 0 0 0 0 0 0 0 0 0
Palmar-plantar erythrodysesthesia syndrome 6 6 0 0 5 5 0 0 1 1 0 0
Pain of skin 0 0 0 0 0 0 0 0 0 0 0 0
Paronychia 0 0 0 0 0 0 0 0 0 0 0 0
Prutitus 0 0 0 0 0 0 0 0 0 0 0 0
Rash acneiform 1 1 0 0 1 1 0 0 0 0 0 0
Rash papulopustula 1 1 0 0 1 1 0 0 0 0 0 0
Thromboembolic event 0 0 0 0 0 0 0 0 0 0 0 0
Psychiatric disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Vascular disorders
Key: CTCAE, Common Terminology Criteria for Adverse Events (version 4.0)
Blood and lymphatic system disorders
Cardiac disorders
Eye disorders
Gastrointestinal disorders
General disorders conditions
Infections and infestations
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Nervous system disorders
All patients receiving 
chemotherapy between staged 
surgeries
Bowel First Liver First
36 30 6
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6.1.16 Adjuvant Chemotherapy 
Details of adjuvant chemotherapy are shown in Table 42. Nearly two-thirds of patients received 
adjuvant systemic chemotherapy after a mean of 2.8 ± 2.3 months following their surgery. The 
duration of adjuvant chemotherapy was 4.8 ± 4.4 months, and most patients received 5-FU and 
oxaliplatin-based chemotherapy. More synchronous patients received adjuvant chemotherapy (71.4%) 
compared to liver-first (50.0%) and bowel-first (61.9%) groups.  
The adverse events experienced by patients undergoing adjuvant chemotherapy is shown in Table 43. 
 
Table 42. Adjuvant Chemotherapy 
All Elective Emergency
n 109 18 75 59 16 16
Adjuvant Chemotherapy 54 (62.1%) 5 (50.0%) 39 (61.9%) 30 (61.2%) 9 (64.3%) 10 (71.4%)
Adjuvant Chemotherapy Duration, months (range) 4.8 (4.4) 4.1 (2.6) 4.7 (5.0) 5.0 (5.6) 3.8 (1.9) 5.5 (2.8)
Lines of Neoadjuvant Chemotherapy Lines, mean (SD) 1.0 (0.3) 1.2 (0.4) 1.0 (0.3) 1.0 (0.3) 1.0 (0.0) 1.0 (0.0)
5-FU 52 (47.7%) 5 (27.8%) 37 (49.3%) 29 (49.2%) 8 (50.0%) 10 (62.5%)
Oxaliplain 27 (24.8%) 4 (22.2%) 17 (22.7%) 12 (20.3%) 5 (31.2%) 6 (37.5%)
Irinotecan 10 (9.2%) 1 (5.6%) 6 (8.0%) 4 (6.8%) 2 (12.5%) 3 (18.8%)
Raltitrexed 2 (1.8%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 0 (0.0%) 1 (6.2%)
Mitomycin 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Lonsurf 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Bevacizumab 2 (1.8%) 0 (0.0%) 2 (2.7%) 2 (2.7%) 2 (2.7%) 0 (0.0%)
Cetuximab 1 (0.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
Panitumumab 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Aflibercept 1 (0.9%) 0 (0.0%) 1 (1.3%) 1 (1.7%) 1 (1.7%) 0 (0.0%)
Grade 1 3.4 (0.0 - 8.0) 1.4 (0.0 - 3.0) 3.5 (0.0 - 8.0) 3.3 (0.0 - 8.0) 4.0 (2.0 - 6.0) 3.8 (2.0 - 7.0)
Grade 2 0.6 (0.0 - 3.0) 0.6 (0.0 - 2.0) 0.6 (0.0 - 3.0) 0.7 (0.0 - 3.0) 0.1 (0.0 - 1.0) 0.5 (0.0 - 2.0)
Grade 3 0.2 (0.0 - 2.0) 0 0.2 (0.0 - 2.0) 0.2 (0.0 - 2.0) 0 0.1 (0.0 - 1.0)
Grade 4 0 0 0 0 0 0
Grade 5 0 0 0 0 0 0
RECIST, Response Evaluation Criteria In Solid Tumours; CTCAE Common Terminology Criteria for Adverse Events v2.
Synchronous
Bowel First
Chemotherapy Agents
Biologic Agents
CTCAE Adverse events, mean (range)
All Surgical 
Patients Liver First
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Table 43. Adverse events experienced by patients undergoing adjuvant chemotherapy 
 
Patients (n)
                                               Adverse Event Grade
CTCAE All G1 G2 G3 All G1 G2 G3 All G1 G2 G3 All G1 G2 G3
Neutropenia 4 4 0 0 2 2 0 0 1 1 0 0 1 1 0 0
Cardiac chest pain 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dry eye 2 2 0 0 2 2 0 0 0 0 0 0 0 0 0 0
Watering eyes 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Abdominal pain 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0
Anal pain 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Constipation 25 24 1 0 20 20 0 0 1 1 0 0 4 3 1 0
Dental caries 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
GORD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nausea 36 33 3 0 31 29 2 0 1 0 1 0 4 4 0 0
Oral pain 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Vomiting 9 7 2 0 8 6 2 0 1 1 0 0 0 0 0 0
Diarrhoea 43 39 3 1 34 30 3 1 2 2 0 0 7 7 0 0
Dry mouth 2 2 0 0 1 1 0 0 0 0 0 0 1 1 0 0
Mucositis oral 37 28 7 2 28 20 6 2 1 1 0 0 8 7 1 0
Fatigue 23 19 3 1 18 14 3 1 2 2 0 0 3 3 0 0
Sepsis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Thrush 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Urinary tract infection 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hypokalaemia 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Hypomagnesemia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Joint range of motion decreased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dysgeusia 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Lethargy 45 39 5 1 37 31 5 1 2 2 0 0 6 6 0 0
Peripheral Motor Neuropathy 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Peripheral Sensory Neuropathy 34 28 5 1 26 23 2 1 2 0 2 0 6 5 1 0
Depression 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hiccups 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0
Alopecia 24 23 1 0 19 18 1 0 1 1 0 0 4 4 0 0
Dry Skin 3 3 0 0 3 3 0 0 0 0 0 0 0 0 0 0
Palmar-plantar erythrodysesthesia syndrome 29 17 9 3 24 16 6 2 1 0 1 0 4 1 2 1
Pain of skin 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0
Paronychia 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0
Prutitus 2 1 0 1 2 1 0 1 0 0 0 0 0 0 0 0
Rash acneiform 4 1 3 0 3 1 2 0 0 0 0 0 1 0 1 0
Rash papulopustula 3 3 0 0 2 2 0 0 0 0 0 0 1 1 0 0
Thromboembolic event 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0
Psychiatric disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Vascular disorders
Key: CTCAE, Common Terminology Criteria for Adverse Events (version 4.0)
Blood and lymphatic system disorders
Cardiac disorders
Eye disorders
Gastrointestinal disorders
General disorders conditions
Infections and infestations
Metabolism and nutrition disorders
Musculoskeletal and connective tissue disorders
Nervous system disorders
All patients undergoing surgery 
receiving adjuvant chemotherapy Bowel First Liver First Synchronous
55 40 5 10
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6.2 Quality of Life 
The EuroQol-5-Domain, 5-Level (EuroQoL) and EORTC Quality of Life Core Questionnaire (QLQ C30) 
scores are shown in Table 44. EORTC colorectal liver cancer-specific quality of life module (QLQ-
LMC21) scores are shown in Table 45. Complete quality of life questionnaires was recorded for 61 
patients prior to surgery, and 36 patients between 1 and 2 years after surgery. In general, the quality of 
life scores was similar before and after surgery. In the liver-first group, the global health status was 
higher following surgery, particularly in domains such as nutrition, nausea and vomiting, fatigue and 
weight loss. Interestingly, the global health status for synchronous patients was lower following 
surgery, particularly with pain and insomnia problems. The results are likely to be imprecise due to low 
questionnaire numbers. 
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6.3 Prognostic Scores 
Several prognostic scoring systems have been developed and published for patients undergoing 
resection of colorectal liver metastases. Scores, such as the Basingstoke Predictive Index[104], may 
be used for risk stratification for intensive follow-up and/or selection for adjuvant chemotherapy. 
Several other scores stratify prognosis based on specific clinical, serological and histological variables. 
The Fong clinical score was developed from proportional hazards regression from a clinical dataset of 
1001 consecutive patients undergoing liver resection at the Memorial Sloan-Kettering Cancer Centre 
between 1985 and 1998, and predicts recurrence after liver resection for colorectal metastatic 
disease[105]. The Iwatsuki Prognostic Scoring System was developed from a multivariate analysis of 
305 consecutive treated for liver metastatic disease at the University of Pittsburgh Medical Centre 
between 1981 and 1996[106]. The Nordlinger Prognostic Scoring System was developed from 
retrospective clinical dataset of 1,895 patients undergoing liver resection at 85 different centres[107]. 
The Mayo scoring system[108], derived from a retrospective cohort of 662 patients with colorectal liver 
metastases, of which 221 were identified as synchronous patients, was excluded from this analysis as 
the CoSMIC dataset does not contain information on the hepatoduodenal lymph node status. A 
summary of the prognostic scoring systems is shown in Table 46.  
 
Table 46. Summary of Prognostic Scores in Colorectal Liver Metastasis 
Risk Scoring System n Study Period Independent Risk Factors in Score
Positive margin
Extrahepatic disease
Node-positive primary
Disease-free interval from primary to metastasis (< 12 months)
Number of hepatic tumours > 1
Largest hepatic tumour > 5cm
CEA levels > 200 ng/ml
Age (>= 60 years)
Largest hepatic tumour (>= 5cm)
CEA >30 ug/ml
Stage of primary tumour (serosal / lymphatic spread)
Disease free interval (>=2 years)
Number of liver nodules (>3)
Resection margin (< 1cm)
Number of liver metastases (>2)
Largest hepatic tumour (>8cm)
Time to hepatic recurrence (30 months or less)
Bilobar tumours
Primary tumour lymph node status
Primary tumour differentiation (well/mod/poor)
CEA level at hepatectomy
Number of hepatic metastases (>3)
Largest tumour diameter (<5, 5-10, >10)
Hepatic resection margin
Extrahepatic metastatic disease
Survival
-        Largest hepatic metastasis diameter > 8cm
-        Interval to metastasis < 30 months
-        Hepatoduodenal lymph node
-        Transfusions
Recurrence
-        Hepatoduodenal lymph node
-        Transfusions
-        Primary cancer regional lymph nodes
-        Number of hepatic metastases >1
Fong / Memorial Sloan-Kettering 
Cancer Centre (MSKCC) Score 1001 1985 - 1998
Nordlinger Score 1568 1968 - 1990
Mayo scoring system 662 1960 - 1995
Iwatsuki Score 305 1981 - 1996
Basingstoke Predictive index 929 1987 - 2005
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A summary of the prognostic scores applied to the CoSMIC dataset is shown in Table 47. 
 
Table 47. Prognostic scores applied to the CoSMIC dataset 
 
6.4 Outcomes Measures 
The perioperative outcome measures described in the protocol are detailed in this section. The 
perioperative outcomes for patients undergoing bowel resection surgery is shown in Table 48. The 
mean critical care stay for a bowel resection was 2.8 days, and this was significantly higher in the 
synchronous surgery group (ANOVA, p<0.001). The mean hospital stay for a bowel resection was 
10.6 days which again was significantly higher in the synchronous group (ANOVA, p=0.002). We 
report no deaths within 30 days of surgery. An R0 resection margin status was achieved in 90.0% of 
patients, with no statistical significance between the groups (ANOVA, p=0.855). There were higher 
postoperative complications (Clavien-Dindo stage III or above) in the synchronous group than staged 
groups (Oneway ANOVA, p=0.003). There was no difference in leak rate for patients with a primary 
anastomosis (ANOVA, p=0.990).  
 
Table 48. Outcome measures for patients undergoing bowel resection surgery 
All Elective Emergency
Basingstoke (preoperative), Median (range) 86 7 (1 - 16) 6 (3 - 9) 7 (3 - 16) 7 (3 - 16) 7 (5 - 13) 7 (1 - 16)
Basingstoke (postoperative), Median (range) 75 5 (1 - 25) 4 (2 - 15) 6 (2 - 25) 6 (2 - 25) 5 (3 - 16) 5 (1 - 25)
Fong, Median (range) 87 3 (1 - 4) 2 (1 - 4) 3 (1 - 4) 3 (1 - 4) 3 (2 - 4) 2 (2 - 4)
Iwatsuki, Median (range) 97 3 (1 - 6) 3 (2 - 6) 4 (1 - 6) 4 (1 - 6) 3 (2 - 6) 3.5 (2 - 6)
Nordlinger, Median (range) 88 2 (1 - 4) 2 (1 - 3) 2 (1 - 3) 2 (1 - 3) 2.5 (2 - 3) 2 (2 - 4)
All Liver First
Bowel First
Synchronousn
Critical Care Occupancy, mean days (SD) 2.8 (3.7) 1.9 (1.6) 2.0 (3.8) 5.2 (2.9) ANOVA < 0.001
Inpatient Stay, mean days (SD) 10.6 (7.9) 10.9 (7.5) 8.7 (6.2) 16.8 (10.3) ANOVA 0.002
30 Day Mortality, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) ANOVA -
R0 Resection margin status, n (%) 90 (90.0%) 8 (80.0%) 67 (90.5%) 15 (93.8%) ANOVA 0.855
Defunctioning stoma*, n (%) 20 (28.6%) 5 (83.3%) 11 (21.2%) 4 (33.3%) ANOVA 0.087
CD Grade I 50 (64.1%) 8 (88.9%) 38 (71.7%) 4 (25.0%)
CD Grade II 20 (25.6%) 0 (0.0%) 12 (22.6%) 8 (50.0%)
CD Grade IIIA 5 (6.4%) 1 (11.1%) 1 (1.9%) 3 (18.8%)
CD Grade IIIB 2 (2.6%) 0 (0.0%) 2 (3.8%) 0 (0.0%)
CD Grade IV 1 (1.3%) 0 (0.0%) 0 (0.0%) 1 (6.2%)
CD Grade V 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Anastomotic Leak** 2 (3.3%) 1 (16.7%) 1 (2.3%) 0 (0.0%) ANOVA 0.990
Complications
Statistical 
Test
p-valueBowel FirstAll Surgical Patients Liver First Synchronous
CD, Clavien-Dindo Classification of Complications; *Defunctioning stomas fashioned for those patients undergoing primary anastomoses; **Includes only 
patients where a primary Anastomoses was performed (excludes Hartmann's Procedures and Abdominoperoneal Resections)
Oneway 
ANOVA 0.003
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The perioperative outcomes for patients undergoing liver resection surgery is shown in Table 49. The 
mean critical care stay for a liver resection was 3.9 days, and this wasn’t significantly different between 
the surgical groups (ANOVA, p=0.061). The mean inpatient hospital stay for a liver resection was 9.4 
days, and this was higher in the synchronous surgery group (ANOVA, p=0.005). We report no deaths 
within 30 days of liver surgery. An R0 resection margin was achieved in 62 patients (66.0%), and this 
was not different between the groups. There was slightly higher number of postoperative complications 
graded III and above on the Clavien-Dindo classification (Oneway ANOVA, p=0.003). Bile leaks were 
seen in 9 patients (9.7%), and this was not significantly different between the groups (ANOVA, 
p=0.802). Liver failure was seen in only 2 patients (2.1%). 
 
Table 49. Outcome measures for patients undergoing liver resection surgery 
There is no difference in critical care occupancy or inpatient hospital stay between the staged and 
synchronous groups if both staged surgeries are grouped together (Table 50). The mean total critical 
care occupancy for both bowel and liver resection was 5.6 days compared to a synchronous resection 
of 5.2 days (t-test, p=0.920). Similarly, the mean total inpatient stay was 16.5 days for the staged 
group compared to 16.8 days for the synchronous group (t-test, p=0.917).  
 
Table 50. Critical care occupancy and inpatient hospital stay 
Critical Care Occupancy, mean days (SD) 3.9 (2.3) 4.1 (2.5) 3.4 (1.9) 5.2 (2.9) ANOVA 0.061
Inpatient Stay, mean days (SD) 9.4 (6.8) 10.1 (5.9) 7.4 (4.5) 16.8 (10.3) ANOVA 0.005
30 Day Mortality, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) ANOVA -
R0 Resection margin status, n (%) 62 (66.0%) 12 (66.7%) 39 (63.9%) 11 (73.3%) ANOVA 0.505
CD Grade I 53 (56.4%) 8 (47.1%) 42 (67.7%) 4 (25.0%)
CD Grade II 28 (29.8%) 4 (23.5%) 16 (25.8%) 8 (50.0%)
CD Grade IIIA 11 (11.7%) 5 (29.4%) 3 (4.8%) 3 (18.8%)
CD Grade IIIB 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
CD Grade IV 2 (2.1%) 0 (0.0%) 1 (1.6%) 1 (6.2%)
CD Grade V 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Bile Leak* 9 (9.7%) 2 (11.8%) 6 (9.8%) 1 (6.7%) ANOVA 0.802
Liver Failure 2 (2.1%) 1 (5.6%) 1 (1.6%) 0 (0.0%) ANOVA 0.984
Complications
Statistical 
Test
p-value
CD, Clavien-Dindo Classification of Complications; *Includes all grades of bile leak as classified by the International Study Group for Liver Surgery
Bowel FirstAll Surgical Patients Liver First Synchronous
Oneway 
ANOVA 0.003
Critical Care Occupancy, mean days (SD) 5.6 (4.1) 5.2 (2.9) 0.920
Inpatient Stay, mean days (SD) 16.5 (8.1) 16.8 (10.3) 0.917
p-value
Synchronous 
Resection
 Staged Resection 
(Bowel and Liver 
Total)
t-test
Statistical 
Test
130
  
 
Disease status upon completion of the treatment protocol and at 12 months is shown in Table 51. Over 
half of the surgical patients had no disease seen on exit cross-sectional imaging at the end of the 
treatment protocol, and there was no difference between the groups (ANOVA, p=0.970). There was 
also no difference in disease-free survival at 12 months (ANOVA, p=0.448). 
 
Table 51. Disease-free survival 
 
6.5 Survival Analysis 
Reflecting the principal aim of CoSMIC, Kaplan-Meier survival curves were used to explore and 
contrast survival between patient groups. These analyses usefully visualise survival but are 
unadjusted for any potentially confounding differences between groups. Figure 9 shows the 
dramatically poorer prognosis of patients not undergoing surgery, but these patients are known to 
have more advanced disease and comorbidity (Log rank test, p< 0.001). Survival is statistically similar 
between surgical groups, although absolute numbers are not large enough to discern small 
differences. Exploring treatment groups further, sequential and synchronous surgery groups are 
contrasted in Figure 10, which shows a trend of better outcome for sequential surgery, although 
patients generally have a better prognosis following synchronous surgery (p=0.224). There was no 
discernible difference in outcome comparing sequential approaches (Figure 11, p=0.872) or comparing 
minor and major liver resections (Figure 12, p=0.839) although patient numbers are inadequate to 
explore such aspects of care.  Cox regression is required to adjust for patient characteristics which 
may underpin differences in survival: this approach is explored in the next section. 
Disease-free at the end of the protocol, n (%) 58 (53.7%) 9 (50.0%) 40 (54.1%) 9 (56.2%) ANOVA 0.970
Disease-free survival at 12 months, n(%) 36 (35.0%) 4 (25.0%) 27 (38.0%) 5 (31.2%) ANOVA 0.448
Statistical 
Test
p-value
All Surgical 
Patients Liver First SynchronousBowel First
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Figure 9. Survival by Sequence of Surgery 
 
Figure 10. KM Curve - Staged vs Synchronous Resections 
132
  
 
 
Figure 11. KM Curve - Bowel-first vs Liver first Resections 
 
Figure 12. KM Curve - Major vs minor liver resection 
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Figure 13. KM Curve - Unilobar vs bilobar liver metastatic disease 
 
Figure 14. KM Curve - Size of the largest liver metastasis  
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6.6 Survival Analysis Modelling 
6.6.1 Proportional Hazard Modelling using CoSMIC variables  
A proportional hazard (Cox regression) model was used to explore survival within the CoSMIC 
inception cohort. An adjusted model of survival was developed using forward stepwise Cox regression. 
The baseline hazard model chosen for the regression modelling included patient age and gender as 
covariates: these two variables are included as base epidemiological variables. The base model 
shows progressively lower survival (higher risk of death) for older patients, and for patients of female 
sex (hazard ratios of 1.03/year and 1.77 respectively) (Table 52). 
 
Table 52. Cox Regression Model Exploration - Base model 
Initially each putative variable was fitted individually to the base model. Variables were selected for 
further modelling that were prognostic at the time of diagnosis and were significant when tested for 
inclusion using a log-likelihood ratio (LLR) test. Since numbers of patients with information for each 
covariate varied, LLR used the sample size of the new model to calculate the LL in both new and base 
models.  Exploratory variables were grouped into patient demographics (Table 53), primary tumour 
characteristics (Table 54), liver metastatic disease (Table 55) and treatment (Table 56). 
Model name Covariate HR SE z P>|Z|
basemodel Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Log likelihood: -269.801
Likelihood ratio: chi-aquare = 8.393, df = 2, p=0.015
C.I.
HR, hazard ratio; SE, Standard Error; C.I. 95% Confidence Interval
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Table 53. Cox Regression Model Exploration - Patient demographics 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Age 1.017 0.014 1.192 0.233 0.989 1.045
Gender 1.676 0.605 1.429 0.153 0.826 3.401
Height 0.609 1.030 -0.293 0.769 0.022 16.729
Age 1.014 0.013 1.020 0.308 0.988 1.040
Gender 1.826 0.548 2.008 0.045 1.015 3.287
Weight 0.991 0.009 -1.014 0.311 0.973 1.009
Age 1.016 0.014 1.141 0.254 0.989 1.044
Gender 1.771 0.512 1.977 0.048 1.005 3.122
BMI** 0.978 0.025 -0.888 0.374 0.931 1.027
Age 1.016 0.014 1.127 0.260 0.988 1.045
Gender 1.861 0.569 2.031 0.042 1.022 3.389
BMI Groups***
Less than 25
25 - 29.9 1.053 0.347 0.157 0.875 0.552 2.007
30 - 39.9 1.005 0.451 0.010 0.992 0.417 2.422
More than 40 0.647 0.490 -0.575 0.565 0.147 2.855
Age 1.018 0.014 1.250 0.211 0.990 1.046
Gender 1.697 0.513 1.750 0.080 0.939 3.068
Alcohol 0.970 0.297 -0.099 0.921 0.532 1.769
Age 1.024 0.014 1.775 0.076 0.997 1.052
Gender 1.748 0.489 1.999 0.046 1.011 3.024
Smoker***
Non-smoker
Ex-smoker 1.003 0.327 0.008 0.994 0.529 1.899
Current smoker 1.263 0.535 0.552 0.581 0.551 2.895
Age 1.025 0.026 0.956 0.339 0.975 1.077
Gender 1.864 0.496 2.338 0.019 1.106 3.141
Charlson Score***
7 or less
8 1.095 0.780 0.128 0.898 0.271 4.425
9 1.388 1.152 0.395 0.693 0.273 7.066
10 0.864 0.821 -0.153 0.878 0.134 5.561
11 or more 1.360 1.341 0.311 0.756 0.197 9.403
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood Ratio; 
df, degrees of freedom
basemodel
model_1
model_2
model_3
model_3a
model_5
model_4
model_6
CI
-269.801 8.393 2 0.015
-196.037 5.719 3 0.126
-195.847 6.098 5.000 0.297
-212.243 5.208 3.000 0.157
-230.829 9.127 3 0.028
-195.648 6.496 3.000 0.090
-232.416 6.955 4.000 0.138
-268.718 10.558 6.000 0.103
-
0.464
-
0.084 0.772
1.070 0.301
0.861 0.353
0.927
0.010 0.921
0.302 0.860
2.165 0.705
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Table 54. Cox Regression Model Exploration – Primary tumour characteristics 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.027 0.014 1.957 0.050 1.000 1.054
Gender 1.633 0.437 1.836 0.066 0.967 2.758
T Stage***
T1-2
T3 1.077 0.482 0.167 0.868 0.449 2.587
T4 1.008 0.486 0.016 0.987 0.392 2.593
Age 1.028 0.013 2.099 0.036 1.002 1.054
Gender 1.574 0.444 1.608 0.108 0.906 2.737
N Stage***
N0
N1 2.117 0.892 1.781 0.075 0.927 4.835
N2 1.853 0.818 1.398 0.162 0.781 4.401
Age 1.023 0.014 1.639 0.101 0.995 1.052
Gender 1.839 0.497 2.254 0.024 1.083 3.123
Primary Site***
Caecum
Ascending 2.943 1.537 2.066 0.039 1.057 8.191
Transverse/Splenic 0.700 0.424 -0.589 0.556 0.214 2.294
Descending 1.513 0.919 0.681 0.496 0.460 4.976
Sigmoid 0.864 0.373 -0.338 0.735 0.371 2.013
Rectosigmoid 1.033 0.593 0.057 0.955 0.336 3.180
Rectum 0.927 0.413 -0.170 0.865 0.387 2.219
Age 1.006 0.016 0.357 0.721 0.975 1.037
Gender 1.952 0.621 2.101 0.036 1.046 3.641
KRAS Status 0.976 0.307 -0.079 0.937 0.527 1.807
Age 1.025 0.014 1.831 0.067 0.998 1.052
Gender 1.544 0.422 1.587 0.112 0.903 2.640
CEA 1.001 0.000 2.760 0.006 1.000 1.001
Age 1.027 0.014 1.986 0.047 1.000 1.054
Gender 1.757 0.452 2.193 0.028 1.062 2.908
Emergency Presentation 0.710 0.285 -0.852 0.394 0.324 1.560
Age 1.027 0.013 2.022 0.043 1.001 1.054
Gender 1.771 0.454 2.226 0.026 1.071 2.928
Presentation Type***
Asymptomatic
Symptomatic 1.583 0.642 1.133 0.257 0.715 3.505
Emergency 1.048 0.561 0.087 0.930 0.367 2.992
model_11 -232.749 11.352 3.000 0.010 4.807 0.028
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood Ratio; 
df, degrees of freedom
model_12
model_13
model_9
model_10
model_7
model_8
CI
-266.112 15.772 8.000 0.046
-167.494 4.615 3.000 0.202
-259.842 7.169 4.000 0.127
-258.013 10.828 4.000 0.029
-269.405 9.186 3.000 0.027
-268.687 10.621 4.000 0.031
0.793 0.373
2.228 0.328
0.006 0.937
7.379 0.287
0.066 0.967
3.725 0.155
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Table 55. Cox Regression Model Exploration - Liver metastatic disease 
 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.031 0.014 2.207 0.027 1.003 1.060
Gender 1.707 0.438 2.082 0.037 1.032 2.824
Bilobar Liver Mets 1.745 0.448 2.170 0.030 1.055 2.886
Age 1.026 0.015 1.830 0.067 0.998 1.055
Gender 1.569 0.426 1.658 0.097 0.921 2.673
No. of Liver Lesions** 0.966 0.057 -0.592 0.554 0.861 1.084
Age 1.032 0.015 2.156 0.031 1.003 1.062
Gender 1.650 0.455 1.817 0.069 0.961 2.834
No. of Liver Lesions***
1
2 0.647 0.237 -1.188 0.235 0.315 1.327
3 1.130 0.459 0.300 0.764 0.509 2.507
4 - 5 0.928 0.383 -0.181 0.856 0.413 2.084
6 or more lesions 1.044 0.532 0.085 0.932 0.385 2.833
Age 1.024 0.014 1.762 0.078 0.997 1.051
Gender 1.702 0.450 2.009 0.045 1.013 2.859
Largest Liver Lesion** 1.111 0.052 2.237 0.025 1.013 1.218
Age 1.030 0.014 2.149 0.032 1.003 1.058
Gender 1.935 0.525 2.433 0.015 1.137 3.292
Largest Liver Lesion***
Less than 1 cm
1 - 2 cm 0.565 0.314 -1.026 0.305 0.190 1.682
2 - 3 cm 0.434 0.266 -1.364 0.173 0.130 1.441
3 - 4 cm 0.549 0.327 -1.006 0.315 0.171 1.766
4 - 5 cm 0.249 0.195 -1.778 0.075 0.054 1.152
5 - 6 cm 1.365 0.981 0.433 0.665 0.334 5.586
More than 6 cm 1.023 0.608 0.038 0.970 0.319 3.280
Age 1.032 0.013 2.493 0.013 1.007 1.057
Gender 1.596 0.426 1.749 0.080 0.945 2.694
Surgery Sequence***
Bowel-first
Liver-first 1.125 0.412 0.322 0.748 0.549 2.304
Synchronous 1.017 0.431 0.039 0.969 0.443 2.334
No Surgery 7.458 2.494 6.008 0.000 3.872 14.364
CI
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood Ratio; 
df, degrees of freedom
9.531 0.146model_16a
2.011 0.734model_15a
model_14
model_15
model_16
0.386 0.534
4.381 0.036-257.768 12.147 3.000 0.007
0.030
model_17
-245.162 8.706 6.000 0.191
-267.455 13.085 3.000 0.004
-245.974 7.081 3 0.069
-255.439 37.117 5.000 0.000
-255.193 17.297 8.000 0.027
28.724 0.000
4.692
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Table 56. Cox Regression Model Exploration - Treatment 
 
6.6.2 Proportional Hazard Modelling using Prognostics Scores Components 
Multivariable analysis was also performed against the Fong score (Table 57), Iwatsuki score (Table 
58), Nordlinger score (Table 59), and the Basingstoke pre-operative and postoperative scores (Table 
60) as well as their individual components.  
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.014 0.015 0.905 0.366 0.984 1.044
Gender 1.483 0.457 1.277 0.202 0.810 2.714
Resection Type***
Staged Resection
Synchronous 1.045 0.436 0.105 0.916 0.461 2.369
Age 1.006 0.015 0.417 0.677 0.977 1.037
Gender 1.331 0.461 0.826 0.409 0.675 2.625
Staged Resection***
Bowel-first
Liver-first 1.152 0.423 0.386 0.700 0.561 2.367
Age 1.030 0.023 1.30 0.193 0.986 1.074
Gender 1.486 0.607 0.57 0.566 0.525 3.250
Major Liver Resection 1.223 0.430 -0.03 0.973 0.419 2.318
Age 1.011 0.015 0.747 0.455 0.982 1.042
Gender 1.467 0.447 1.258 0.209 0.807 2.666
Neoadjuvant Chemo 0.802 0.236 -0.749 0.454 0.451 1.428
Age 1.016 0.016 1.007 0.314 0.985 1.048
Gender 1.562 0.529 1.317 0.188 0.804 3.034
Chemo between Stages 1.964 0.625 2.122 0.034 1.053 3.666
Age 1.036 0.019 1.922 0.055 0.999 1.074
Gender 1.733 0.616 1.546 0.122 0.863 3.478
Adjuvant Chemo 0.993 0.357 -0.021 0.983 0.490 2.009
CI
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood Ratio; 
df, degrees of freedom
0.000 0.983
0.351 0.553model_20
model_23
0.145 0.703model_19 0.793
0.011 0.916model_18
model_21 0.565 0.452
model_22 -157.644 6.397 3.000 0.094
-129.281 6.437 3.000 0.092
-145.231 4.352 3.000 0.226
-196.918 2.867 3.000 0.413
-200.930 2.522 3.000 0.471
-166.066 1.035 3.000
4.450 0.035
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Table 57. Cox Regression Model Exploration using components of the Fong Score 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Age 1.023 0.017 1.343 0.179 0.990 1.058
Gender 1.392 0.497 0.925 0.355 0.691 2.804
Fong Score 1.522 0.334 1.911 0.056 0.989 2.340
Age 1.019 0.016 1.144 0.253 0.987 1.051
Gender 1.635 0.562 1.430 0.153 0.833 3.207
Lymph Node Status
Negative
Positive 5.259 3.179 2.746 0.006 1.608 17.199
Age 1.027 0.014 1.883 0.060 0.999 1.055
Gender 1.590 0.435 1.694 0.090 0.930 2.719
Number of Liver Lesions
One
More than one 0.842 0.231 -0.627 0.531 0.492 1.442
Age 1.024 0.014 1.816 0.069 0.998 1.051
Gender 1.614 0.436 1.773 0.076 0.951 2.740
Carcinoembryonic Antigen
200 ng/ml or less
More than 200 ng/ml 1.406 0.570 0.840 0.401 0.635 3.114
Age 1.026 0.014 1.875 0.061 0.999 1.053
Gender 1.775 0.465 2.193 0.028 1.063 2.966
Size of Largest Liver Lesion
5cm or less
More than 5cm 2.065 0.634 2.362 0.018 1.132 3.770
-257.521 12.641 3.000 0.005 4.875 0.027
-234.828 7.194 3.000 0.066 0.648 0.421
CI
-269.801 8.393 2.000 0.015 - -
-131.073 5.980 3.000 0.113 3.611 0.057
Fong Score
basemodel
model_F1
model_F2 -139.515 15.147 3.000 0.002 11.789 0.001
-245.972 7.085 3.000 0.069 0.390 0.532model_F3
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood 
Ratio; df, degrees of freedom
model_F4
model_F5
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Table 58. Cox Regression Model Exploration using components of the Iwatsuki Score 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Age 1.036 0.018 2.063 0.039 1.002 1.071
Gender 1.631 0.545 1.463 0.143 0.847 3.141
Iwatsuki Score 1.218 0.115 2.093 0.036 1.013 1.466
Age 1.032 0.015 2.134 0.033 1.003 1.063
Gender 1.570 0.427 1.660 0.097 0.922 2.674
Number of Liver Lesions
Two or less
More than two 1.195 0.354 0.602 0.547 0.669 2.137
Age 1.023 0.014 1.751 0.080 0.997 1.050
Gender 1.759 0.466 2.130 0.033 1.046 2.956
Size of Largest Liver Lesion
8cm or less
More than 8cm 1.459 0.695 0.792 0.428 0.573 3.713
Age 1.031 0.014 2.207 0.027 1.003 1.060
Gender 1.707 0.438 2.082 0.037 1.032 2.824
Liver Lesion Location
Unilobar
Bilobar 1.745 0.448 2.170 0.030 1.055 2.886
Age 1.029 0.018 1.625 0.104 0.994 1.064
Gender 1.923 0.695 1.809 0.071 0.947 3.904
Liver Resection Margin
R0
R1 2.044 0.691 2.114 0.034 1.054 3.967
0.007 4.458 0.035
-267.455 13.085
8.336 3.000 0.040 0.570 0.450
Iwatsuki Score
-151.805 12.033 3.000
3.000 0.004 4.692 0.030
-138.871 11.094 3.000 0.011 4.329 0.037
8.393 2.000 0.015 - -
-245.988 7.054 3.000 0.070 0.359 0.549
model_I5
model_I5
model_I3
CI
-269.801
-259.674
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood 
Ratio; df, degrees of freedom
basemodel
model_I1
model_I5
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Table 59. Cox Regression Model Exploration using components of the Nordlinger Score 
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Age 1.046 0.021 2.214 0.027 1.005 1.088
Gender 2.635 1.029 2.479 0.013 1.225 5.666
Nordlinger Score 1.941 0.589 2.183 0.029 1.070 3.520
Age 1.029 0.015 2.007 0.045 1.001 1.059
Gender 1.564 0.425 1.645 0.100 0.918 2.664
Number of Liver Lesions
Four or less
More than four 1.049 0.342 0.147 0.883 0.554 1.987
Age 1.017 0.014 1.219 0.223 0.990 1.046 -203.497 9.218 3.000 0.027 3.201 0.074
Gender 1.638 0.489 1.652 0.099 0.912 2.940
Size of Largest Liver Lesion
5cm or less
More than 5cm 3.060 1.688 2.027 0.043 1.038 9.020
Age 1.022 0.017 1.250 0.211 0.988 1.056
Gender 1.908 0.682 1.807 0.071 0.947 3.845
Extramural venous invasion 1.211 0.491 0.471 0.638 0.546 2.682
Negative
Positive 1.211 0.491 0.471 0.638 0.546 2.682
Age 1.028 0.023 1.243 0.214 0.984 1.074
Gender 1.771 0.455 2.224 0.026 1.070 2.931
Age Group
60 years or less
More than 60 years 0.955 0.443 -0.100 0.920 0.384 2.373
-269.796 8.403 3.000 0.038 0.010 0.920
-125.875 4.923 3.000 0.178 0.229 0.632
-246.156 6.716 3.000 0.082 0.022
Nordlinger Score
0.883
-94.822 16.181 3.000 0.001 4.944 0.026model_N1
model_N2
CI
-269.801 8.393 2.000 0.015basemodel
model_N3
model_N4
model_N5
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood 
Ratio; df, degrees of freedom
- -
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Table 60. Cox Regression Model Exploration using components of the Basingstoke Score 
 
  
Model Name Covariate HR SE z P>|z| LL LLR df p LR Chi LRT p
Age 1.026 0.013 1.985 0.047 1.000 1.053
Gender 1.772 0.455 2.226 0.026 1.071 2.932
Age 1.030 0.020 1.527 0.127 0.992 1.069
Gender 1.375 0.497 0.881 0.379 0.677 2.792
Basingstoke Score (pre-op) 1.121 0.078 1.631 0.103 0.977 1.286
Age 1.025 0.017 1.491 0.136 0.992 1.059
Gender 1.688 0.519 1.701 0.089 0.923 3.084
Bowel Histology Grade
Well differentiated
Moderately differentiated 0.316 0.241 -1.513 0.130 0.071 1.405
Poorly differentiated 0.225 0.200 -1.679 0.093 0.039 1.284
Age 1.027 0.014 1.878 0.060 0.999 1.055
Gender 1.495 0.407 1.478 0.139 0.877 2.549
Carcinoembryonic Antigen
Less than 6 ng/ml
6 - 60 ng/ml 1.959 0.616 2.140 0.032 1.058 3.629
More than 60 ng/ml 2.732 1.029 2.668 0.008 1.306 5.718
Age 1.026 0.014 1.876 0.061 0.999 1.054
Gender 1.633 0.443 1.806 0.071 0.959 2.779
Size of Largest Liver Lesion
Less than 5 cm
5 - 10 cm 1.794 0.584 1.793 0.073 0.947 3.397
More than 10 cm 13.284 9.201 3.735 0.000 3.418 51.630
Age 1.029 0.015 2.007 0.045 1.001 1.059
Gender 1.564 0.425 1.645 0.100 0.918 2.664
Number of Liver Lesions
Less than 3
Three or more 1.049 0.342 0.147 0.883 0.554 1.987
Age 1.045 0.021 2.161 0.031 1.004 1.088
Gender 1.433 0.603 0.854 0.393 0.628 3.270
Basingstoke Score (post-op) 1.047 0.036 1.339 0.181 0.979 1.119
-231.018 14.814 4.000
-87.354 7.546 3.000 0.056 1.786 0.181
0.005 8.269 0.016
-254.336 19.011 4.000 0.001 11.245 0.004
Basingstoke Score (pre-operative)
-188.901 6.855 4.000 0.144 2.317 0.314
-128.484 4.749 3.000 0.191 2.550 0.110
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; LLR, Log Likelihood 
Ratio; df, degrees of freedom
Basingstoke Score (post-operative)
Lymph node status as above
-246.156 6.716 3.000 0.082 0.022 0.883
model_B6
model_B1
model_B2
model_B3
model_B4
model_B5
basemodel
CI
-269.801 8.393 2.000 0.015 - -
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6.6.3 Proportional Hazard Modelling Analysis  
The following covariates were identified which could potentially improve the base model: 
• The presence of bilobar liver metastases (model_14, model_I5) 
• The size of the largest liver lesion (model_15, model_F5, model_B4) 
• The sequence of surgery (model_17) 
• Lymph node status of the primary resection (model_F2) 
• Liver resection margin (model_I5) 
• Carcinoembryonic antigen levels (model_11, model_B3) 
• Chemotherapy given between staged surgeries (model_22) 
The sequence of surgery was added to the base model (Table 62) resulting in an improved model (chi2 
(df=3) = 31.24, p<0.001). The largest liver lesion size (a continuous variable) was added to this 
expanded model (model_16, Table 61), but did not provide further improvement (chi2 (df=1) = 1.09, 
p=0.2976). After excluding the No Surgery group of patients, liver lesion size and the 
carcinoembryonic antigen levels do not improve the model. The lymph node status of the primary 
tumour resection did improve the model (chi2 (df=5) = 9.159, p=0.015), but was not integrated into the 
final model as the lymph node status would not be known until after the bowel resection surgery. 
 
Table 61. Cox Regression Model Exploration - Base model with sequence of surgery and largest liver 
lesion size 
Thus, a simple model of age, gender and sequence of treatment provides the best model for the 
CoSMIC inception cohort.  As with the Kaplan-Meier presentation the final model (model_17, Table 
62), having adjusted for age and sex, shows dramatically poorer prognosis for patients not undergoing 
surgery (HR = 9.4, p<0.001). Survival is statistically similar between surgical groups, although absolute 
numbers are not large enough to discern smaller differences.  
 
Model Name Covariate* HR SE z P>|z| LL LLR df p
model_16 Age 1.030 0.016 1.93 0.054 1.000 1.062
Gender 1.710 0.529 1.73 0.083 0.933 3.134
Largest Liver Lesion** 1.148 0.060 2.65 0.008 1.037 1.270
Surgery Sequence***
Bowel-first
Liver-first 0.868283 0.438846 -0.28 0.78 0.32244 2.338156
Synchronous 1.394946 0.664185 0.7 0.485 0.548616 3.546875
No Surgery 9.401007 3.464637 6.08 0 4.565344 19.35866
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; 
LLR, Log Likelihood Ratio; df, degrees of freedom
CI
-160.098 38.480 4 < 0.001
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Table 62. Cox Regression Model Exploration - Best Model 
The lack of discrimination between surgical groups is unsurprising given the patient numbers involved. 
Assuming equal group sizes, no censoring and 90% power, 852 patients would be required to find a 
Hazard Ratio of 0.8 (or 1.25) comparing surgical groups. While CoSMIC provides a useful illustration 
of the potential for this form of epidemiological enquiry, definite findings would only result from a 
different scale of enquiry. 
 
 
6.7 Future Data Collection (Follow-up data) 
Future data collection for the CoSMIC cohort will focus on details of disease recurrence and overall 
survival at 5 and 10 years. 
 
  
Model Name Covariate* HR SE z P>|z| LL LLR df p
model_17 Age 1.031 0.015 2.10 0.036 1.002 1.061
Gender 1.457 0.471 1.16 0.244 0.773 2.746
Surgery Sequence***
Bowel-first
Liver-first 0.868 0.439 -0.28 0.780 0.322 2.338
Synchronous 1.395 0.664 0.70 0.485 0.549 3.547
No Surgery 9.401 3.465 6.08 0.000 4.565 19.359
CI
-179.201 31.240 3 < 0.001
*fixed covariates;** Continuous or discrete data; ***categorical data; HR, hazard ratio; SE, standard error; CI 95% confidence interval; LL Log likelihood; 
LLR, Log Likelihood Ratio; df, degrees of freedom
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6.8 Summary Discussion of CoSMIC Inception Cohort Study 
The CoSMIC Inception Cohort study is a mixed retrospective and prospective analysis of patients 
diagnosed with synchronous colorectal cancer and liver metastatic disease. Between the study period 
between April 2015 and 2017, there were a total of 2,302 patients discussed at the HPB MDT at the 
MRI, of which 458 (19.9%) patients were diagnosed with colorectal cancer liver metastatic disease. 
For comparison, the specialist HPB liver MDT at Aintree University Hospitals[109], which serves a 
catchment population of 3 million people covering North Wales, Merseyside, Cheshire and the Isle of 
Man, discussed 1,067 referrals between April 2010 and March 2011. Similarly, the HPB Unit in 
University Hospitals of Leicester has a catchment population of 2.5 million people covering the East 
Midlands and East Anglia. In 2013, the Leicester unit discussed 1,519 referrals in their HPB MDT with 
1,028 confirmed cancer cases, although this figure also includes pancreatic malignancies[110].  
One hundred and twenty-five patients were included in the CoSMIC Inception Cohort study, of which 
107 patients were referrals from 14 secondary care hospitals. There was a high rate (25.6%) of 
patients who underwent elective bowel surgery prior to referral to the MRI and discussion at the 
specialist HPB MDT. Studies describing other healthcare conurbations have shown that up to a third of 
patients diagnosed with synchronous colorectal liver metastatic disease are not referred to a specialist 
HPB MDT for discussion[14]. Guidelines for colorectal cancer with liver metastatic disease mandate 
discussion at a specialist HPB MDT prior to treatment to determine a personalised management plan 
for the patient. Contemporary treatment pathways include systemic chemotherapy as well as 
identifying the potentially more beneficial first surgical stage of treatment. Also, in terms of curative 
treatment, retrospective studies have shown that an additional 12.9% of patients’ tumours are 
potentially deemed resectable following HPB MDT discussion[13]. Other studies have shown that up 
73.6% of patients had primary tumour resected prior to referral, but when compared to a liver-first 
strategy group, there was no change in median survival[111]. Timely referral to an HPB MDT at the 
time of diagnosis has been shown to be beneficial. The introduction of the MDT into clinical pathways 
has been attributed to an increase in survival (22.3 to 32.9%)[112]. The inclusion of the relevant HPB 
quorum has also been associated with increased survival, with MDTs consisting of surgeons from both 
colorectal and hepatobiliary subspecialties have better survival than those with only one speciality[15]. 
Synchronous cases should ideally be referred to the HPB MDT following diagnosis prior to any 
surgical or oncology treatment being started. The obvious exception to this would be patients 
presenting acutely with bowel emergencies such as intestinal obstruction or colonic perforation. 
Obstacles to following guidance might include a reluctance of colorectal centres without on-site HPB 
services to make such referrals for fear of losing cases. Concerns about patients travelling too far 
appear unfounded as CoSMIC-Q found that patients are willing to travel further for better care and 
outcomes. 
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For patients in the CoSMIC study, there was no difference in baseline characteristics between any of 
the surgical strategies, between emergency and elective bowel-first groups, and (surprisingly) between 
patients undergoing surgery and no surgery. Assessments of the baseline characteristics (BMI, pre-
existing co-morbidities, smoking status and alcohol) may be too generalised to distinguish between 
treatment groups. The WHO Performance Status and particularly cardiopulmonary exercise testing 
were better measures used to discriminate between the treatment groups. CPET examination in 
particular changed the treatment in a significant number of patients, and it has been previously shown 
to be a useful prognostic indicator in pre-operative assessments for patients having liver 
resection[113]. 
Although there is great variation in surgical treatment given the vast number of disease primary and 
secondary site permutations, there were no perioperative deaths recorded in the CoSMIC cohort, 
suggesting treatment allocation and preoperative assessment was effective between the surgical 
treatment groups. There are also no significant survival differences between any of the surgical 
strategy groups, but due to the small numbers in CoSMIC, there is limited capacity to explore 
determinants of survival. Accepting this limitation, the results in CoSMIC are in keeping with other 
studies, including that of the systematic review performed in section 2.2. Compared to previous 
retrospective studies, the follow-up period in CoSMIC is much smaller and so the effects of time-
dependent confounding factors such as the type of systemic chemotherapy are minimised. Treatment 
selection currently does not impact on perioperative outcomes or early recurrence. The long-term 
survival of this cohort, however, remains to be explored as the dataset matures.  
The greater number of left sided colonic resections for patients undergoing liver-first surgery may 
represent the ‘window’ for treatment following long-course chemoradiotherapy. This finding is in line 
with other studies[20] where the liver-first strategy sees a much higher rate of patients with rectal 
tumours. The synchronous group consisted of more patients with caecal tumours than any other 
group, and a lower rate of anterior resections and abdominoperineal resections. There is also a lower 
rate of major liver resections (more than 3 segments), providing evidence that the selection for 
synchronous patients is biased towards those patients with right sided colonic resections and minor 
liver resections. Transection time and Pringle time were also significantly lower during synchronous 
resections. We found no significant difference in resection margin status between the sequence of 
surgery. We show that the KRAS mutation potentially does not increases the risk of death (HR=0.42), 
although this was not statistically significant (p=0.08). Although it is accepted that a mutant KRAS 
status is associated with poorer outcomes in colorectal cancer, some studies have been unequivocal 
about its impact[114]. 
The implications of the CoSMIC inception study and CoSMIC-Q study are drawn together in the next 
chapter, in terms of their addition to the understanding of synchronous disease. 
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7. INTEGRATED DISCUSSION 
The CoSMIC inception cohort study was designed to explore outcomes in patients with colorectal 
cancer with synchronous liver-limited metastatic disease, from the point of diagnosis and receiving 
sequential, synchronous or no surgery.  Additionally, the CoSMIC qualitative study explored the 
perspectives of clinicians, patients and their relatives who have completed their treatment pathway and 
their relatives. CoSMIC and CoSMIC-Q appear from the literature to be the first studies of their type 
with respect to design, inclusion and treatment pathway.  
The value of mixed methods research is in integrating qualitative and quantitative findings. CoSMIC-Q 
found clinicians expressed uncertainty about the evidence for the sequence of surgery: a reasonable 
reflection of the literature review of outcomes presented in 2.3. However, clinicians reported having 
firm convictions about the best pathway for individual patients, based on an unproven biological model 
of the primary tumour being the cause and continued threat by further seeding. Modern theories 
derived from next generation genomic sequencing indicate that metastatic disease should be 
considered as a separate disease entity[43]. Thus, clinicians lacked equipoise and were reticent about 
their willingness to recruit to future clinical trials to inform surgical sequencing. (This was in fact the 
experience of both supervisors of this thesis seeking funding for such a trial in the years preceding 
CoSMIC). Patient views about the preferred sequence of surgery and concerns about research seem 
to echo clinical views and may not be wholly independent. For a patient, cancer surgery is a high risk, 
one-off decision which violates the tenets of rational choice and inevitably is heavily guided by the 
experience and training of the surgeon. This is referred to as an agency relationship, where the patient 
depends upon the surgeon (as their agent) and where the surgeon’s preferences are substituted for 
the patient[115]. The clinicians’ established beliefs and consequent patterns of clinical management 
appear empirically entrenched. Consequently, the only design readily available to further 
understanding is by observational research and confirms the rationale for the inception cohort design. 
A simple survival model of age, gender and sequence of treatment provided an effective summary of 
the CoSMIC inception cohort. Adjusted for age and sex, patients not receiving surgery had a much 
poorer prognosis than those undergoing surgery. There was some weak evidence that synchronous 
patients’ survival may not be as good as the sequential approach, but CoSMIC was underpowered to 
discriminate between surgical groups.  However, the potential of the approach is apparent, if taken 
forward. CoSMIC and CoSMIC-Q together provide some clear pointers for future research in this 
patient population. 
CoSMIC-Q is the first study that explores the collective views of patients and relatives who have been 
diagnosed with synchronous disease and who have completed the treatment pathways. The views of 
the clinicians are also explored.  
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7.1 Principal findings 
The CoSMIC and CoSMIC-Q studies are coherent attempts to study outcomes following synchronous 
or staged surgery using mixed methods study of quantitative and qualitative measures. CoSMIC-Q 
provided evidence of a strong clinical preference from both clinicians and patient. CoSMIC provided 
evidence showing no significant difference in outcomes according to the treatment pathways.  
Where indicated, resection of both the colorectal primary and liver metastasis in one surgical 
procedure remains the preference for both clinicians and surgeons. Patients, although preferring a 
synchronous resection, were willing to be guided clinically about the risks of longer operations. Both 
relatives and patients alike understood that, together with existing co-morbidities, synchronous surgery 
presented a much greater perioperative risk. 
CoSMIC reported a failure to complete the pathway rate of 18.4%. The main reasons for this in both 
bowel-first and liver-first groups is progression of disease and deterioration of performance status. 
Previous studies have shown that up to a third of patients fail to complete treatment in both liver-first 
and bowel-first groups, with disease progression cited to be the most common reasons[111]. The role 
of neoadjuvant chemotherapy has previously been shown to be beneficial: response to neoadjuvant 
chemotherapy (as measured by the RECIST criteria) improved overall- and disease-free survival[116].  
The decision-making process for the management of synchronous colorectal cancer and liver-limited 
metastatic disease is complex. CoSMIC-Q reported that clinicians felt there was no robust research 
evidence to guide treatment, and at the MDT meetings, management plans varied greatly between 
meetings. A survey of HPB surgeons based in Ontario also found significant differences in the 
management plans of different clinical scenarios between each surgeon[117]. A survey by Howard and 
colleagues showed that many colorectal surgeons (46%) did not believe a liver-first strategy would be 
of any clinical benefit, and that only a quarter of surgeons surveyed were actually familiar with the 
evidence-based guidelines[101]. There is consensus on broad topics, as shown by a recent survey of 
members of the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the 
Association of Upper Gastrointestinal Surgeons (AUGIS), where it was reported that both colorectal 
and liver surgeons find synchronous resections to acceptable in carefully selected patients[118]. There 
was an agreement of benefit (reduced hospital stays, cost and anxiety) as well as of major concerns of 
a great physiological insult. These data, together with the findings of the systematic review of 
guidelines show that there is currently no universally accepted comprehensive guidelines for the 
management of synchronous colorectal cancer and liver-limited metastatic disease.  
It is generally accepted that surgeons prefer staged resections for patients requiring left sided bowel 
resections and/or major hepatectomy[119]. Right sided colonic resections as part of a synchronous 
resection accounted for less than a third of cases, with a relatively high proportion of patients 
undergoing a sigmoid colectomy. The rate of major hepatectomy as part of a synchronous resection, 
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however, remains low. Only 2 patients in the CoSMIC cohort underwent a synchronous right 
hepatectomy, with the majority undergoing single segmentectomy, left lateral sectionectomy or 
parenchymal-sparing resection. The colorectal surgeons interviewed in the CoSMIC-Q study have also 
expressed an openness to consider left sided resections as part of a synchronous resection, although 
a colonic anastomosis is likely to be covered by a defunctioning stoma. This is reflected in the rate of 
defunctioning stoma formation which is higher in the synchronous group (33%) than the elective 
bowel-first group (21.2%).  
We show no difference in the total duration of critical care occupancy or inpatient hospital stay 
between patients undergoing staged surgery and those having a synchronous resection. Some studies 
have reported a shorter hospital stay period for patients undergoing synchronous resection[119, 120], 
although this may be attributed to a slightly higher number of anterior resections and 
abdominoperineal resections in the staged group. 
 
7.2 Implications for Current Clinical Pathways 
The following implications for current clinical pathways follow from the CoSMIC findings: 
1) Cases should be referred to the HPB MDT ideally before commencing surgery or 
chemotherapy  
2) All patients with a new diagnosis with metastatic liver disease (whether synchronous or 
metachronous) should be referred to the local MDT for discussion 
3) CPET testing can be useful as part of preoperative assessment for patients undergoing liver 
resection and synchronous colorectal and liver resections. Although we show that CPET 
testing that potentially changes the treatment strategy for some patients, further studies with 
greater patient numbers are needed to fully explore this effect.  
 
 
7.3 Study Limitations  
By design, epidemiological deigns are vulnerable to a number of biases.  Potentially explanatory 
variables may be correlate and confound one another.  The causal chain may not be simple but 
complex and multifaceted, although the inception design does allow temporal separation of prognostic 
variables at the time of diagnosis and outcomes.  Completeness of data was inconsistent for some 
variables limiting their exploration. With further opportunity the impact of missing data on survival might 
have been explored with imputation methods as complete data analysis makes strong assumptions. 
However, data were complete for the principle model generated from the inception cohort.  
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The absence of some patients who did not have surgery is a limitation, as their missing records biases 
analysis of the No Surgery group. Those receiving neoadjuvant chemotherapy but not progressing to 
first surgery would not attend the MRI, and thus would not be identified. Thus, only a selection of those 
not receiving surgery are identified. 
With CoSMIC-Q, I participated as an interviewer, which may have affected patient responses.  My 
clinical status and role were known (or easily ascertained) by patients.  Although suboptimal (a neutral 
interviewer would be methodological preferable), the opportunity to participate in interviewing was 
thought integral to the research training aspect of the thesis. 
 
7.4 Core Outcome Set for Colorectal Cancer Liver Metastasis 
Core Outcome Sets are a standardised group of outcomes agreed by a range of stakeholders 
including healthcare professionals, patients and relatives, and are important in the reporting of results 
by reducing heterogeneity and reporting bias[121]. They also allow for the reporting of outcomes 
important from a patient’s perspectives. Currently, there are no core outcome sets defined for studies 
involving colorectal liver metastases[122]. A recently published core outcome set for colorectal 
cancer[123] includes categories for survival and disease control (overall, recurrence-free and 
progression-free survival and resection margin status), short-term complications of treatment, degree 
of health (as measured by quality of life and the presence of a stoma) as well as quality of death such 
as hospital admission at the end of life, hospice care, place of death and preference for a place of 
death.   
Although the CoSMIC dataset is comprehensive in the clinical data collected, the outcomes reported 
by future studies should be defined using consensus methods (such as the modified Delphi technique) 
and involve participation from a wider range of stakeholders, particularly from patients and their 
relatives. For example, although CoSMIC-Q was not designed to identify outcome set data, a common 
theme mentioned by both patients and their relatives was the formation of a stoma.  
 
7.5 Feasibility of a Future Randomised Controlled Trial 
There are currently no randomised controlled trials published in Pubmed and OvidSP indexed journals 
that compare the clinical outcomes following surgery for synchronous colorectal cancer and liver-
limited metastatic disease. A review of the ClinicalTrials.gov database using keywords colorectal 
cancer and liver revealed only 3 trials comparing simultaneous resection and staged surgical 
strategies for synchronous liver metastases. 
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The first randomised controlled trial - 1 Phase Surgery Versus Staged Surgery for Synchronous Liver 
Metastasis of Colorectal Cancer - compares the safety and long-term outcomes of staged colorectal 
and liver resection versus simultaneous resection strategies for patients with patients with 
synchronous disease[124]. The trial has been marked as complete, but no results have yet been 
published.  
The second randomised controlled trial - Evaluation of 2 Resection Strategies of Synchronous 
Colorectal Cancer Metastases (METASYNC) – compares the outcomes patients with synchronous 
disease undergoing simultaneous surgery versus sequential surgery[125]. The trial was terminated 
early after enrolling only 105 patients out of a 222-patient target following a ‘recommendation from a 
sequential analysis’, with no other details given. 
Finally, there is an ongoing feasibility study - Simultaneous Resection of Colorectal Cancer With 
Synchronous Liver Metastases (RESECT) – with a single pilot arm of patients undergoing 
simultaneous resection of the colorectal primary together with a major liver resection of 3 or more 
segments[126]. The aim of the RESECT study is to assess the perioperative outcomes following 
simultaneous resection with the aim to developing a larger randomised controlled trial comparing 
staged versus simultaneous resection. 
The optimal management of synchronous colorectal cancer and liver-limited metastatic disease 
remains an area of evidential equipoise. However, CoSMIC-Q confirms the difficultly of conducting a 
randomised controlled trial given a lack of clinical equipoise. Even though there is no clear evidence 
for a preferred strategy, clinicians would be unlikely to recruit to a trial. Perhaps unsurprisingly, while 
patients similarly were generally very supportive of research in principle, they were not personally 
willing to be randomised into a bowel-first and liver-first treatment strategy. Success rests on the 
acceptability of the design to patients, which is unlikely to be forthcoming if not encouraged by their 
clinicians. A previously published protocol[127] from Liverpool concluded that an RCT for patients with 
synchronous disease was not feasible.  
 
7.6 Future Work 
Evidentially, the surgical pathway for patients with synchronous colorectal cancer and liver-limited 
metastatic disease remains an area of equipoise. It is a complex research question, linking surgical 
and chemotherapeutic pathways with their respective influences upon pathogenesis.  CoSMIC 
demonstrates the feasibility of the prospective approach and data collection could be reduced and 
streamlined in subsequent research, making use of routine data where available and if of adequate 
quality. Thus, one strategy would be to strip down CoSMIC to a minimum dataset capturing key 
covariates, surgical and treatment variables within a prospective registered database conducted at 
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multiple sites if the goal is to analyse 1,000 rather than 100 patients.  The initial investment would be in 
establishing the feasibility of recruiting to and maintaining the database, alongside governance issues 
of collecting and sharing data. This would retain the advantages of the observational (non-
experimental) design that saw high levels of recruitment in CoSMIC.   
CoSMIC has simplistically reduced the survival comparison to an exploratory analysis of type of 
surgery but future more discriminant research may uncover nuances in outcome as a function of 
chemotherapeutic regimens, extent of pathologies and other covariates.  These nuances would not 
readily be discerned using randomised designs and further epidemiological research may be most 
appropriate to enhance understanding of synchronous disease.    
A useful stepping stone might be a national survey to establish the generalisability of key findings from 
this thesis and willingness to participate in future research designs. 
Not all of the potential analyses discussed of CoSMIC data were possible within the time frame of the 
thesis, further analysis and publication of principle findings is anticipated in the future. 
 
7.7 Conclusions 
The CoSMIC and CoSMIC-Q studies provide a first mixed method approach to study the process of 
care outcomes following synchronous or staged surgery in patients with colorectal cancer with 
synchronous liver-limited metastatic disease. Together these studies find a juxtaposition of evidential 
equipoise for the sequencing of surgery with lack of clinically equipoise.  
Optimal management of synchronous disease is a complex research question, linking surgical and 
chemotherapeutic pathways.  Given this interplay of aspects of treatment and presentation of disease, 
further epidemiological research may be most appropriate research design to further enhance 
understanding. 
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8. APPENDICES 
8.1 PRISMA Checklist (Systematic Review) 
The ‘Preferred reporting items for systematic reviews and meta-analyses’ checklist[47] applied to the 
CoSMIC systematic review. 
PRISMA-P 2015 Checklist 
Title  Item  
   Identification 1a Yes 
   Update 1b N/A 
Registration 2 PROSPERO database 2016 CRD42016039163 
Authors Contact 3a See title page 
Authors 
Contributions 
3b AKS conceived the idea; AKS and AC developed the systematic 
review protocol (PRISMA-P); AC carried out the systematic review 
and extracted the data; AKS and AC analysed the data; All authors 
contributed to writing the final manuscript. 
Amendments 4 N/A 
Support   
   Sources 5a This review was supported by a small grant from the Dickinson 
Trust. 
   Sponsor 5b N/A 
   Role of Sponsor 5c N/A 
INTRODUCTION 
Rationale 6 Surgery can improve the 5-year survival of patients diagnosed with 
synchronous colorectal cancer and liver metastases to 40%. The 
traditional ‘bowel-first’ approach removes the colorectal primary in 
the first operation, followed by the liver metastasis in a subsequent 
operation. Recent advances in liver surgery have allowed the ‘liver-
first’ approach and simultaneous bowel/liver resection to be safe 
alternatives. Simultaneous resection removes the macroscopic 
tumour burden in a single but more extensive operation that 
requires careful patient selection. Currently, there is no evidence-
based criteria of either patient comorbid factors or oncological 
considerations that determine the suitability of patients for the 
simultaneous approach. This systematic review identifies these 
factors based on current practice, published in studies that also 
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report 30-day and long term 1-5-year outcomes. It is anticipated that 
the study population will be heterogeneous between studies. A 
homogenous subgroup meta-analysis will allow for a comparison of 
outcomes, thus identifying the critical factors in patient selection. 
Objectives 7 For  
[P] patients diagnosed with synchronous colorectal cancer and liver 
metastases  
[I] undergoing simultaneous bowel and liver resection surgery, 
[C] comparing patient selection factors (co-morbid and oncological) 
[O] with 30-day and long term 1-5 year outcomes. 
 
METHODS 
Eligibility Criteria 8 All studies reporting original data for patients undergoing a 
simultaneous bowel and liver resection for synchronous colorectal 
cancer and liver metastases. The selection criteria must be stated 
in the study methodology, and 30-day and 1-5 year outcomes 
reported. Limited to the English-language publications over the last 
10 years. 
Information 
Sources 
9 PubMed and OvidSP medical databases 
Search Strategy 10 #1 (cancer AND (colon OR rectal OR colorectal)) 
#2 synchronous 
#3 (liver AND metasta*) 
#4 (surgery AND (simultaneous OR combined)) 
#5 metachronous OR lung 
#6 #1 AND #2 AND #3 AND #4 NOT #5 
#7 #6 (limited to English language, Jan 2006 to Feb 2016) 
#8 #7 (limited to NOT reviews) 
 
Study Records 
Data Management 11a Studies and the data will be managed in electronic format 
throughout the review period. 
 
Selection Process 11b Studies will be selected for the review, and data extracted, by two 
independent reviewers.  
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Data Collection 
Process 
11c Data will be extracted from the full papers of the included studies, 
and stored on a software spreadsheet 
 
Data Items 12 • Patient demographics (age, sex) 
• Patient co-morbidity (Charlson index) 
• Cancer staging (TNM) 
• Bowel primary site 
• Minor / Major (>3 segments) liver resection 
• Descriptive criteria/rationale for selecting to simultaneous 
resection  
•  
Outcomes and 
Prioritization 
13 • Length of hospital stay 
• 30-day mortality (Clavien-Dindo score) and morbidity 
• 1-5-year outcome / survival curves 
Risk of bias in 
individual studies 
14 Studies may not publish comprehensive details of their study 
population, or their rationale for simultaneous resection 
(“availability of information”). As such, case-mix differences may 
exist among within the subgroup analysis. 
Publication bias may also affect the power of the study. 
 
Data Synthesis 15 Demographic data from the study cohort as well as the rates of 
complications and survival comparing each of the three surgical 
strategies are reported. Details of systemic chemotherapy 
received by each group were also reported. Statistical pooling of 
proportional estimates was explored using fixed effect models. 
 
Meta-bias(es) 16 The long recruitment periods introduce bias though changes in 
diagnostic imaging, standards of surgical care and the availability 
of bowel-cancer specific chemotherapy. 
 
RESULTS 
Study Selection 17 The search strategy identified 223 unique citations of which 23 
provided comparative data. Of these, 3 cohort studies met the 
inclusion criteria by reporting outcomes separately for the three 
surgical treatment pathways 
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Study 
Characteristics 
18 156 patients by van der Pool and colleagues 
57 patients by Brouquet and colleagues 
1,004 patients by Mayo and colleagues. 
Risk of bias within 
studies 
19 MINORS score was 14/22 (van der Pool and colleagues), 14/ 22 
(Brouquet and colleagues) and 13/22 (Mayo and colleagues). 
Results of 
individual studies 
20 Table 6. Demographic profile of patients with colorectal cancer 
with synchronous liver metastases. 
Table 7. Treatment allocations 
Table 8. Chemotherapy protocols 
Synthesis of 
results 
21 Patients were allocated to bowel-first surgery (748 patients, 
62.2%), liver-first surgery (75, 6.2%) or synchronous liver/bowel 
surgery (380, 31.6%). Minor complications were similar between 
procedures. Major complications were consistent with a pooled 
fixed estimate of 9.1% (95%CI: 7.6%-10.8%, I(2) = 48%). Post-
operative death was rare and consistent with a pooled fixed effect 
estimate of 3.1% (95%CI: 2.2%-4.3%, I(2) = 0%). Median follow-
up ranged from 25.1 to 40.0 months, with a pooled underlying 5-
year survival fixed effect estimate of 44% (I(2) = 39%). 
 
Risk of bias 
across studies 
22 - 
Additional 
analysis 
23 - 
DISCUSSION 
Summary of 
evidence 
24 3 cohort studies were identified comprising a pooled population of 
1203 patients who completed treatment protocols between 1982 
and 2011. Patients were allocated to bowel-first surgery (748 
patients, 62.2%), liver-first surgery (75, 6.2%) or synchronous 
liver/bowel surgery (380, 31.6%). Minor complications were similar 
between procedures. Major complications were consistent with a 
pooled fixed estimate of 9.1%. Post-operative death was rare and 
consistent with a pooled fixed effect estimate of 3.1%. Median 
follow-up ranged from 25.1 to 40.0 months, with a pooled 
underlying 5-year survival fixed effect estimate of 44%. 
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Limitations 25 The definitions of ‘synchronous’ are inconsistent between the 
studies included in the review. The long recruitment periods also 
introduce bias though changes in diagnostic imaging, standards of 
surgical care and the availability of bowel-cancer specific 
chemotherapy.  
Conclusions 26 This review assesses outcomes of patients with colorectal cancer 
with synchronous liver metastases managed by either 
synchronous, sequential liver-first or bowel-first surgery. Overall 
treatment-related mortality is low, and survival is similar among 
the three groups. These findings provide support for the continued 
use of all three pathways until better evidence to guide selection 
of an individual treatment option is available. 
FUNDING 
Funding 27 This review was supported by a small grant from the Dickinson 
Trust. 
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8.2 STROBE Checklist (CoSMIC) 
The ‘Strengthening the reporting of observational studies in epidemiology’ checklist[91] applied to the 
CoSMIC study is shown below. 
 Item Recommendation 
Title and 
abstract 
1 (a) CoSMIC: Colorectal Cancer and Synchronous Liver-Limited 
Metastases: An Inception Cohort  
(b) CoSMIC provides a first mixed method approach to study the 
process of care and outcomes following synchronous or staged 
surgery in patients with colorectal cancer and synchronous liver-
limited metastases. CoSMIC found no significant difference in survival 
according to treatment pathway, with the exception of the No Surgery 
group who had a poorer survival consistent with more advanced 
disease and comorbidity. In line with previous findings, the lack of 
survival difference for the sequence of surgery suggests equipoise. 
INTRODUCTION 
Background / 
rationale 
2 Colorectal cancer is the fourth most common cancer in the UK and 
contributes to over 700,000 deaths worldwide per year. When first 
diagnosed, colorectal cancer has already metastasized in 20% of 
patients to the liver and beyond (termed ‘synchronous’). In these 
patients, 5-year survival is less than 7%. For patients with metastases 
limited to the liver, surgery and systemic chemotherapy can improve 
5-year survival up to 25-40%. Conventional surgery removes the 
colorectal primary first, followed by chemotherapy, and then resection 
of the liver metastases. Advances in critical care and innovations 
such as colonic stenting have allowed liver-first and simultaneous 
bowel and liver surgery to become viable options. Currently, there is 
no conclusive evidence to show which approach is optimum, and 
therefore no standardised clinical pathway.  
Objectives 3 To develop the current evidence base and understanding, the 
CoSMIC inception cohort study has been designed to provide (for the 
first time) comparable outcome data on patients with colorectal 
cancer with liver-limited metastatic disease treated by synchronous or 
sequential surgery. Working to a prospective analysis plan, an 
exploratory analysis of the data will be performed by applying a 
hypothesis generating rather than hypothesis testing framework.  
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Study design 4 Inception cohort study  
 
Setting 5 Tertiary HPB referral (Manchester Royal Infirmary, MRI). The final 
number of patients prospectively recruited was 77, and together with 
48 patients retrospectively identified in the Pre-CoSMIC audit, gives a 
total study population for CoSMIC of 125 patients identified over the 
period between April 2014 and March 2017. 
 
Participants 6 Colorectal cancer and synchronous liver-limited metastatic disease.  
 
Inclusion criteria: 
1. At least 18 years of age 
2. Able to give informed consent 
3. Have a histological diagnosis of colorectal cancer 
4. No prior history of malignancy 
5. Have radiological evidence either on contrast-enhanced CT 
or contrast-enhanced MR scanning of hepatic metastatic 
disease at the time of diagnosis of the primary tumour or 
within 3 months thereof. Liver biopsies should not be taken 
to confirm the diagnosis due to the risk of tumour seeding 
6. CT and/or [18F]Fluorodeoxyglucose positron emission 
tomography / computed tomography ([18F]FDG PET/CT) 
evidence of the absence of extrahepatic metastatic disease 
7. MR scan assessment of local stage in those patients with 
rectal primary tumours 
8. WHO performance status 0, 1 and 2 and considered by the 
MDT to be suitable for surgery and systemic chemotherapy 
 
Variables 7 Baseline staging investigations, predictors of treatment allocation, 
timelines for completion of the treatment protocol, failure to complete 
treatment protocol, study outcomes (disease-free survival, disease 
progression, resection margin status, morbidity profiles, mortality, 
quality of life) 
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Data sources / 
measurement 
8 Case note review and questionnaires for quality of life. Comparisons 
made between bowel-first, liver-first and synchronous resection 
groups. Data was collected prospectively using study clinical case 
report forms. These were anonymised for electronic storage and 
analysed prospectively during the study to maximise data completion 
and resolve emergent problems in a timely fashion. The principal 
source of data was the individual patient records. Vital status beyond 
the duration of the study was determined through the Demographics 
Batch Service of the NHS.  Data was reported at the end of year 3 
allowing for a minimum 12 months outcome data in the entire cohort. 
It was also proposed (contingent on separate funding) that 
information on outcome will be collected for up to 10 years from study 
commencement, providing an informative survival analysis of 
treatment options. 
 
Bias 9 Referral, ascertainment bias and confounding factors 
 
Study size 10 Based on clinical registers, the HPB unit at the MRI sees 
approximately 75 patients with colorectal cancer with synchronous 
liver-limited hepatic metastases per annum.  As there are no study-
related interventions, recruitment rates were predicted to be high and 
drop-out low and is estimated to provide 150 patients in the two-year 
recruitment period.  A formal power calculation was not performed for 
this inception cohort study. Instead, the sample size was informed by 
the need to provide stable estimates of variance for a range of 
outcomes; explore the relationship between the treatment pathway 
and health outcomes; estimate acceptability and recruitment rates; 
and describe patient and clinician experiences. 
 
Quantitative 
variables 
11 The care of patients within the study pathway was characterised by 
their principal treatment route as synchronous, liver-first or bowel-first.  
All patients with data provided outcomes included within analyses, 
grouped according to the treatment sequence received.  Complication 
profiles in patients according to treatment group were reported. 
Summary characteristics of patients, patient care provided, and 
patient outcomes were reported.  
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Statistical 
methods 
12 Analyses were conducted to a prospectively agreed analysis plan. 
Given the exploratory nature of the analysis and multiplicity of 
comparisons, a hypothesis generating (rather than testing) framework 
was applied, where statistical significance (arbitrarily at 5%) was 
viewed as a marker of potential interest for further enquiry. 
Exploratory analysis of process and clinical outcomes was 
undertaken to explore the influence of patient, clinician, centre and 
treatment covariates, using appropriate regression methods. The 
primary aim is to contrast survival of patients according sequence of 
care received (Kaplain Meier, log rank test) adjusting for prognostic 
co-variants (Cox regression). Model building followed a prospectively 
agreed forward stepwise process. 
 
Participants 13 125 patients in total; 75 patients (60.0%) underwent a bowel-first 
treatment strategy, 18 patients (14.4%) underwent a liver-first 
approach, 16 patients (12.8%) underwent a synchronous colorectal 
and liver resection and 16 patients (12.8%) had no surgery. 
 
Descriptive data 14 Table 25. CoSMIC Patient Demographics 
 
Outcome data 15 Table 37. Summary of overall surgical pathway 
Table 62. Cox Regression Model Exploration - Best Model 
 
Main results 16 Table 52. Cox Regression Model Exploration - Base model 
Table 53. Cox Regression Model Exploration - Patient demographics 
Table 54. Cox Regression Model Exploration – Primary tumour 
characteristics 
Table 55. Cox Regression Model Exploration - Liver metastatic 
disease 
Table 56. Cox Regression Model Exploration - Treatment 
 
Other analyses 17 Table 44. Quality of life scores  
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Key results 18 Table 26. Demographics of Patients undergoing Staged Surgery vs 
Synchronous Surgery 
Table 37. Summary of overall surgical pathway 
 
Limitations 19 By design, epidemiological deigns are vulnerable to a number of 
biases.  Potentially explanatory variables may be correlate and 
confound one another.  The causal chain may not be simple but 
complex and multifaceted, although the inception design does allow 
temporal separation of prognostic variables at the time of diagnosis 
and outcomes.  Completeness of data was inconsistent for some 
variables limiting their exploration. With further opportunity the impact 
of missing data on survival might have been explored with imputation 
methods as complete data analysis makes strong assumptions. 
However, data were complete for the principle model generated from 
the inception cohort.  
 
Interpretation 20 CoSMIC has demonstrated the potential of an inception cohort 
approach to study patients with colorectal cancer with synchronous 
liver-limited metastases. Optimal management of synchronous 
disease is a complex research question, linking surgical and 
chemotherapeutic pathways. Given this interplay of aspects of 
treatment and presentation of disease, further epidemiological 
research may be the most appropriate research design to further 
enhance understanding. 
 
Generalisability 21 Concordance with published literature 
Funding 22 This review was supported by a small grant from the Dickinson Trust. 
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8.3 COREQ Checklist (CoSMIC-Q) 
The ‘Consolidated criteria for reporting qualitative research’ checklist[97] applied to the CoSMIC-Q 
study is shown below. 
Domain 1: Research Team and Reflexivity 
Personal Characteristics 
  Interviewer AC Interviewer AI 
1 Interviewer / Facilitator Both authors conducted the interviews 
2 Credentials BSc, MBChB, FRCS, MPhil BSc, MA, PhD 
3 Occupation Surgical Trainee Qualitative Researcher 
4 Gender Male Female 
5 Experience & Training Doctoral training Postdoctoral specialty 
Relationship with Participants 
6 Relationship 
established 
AC involved with clinical care 
of patients, and previous 
involvement with CoSMIC 
No prior relationship 
7 Participant knowledge 
of the interviewer 
All participants have met AC 
through either the CoSMIC 
study or in the clinical setting, 
prior to being approached 
about the current study. 
No prior knowledge 
8 Interviewer 
characteristics 
AC has a clinical background 
and a subspeciality interest in 
HPB oncology. 
AI is a trained qualitative 
researcher with over five year’s 
experience of conducting 
qualitative health researcher 
with patients and clinicians 
Domain 2: Study Design 
Theoretical Framework 
9 Methodological 
orientation and Theory 
An interpretive phenomenological approach was used. 
Participant selection 
10 Sampling Purposive sampling was used. 
11 Method of approach All participants were approached either during direct contact in 
the outpatient clinic or over the telephone. 
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12 Sample size At least 2 patients in each group until data saturation. Each 
participants was offered the opportunity to have a close family 
member present to take part in the interview. 
13 Non-participation - 
Setting 
14 Setting of data 
collection 
All interviews took place at the MRI in a private interview room 
15 Presence of non-
participants 
No non-participants were present. 
16 Description of sample Patients diagnosed with synchronous colorectal cancer with liver-
limited metastases and who have successfully completed their 
surgical treatment pathway (either bowel-first, liver-first or 
simultaneous bowel/liver surgery). 
Data collection 
17 Interview guide Guiding questions were produced prior to the interview, and used 
as prompts when necessary.  
18 Repeat interviews No. 
19 Audio/Visual recording Audio recording 
20 Field Notes Field notes were made immediately after each interview 
21 Duration 30-45mins 
22 Data saturation - 
23 Transcripts returned Participants will be given the option of receiving their transcript to 
allow feedback to the research team.  
Domain 3: Analysis and findings 
Data Analysis 
24 Number of data coders Authors AC and AI will code the data 
25 Description of the 
coding tree 
Thematically, using constant comparison within a modified 
framework approach. 
26 Derivation of themes Authors AC and AI derived common themes from the data 
27 Software  NVivo 
28 Participant checking Participants will be given the option of receiving their transcript to 
allow feedback to the research team. 
Reporting 
29 Quotations presented See Chapters 4 and 5 
30 Data and findings 
consistent 
Yes 
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31 Clarity of major themes Themes are presented clearly as subheadings in the results 
section 
32 Clarity of minor themes There is a description of minor themes within the major themes 
identified in the results section 
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8.4 CoSMIC Patient Information Sheet 
Colorectal cancer with Synchronous liver-limited hepatic Metastasis – 
an Inception Cohort (CoSMIC) Study  
We would like to invite you to take part in our research study. Before you 
decide we would like you to understand why the research is being done and 
what it would involve for you. One of our team will go through the information 
sheet with you and answer any questions you have. We‘d suggest this 
should take about 20 minutes Talk to others about the study if you wish. Part 
1 tells you the purpose of this study and what will happen to you if you take 
part. Part 2 gives you more detailed information about the conduct of the 
study. Please ask us if there is anything that is not clear. 
 
PART 1 
Cancer of the bowel is the fourth most common cancer in the United 
Kingdom. Unfortunately, in about 20% of patients, the cancer will have 
already spread to the liver when it is diagnosed (called ‘synchronous 
disease’). The approach to surgery for patients with synchronous disease is 
complex and challenging, and may involve removing the bowel tumour first, 
the liver tumour first or, in some cases, both tumours together in one 
operation.  
 
What is the purpose of the study? 
Currently, there is no good evidence to show which surgical approach 
is best for patients with synchronous disease, either in terms of the patient 
journey, quality of life or long-term survival.  Thus, there is no established 
protocol for treatment or optimum clinical pathway. Treatment options offered 
and discussed with patients depend on a multitude of factors: aspects of the 
cancer, patient health and wishes, and clinical experience. The care of each 
patient is discussed amongst specialist doctors at a multidisciplinary team 
meeting.  
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This study will identify patients who have a new diagnosis of bowel 
cancer with synchronous disease limited to the liver, and seek their consent 
to record the care they receive following their diagnosis.  An inception cohort 
study follows a series of patients (a ‘cohort’) from the time of diagnosis (the 
beginning or ‘inception’ of clinical management).  It will record the sequence 
of treatment received by each patient and identify the reasons why each 
sequence was chosen instead of alternatives. Patients’ cancer outcomes, 
quality of life, morbidity and eventual mortality will be recorded. The study will 
compare the different approaches in surgery and their impact upon patient 
experiences and outcomes. The findings are essential to help develop 
evidence for the optimal management of synchronous bowel-liver disease 
and to design future clinical trials. 
This study is part of a PhD research project supervised by Professor 
Siriwardena looking at the care of patients who have been diagnosed with 
colorectal cancer with synchronous liver metastasis. 
 
Why have I been invited? 
You have recently been diagnosed with cancer of the bowel with spread 
limited to the liver. We would like to follow your journey to record details of 
the treatment you receive, and also to measure your quality of life at certain 
points of your treatment. 
 
Do I have to take part? 
Taking part is entirely voluntary, and it is up to you to decide if you want to 
join the study. We will describe the study and go through this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason, and this would 
not affect the standard of care you receive. Participation in the study will not 
influence or change the care you would normally receive.  
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What happens if I wish to take part, and what will I have to do? 
If you agree to take part in the study, we will gather information regarding 
your cancer from your hospital case notes both at Manchester Royal 
Infirmary and at other local hospitals where you may have had treatment. We 
will start recording details of treatments you have already, or will be, 
receiving. We will also ask you to fill out and return a short questionnaire to 
measure your quality of life before and after your surgery, and when we see 
you in clinic for your 1 year and 2 year follow-up appointments. 
 
What are the possibly disadvantages and risks of taking part? 
There will be no changes or added risk to the treatment and surgery you 
have discussed and decided with your hospital consultants. The only 
additions to your treatments will be the quality of life questionnaires that our 
research team will carry out with you.  
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get from 
this study may help improve the treatment of people with cancer in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed. The detailed 
information on this is given in Part 2. 
 
Will my personal details be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The details are included in Part 2. 
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Who will have access to my personal details? 
Your personal details will be kept anonymous and the research team will only 
have access to your personal details on a strictly need-to-know basis. All 
members of the team are bound by patient confidentiality.  
 
This completes part 1. If the information in Part 1 has interested you 
and you are considering participation, please read the additional 
information in Part 2 before making any decision. 
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PART 2 
What will happen if I don’t want to carry on with the study? 
You can decide at any time to withdraw from the study, even after you have 
signed the consent forms. Your treatment and the course of your hospital 
stay will not change in any way if you decide not to take part in the study.  
If you withdraw from the study, we will need to use the data collected up to 
your withdrawal. However, you will not be contacted again for further any 
further information. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak to either Professor Siriwardena or any member of his research team 
who will do their best to answer your questions. They can be contacted via 
Professor Siriwardena’s secretary on 0161 276 4244. If you remain unhappy 
and wish to complain formally, you can do this via the NHS Complaints 
Procedure. Details can be obtained from the Patient Advice and Liaison 
Service (PALS) here at Manchester Royal Infirmary. PALS can also be 
contacted on 0161 276 8686. 
 
Will my taking part in this study be kept confidential? 
Yes. Our procedures for handling, processing, storage and destruction of 
your personal data follow the Caldecott principles (a set of guidelines in the 
NHS confidentiality code of practice to protect your confidentiality). 
All information which is collected about you during the course of the research 
will be kept strictly confidential, and any information about you which leaves 
the hospital/surgery will have your name and address removed so that you 
cannot be recognised. Any data we collect about you that can identify you 
will be stored securely and will not be disclosed to anyone outside the 
research group. The only exception to this is the data may be looked at by 
authorised people to check that the study is being carried out correctly. All 
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will have a duty of confidentiality to you as a research participant and we will 
do our best to meet this duty.  
Any data that can be used to identify you personally will be destroyed at the 
end of the study. All the data that we use in our analysis will be done so in an 
anonymised form, and used in a way that will not personally identify you. At 
the end of the study, we will aim to publish the results of our research in a 
public domain such as a paper in a medical journal or at a medical 
conference. No results that we publish will contain information that can 
personally identify you. The data we collect may also be used to plan further 
research in this area. Again, this will not include any information that can 
personally identify you. 
 
Will my GP be informed if I participate in the study? 
Yes, with your consent, we will write a letter to your GP informing him/her of 
your participation. 
 
What will happen to the information collected about me? 
The information collected about you, the treatment you receive and your 
quality of life will be collated and analysed during the course of the study. 
Only the research team who will be working on this project will have direct 
access to the data.  
 
What will happen to the results of the research study? 
At the end of the study, we will aim to publish the results in a public domain 
such as a paper in a medical journal and/or at a medical conference. No 
results that we publish will contain information that can personally identify 
you. The results and conclusions from this study may also be used to plan 
further research. 
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Who is organising and funding the research? 
Professor Ajith Siriwardena is organising the research. The research is being 
funded locally by the Department of Surgery at Manchester Royal Infirmary, 
Central Manchester University Hospitals NHS Foundation Trust. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by the North West Research Ethics 
Committee. 
 
Where can I get more information about the study? 
More general information about medical research can be found at the NHS 
website (http://www.nhs.uk/Conditions/Clinical-
trials/Pages/Introduction.aspx). Specific information about this research 
project, or advice about your participation, can be provided by any member 
of the research team whom you can ask about any aspect of this study either 
during your hospital stay, or any at time after your leave hospital. 
If you are unhappy about any aspect of this study or have any questions 
about it, you can contact Professor Siriwardena (via his secretary on 0161 
276 4244) to discuss these issues further. 
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8.5 CoSMIC Patient Consent Form 
 
PATIENT CONSENT FORM 
Title of Project: Colorectal cancer with Synchronous liver-limited hepatic 
Metastasis – an Inception Cohort (CoSMIC) Study 
Name of Researcher: Professor A Siriwardena 
Centre Number: 
Study Number: 
Patient ID for this trial: 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 
12/11/2015 (version 1.1) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that the relevant sections of my medical notes and data 
collected both at Manchester Royal Infirmary and other regional 
hospitals during the study period may be looked at by individuals from 
Central Manchester University Hospitals NHS Foundation Trust and/or 
regulatory authorities, where is is relevant to my taking part in this 
research. I give permission for these individuals to have access to my 
records and for the data to be kept for up to 10 years. 
4. I agree to my GP being informed of my participation in the study.  
 
5. I agree to take part in the above study. 
 
     .     .   
Patient Signature  Print Name    Date 
    .     .   
Consenting Clinician Print Name    Date 
  
Affix Patient Sticker 
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